Original Article
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
N Engl J Med 2004; 350:1495-1504April 8, 2004
- Abstract
Background
Lipid-lowering therapy with statins reduces the risk of cardiovascular events, but the optimal level of low-density lipoprotein (LDL) cholesterol is unclear.
Methods
We enrolled 4162 patients who had been hospitalized for an acute coronary syndrome within the preceding 10 days and compared 40 mg of pravastatin daily (standard therapy) with 80 mg of atorvastatin daily (intensive therapy). The primary end point was a composite of death from any cause, myocardial infarction, documented unstable angina requiring rehospitalization, revascularization (performed at least 30 days after randomization), and stroke. The study was designed to establish the noninferiority of pravastatin as compared with atorvastatin with respect to the time to an end-point event. Follow-up lasted 18 to 36 months (mean, 24).
Results
The median LDL cholesterol level achieved during treatment was 95 mg per deciliter (2.46 mmol per liter) in the standard-dose pravastatin group and 62 mg per deciliter (1.60 mmol per liter) in the high-dose atorvastatin group (P<0.001). Kaplan–Meier estimates of the rates of the primary end point at two years were 26.3 percent in the pravastatin group and 22.4 percent in the atorvastatin group, reflecting a 16 percent reduction in the hazard ratio in favor of atorvastatin (P=0.005; 95 percent confidence interval, 5 to 26 percent). The study did not meet the prespecified criterion for equivalence but did identify the superiority of the more intensive regimen.
Conclusions
Among patients who have recently had an acute coronary syndrome, an intensive lipid-lowering statin regimen provides greater protection against death or major cardiovascular events than does a standard regimen. These findings indicate that such patients benefit from early and continued lowering of LDL cholesterol to levels substantially below current target levels.
Media in This Article
Figure 1
Median Low-Density Lipoprotein (LDL) Cholesterol Levels during the Study.Figure 2
Kaplan–Meier Estimates of the Incidence of the Primary End Point of Death from Any Cause or a Major Cardiovascular Event.Article Activity
- Article
Several large, randomized, controlled trials have documented that cholesterol-lowering therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) reduces the risk of death or cardiovascular events across a wide range of cholesterol levels whether or not patients have a history of coronary artery disease.1-7 The doses of statins used in these trials reduced low-density lipoprotein (LDL) cholesterol levels by 25 to 35 percent, and current guidelines recommend a target LDL cholesterol level of less than 100 mg per deciliter (2.59 mmol per liter) for patients with established coronary artery disease or diabetes.8,9 It is not clear whether lowering lipid levels further would increase the clinical benefit. Accordingly, the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 (PROVE IT–TIMI 22) trial was designed to compare the standard degree of LDL cholesterol lowering to approximately 100 mg per deciliter with the use of 40 mg of pravastatin daily2,3 with more intensive LDL cholesterol lowering to approximately 70 mg per deciliter (1.81 mmol per liter) with the use of 80 mg of atorvastatin daily10 as a mean of preventing death or major cardiovascular events in patients with an acute coronary syndrome.
Methods
Patient Population
Between November 15, 2000, and December 22, 2001, 4162 patients were enrolled at 349 sites in eight countries (see the Appendix). The protocol was approved by the relevant institutional review boards, and written informed consent was obtained from all patients. As described previously,11 men and women who were at least 18 years old were eligible for inclusion if they had been hospitalized for an acute coronary syndrome — either acute myocardial infarction (with or without electrocardiographic evidence of ST-segment elevation) or high-risk unstable angina — in the preceding 10 days. Patients had to be in stable condition and were to be enrolled after a percutaneous revascularization procedure if one was planned. Finally, patients had to have a total cholesterol level of 240 mg per deciliter (6.21 mmol per liter) or less, measured at the local hospital within the first 24 hours after the onset of the acute coronary syndrome or up to six months earlier if no sample had been obtained during the first 24 hours. Patients who were receiving long-term lipid-lowering therapy at the time of their index acute coronary syndrome had to have a total cholesterol level of 200 mg per deciliter (5.18 mmol per liter ) or less at the time of screening in the local hospital.
Patients were ineligible for the study if they had a coexisting condition that shortened expected survival to less than two years, were receiving therapy with any statin at a dose of 80 mg per day at the time of their index event or lipid-lowering therapy with fibric acid derivatives or niacin that could not be discontinued before randomization, had received drugs that are strong inhibitors of cytochrome P-450 3A4 within the month before randomization or were likely to require such treatment during the study period (because atorvastatin is metabolized by this pathway), had undergone percutaneous coronary intervention within the previous six months (other than for the qualifying event) or coronary-artery bypass surgery within the previous two months or were scheduled to undergo bypass surgery in response to the index event, had factors that might prolong the QT interval, had obstructive hepatobiliary disease or other serious hepatic disease, had an unexplained elevation in the creatine kinase level that was more than three times the upper limit of normal and that was not related to myocardial infarction, or had a creatinine level of more than 2.0 mg per deciliter (176.8 μmol per liter).
Study Protocol
The protocol specified that patients were to receive standard medical and interventional treatment for acute coronary syndromes, including aspirin at a dose of 75 to 325 mg daily, with or without clopidogrel or warfarin. Patients were not permitted to be treated with any lipid-modifying therapy other than the study drug. Eligible patients were randomly assigned in a 1:1 ratio to receive 40 mg of pravastatin or 80 mg of atorvastatin daily in a double-blind, double-dummy fashion. In addition, patients were also randomly assigned to receive with the use of a two-by-two factorial design a 10-day course of gatifloxacin or placebo every month during the trial. The results of the antibiotic component of the trial are not reported here.
Patients were seen for follow-up visits and received dietary counseling8 at 30 days, at 4 months, and every 4 months thereafter until their final visit in August or September 2003. Patients who discontinued the study drug during the trial were followed by means of telephone calls. Blood samples were obtained at randomization, at 30 days, at 4, 8, 12, and 16 months, and at the final visit for the measurement of lipids and other components that were part of the safety assessment. Measurements were made at the core laboratories listed in the Appendix. LDL cholesterol levels were monitored, and the protocol specified that the dose of pravastatin was to increase to 80 mg in a blinded fashion if the LDL cholesterol level exceeded 125 mg per deciliter (3.23 mmol per liter) on two consecutive visits and the patient had been taking study medication and had returned for the required study visits. The dose of either study drug could be halved in the event of abnormal liver-function results, elevations in creatine kinase levels, or myalgias.
Patients were followed for 18 to 36 months, with an average follow-up of 24 months. The trial continued until 925 events had been reported to the coordinating center, after which time all patients were requested to return for a final study visit. Eight patients (0.2 percent) were lost to follow-up.
End Points
The primary efficacy outcome measure was the time from randomization until the first occurrence of a component of the primary end point: death from any cause, myocardial infarction, documented unstable angina requiring rehospitalization, revascularization with either percutaneous coronary intervention or coronary-artery bypass grafting (if these procedures were performed at least 30 days after randomization), and stroke. Myocardial infarction was defined by the presence of symptoms suggestive of ischemia or infarction, with either electrocardiographic evidence (new Q waves in two or more leads) or cardiac-marker evidence of infarction, according to the standard TIMI and American College of Cardiology definition.12,13 Unstable angina was defined as ischemic discomfort at rest for at least 10 minutes prompting rehospitalization, combined with one of the following: ST-segment or T-wave changes, cardiac-marker elevations that were above the upper limit of normal but did not meet the criteria for myocardial infarction, or a second episode of ischemic chest discomfort lasting more than 10 minutes and that was distinct from the episode that had prompted hospitalization. Secondary end points were the risk of death from coronary heart disease, nonfatal myocardial infarction, or revascularization (if it was performed at least 30 days after randomization), the risk of death from coronary heart disease or nonfatal myocardial infarction, and the risk of the individual components of the primary end point.
Statistical Analysis
Although the trial was designed as a time-to-event study, the definition of noninferiority was arrived at through a consideration of two-year event rates. For the comparison of pravastatin with atorvastatin, we defined the prespecified boundary for noninferiority as an upper limit of the one-sided 95 percent confidence interval of the relative risk at two years of less than 1.17 (corresponding to a hazard ratio throughout follow-up of 1.198). Assuming a two-year event rate of 22 percent in the atorvastatin group and that the two treatments had equivalent efficacy, we determined that enrollment of 2000 patients per group would give the study a statistical power of 87 percent and that this power would be preserved if follow-up continued until 925 end-point events had occurred.14 A central randomization system was used that involved a permuted-block design in which assignment was stratified according to center. Three interim assessments of efficacy and safety were carried out by the data and safety monitoring board. Rules for stopping the study early in the event that the superiority of either treatment was established were not prespecified.
All efficacy analyses are based on the intention-to-treat principle. Estimates of the hazard ratios and associated 95 percent confidence intervals comparing pravastatin with atorvastatin were obtained with the use of the Cox proportional-hazards model, with randomized treatment as the covariate and stratification according to the receipt of gatifloxacin or placebo. (Using the two-by-two factorial design, we conducted a preliminary test for interaction and found none. For the primary end point, the interaction P value was 0.90 and the hazard ratios comparing pravastatin with atorvastatin were almost identical for the gatifloxacin and placebo groups.) When it was determined that noninferiority was not demonstrated, the subsequent assessment of superiority was carried out with the use of two-sided confidence intervals. The investigators designed the trial and had free and complete access to the data. Data coordination was performed by the Nottingham Clinical Research Group (see the Appendix). Investigators at TIMI, the sponsor, and members of the Nottingham Clinical Research Group performed data analysis jointly.
Results
The two groups of patients were well matched with regard to base-line characteristics, with the exception of a history of peripheral arterial disease, which was more common in the pravastatin group than the atorvastatin group (P=0.03) (Table 1Table 1
Base-Line Characteristics of the Patients.). Their average age was 58 years, and 22 percent were women. Before their index event, 18 percent of patients had had a myocardial infarction, 11 percent had previously undergone coronary-artery bypass surgery, and 18 percent had diabetes mellitus. The index event was high-risk unstable angina in approximately one third of the patients, myocardial infarction without electrocardiographic evidence of ST-segment elevation in approximately one third, and myocardial infarction with ST-segment elevation in one third. Sixty-nine percent of patients underwent percutaneous coronary intervention for the treatment of their index acute coronary syndrome before randomization. One quarter of the patients were taking statin drugs at the time of the index event. Concomitant medications were administered to patients during the treatment period as follows: aspirin to 93 percent, warfarin to 8 percent, clopidogrel or ticlodipine to 72 percent initially and 20 percent at one year, beta-blockers to 85 percent, angiotensin-converting–enzyme inhibitors to 69 percent, and angiotensin-receptor blockers to 14 percent.At the time of randomization, a median of seven days after the onset of the index event, the median LDL cholesterol levels were 106 mg per deciliter (2.74 mmol per liter) before treatment in each group (Figure 1Figure 1
Median Low-Density Lipoprotein (LDL) Cholesterol Levels during the Study.). The LDL cholesterol levels achieved during follow-up were 95 mg per deciliter (2.46 mmol per liter; interquartile range, 79 to 113 mg per deciliter [2.04 to 2.92 mmol per liter]) in the pravastatin group and 62 mg per deciliter (1.60 mmol per liter; interquartile range, 50 to 79 mg per deciliter [1.29 to 2.04 mmol per liter]) in the atorvastatin group (P<0.001). Among 2985 patients (75 percent) who had not previously received statin therapy, the median LDL cholesterol levels had fallen by 22 percent at 30 days in the pravastatin group and by 51 percent in the atorvastatin group (P<0.001). As anticipated, among the 990 patients who had previously received statin therapy (25 percent), LDL cholesterol levels were essentially unchanged from base line (during statin therapy) in the pravastatin group, whereas they fell by an additional 32 percent in the atorvastatin group (P<0.001). Median high-density lipoprotein cholesterol levels rose during follow-up by 8.1 percent in the pravastatin group and 6.5 percent in the atorvastatin group (P<0.001). Median C-reactive protein levels fell from 12.3 mg per liter at base line in each group to 2.1 mg per liter in the pravastatin group and 1.3 mg per liter in the atorvastatin group (P<0.001).Primary End Point
For all randomized patients, the Kaplan–Meier event rates of the primary end point at two years were 26.3 percent in the standard-dose pravastatin group and 22.4 percent in the high-dose atorvastatin group, representing a 16 percent reduction in the hazard ratio favoring atorvastatin (P=0.005; 95 percent confidence interval, 5 to 26 percent) (Figure 2Figure 2
Kaplan–Meier Estimates of the Incidence of the Primary End Point of Death from Any Cause or a Major Cardiovascular Event.); this difference did not meet the criteria for equivalence. The benefit of high-dose atorvastatin as compared with standard-dose pravastatin emerged as early as 30 days and was consistent over time (Figure 3Figure 3
Hazard Ratio for the the Primary End Point of Death from Any Cause or a Major Cardiovascular Event at 30, 90, and 180 Days and at the End of Follow-up in the High-Dose Atorvastatin Group, as Compared with the Standard-Dose Pravastatin Group.). The risk of the secondary end point of death due to coronary heart disease, myocardial infarction, or revascularization was similarly reduced by 14 percent in the atorvastatin group (P=0.029), with a two-year event rate of 19.7 percent, as compared with 22.3 percent in the pravastatin group. The risk of death, myocardial infarction, or urgent revascularization was reduced by 25 percent in the atorvastatin group (P<0.001).Among the individual components of the primary end point, there was a consistent pattern of benefit favoring high-dose atorvastatin over standard-dose pravastatin, which included a significant 14 percent reduction in the need for revascularization (P=0.04), a 29 percent reduction in the risk of recurrent unstable angina (P=0.02), and nonsignificant reductions in the rates of death from any cause (28 percent, P=0.07) and of death or myocardial infarction (18 percent, P=0.06) (Figure 4Figure 4
Estimates of the Hazard Ratio for the Secondary End Points and the Individual Components of the Primary End Point in the High-Dose Atorvastatin Group, as Compared with the Standard-Dose Pravastatin Group.). Stroke was infrequent, but the rates did not differ significantly between the groups.The benefit of high-dose atorvastatin was consistent across the prespecified subgroups, including men and women, patients with unstable angina and those with myocardial infarction, and those with and those without diabetes mellitus (Figure 5Figure 5
Two-Year Event Rates and Estimates of the Hazard Ratio for the Primary End Point in the High-Dose Atorvastatin Group, as Compared with the Standard-Dose Pravastatin Group, According to Base-Line Characteristics.). The benefit appeared to be greater among patients with a base-line LDL cholesterol level of at least 125 mg per deciliter, a prespecified subgroup, with a 34 percent reduction in the hazard ratio, as compared with a 7 percent reduction among patients with a base-line LDL cholesterol below 125 mg per deciliter (P for interaction = 0.02).Tolerability and Safety
The rates of discontinuation of treatment because of an adverse event or the patient's preference or for other reasons were 21.4 percent in the pravastatin group and 22.8 percent in the atorvastatin group at one year (P=0.30) and 33.0 percent and 30.4 percent, respectively, at two years (P=0.11). During treatment, the dose of pravastatin was increased to 80 mg in 8 percent of patients, and the dose was halved among 1.4 percent of the patients in the pravastatin group and 1.9 percent of those in the atorvastatin group (P=0.20), owing to side effects or liver-function abnormalities. The percentages of patients who had elevations in alanine aminotransferase levels that were more than three times the upper limit of normal were 1.1 percent in the pravastatin group and 3.3 percent in the atorvastatin group (P<0.001). The study medication was discontinued by the investigators because of a report of myalgias or muscle aches or elevations in creatine kinase levels in 2.7 percent of pravastatin-treated patients, as compared with 3.3 percent of atorvastatin-treated patients (P=0.23). There were no cases of rhabdomyolysis in either group.
Discussion
In this comparison of two statin regimens of different lipid-lowering intensities for the prevention of cardiovascular events, intensive therapy with high-dose atorvastatin resulted in a median LDL cholesterol level of 62 mg per deciliter, as compared with a level of 95 mg per deciliter for standard-dose pravastatin. Among patients who had recently been hospitalized for an acute coronary syndrome, the more intensive regimen resulted in a lower risk of death from any cause or major cardiac events than did a more moderate degree of lipid lowering with the use of a standard dose of a statin. Although prior placebo-controlled studies have shown that a standard-dose statin is beneficial,1-7 we demonstrated that more intensive lipid lowering significantly increased this clinical benefit.
Although the exact mechanism of the benefit cannot be established solely on the basis of our results, the extent of the benefit afforded by the 80-mg dose of atorvastatin is in keeping with what would be expected on the basis of the greater degree of lipid lowering produced by this regimen. In the Heart Protection study, statin treatment resulted in an LDL cholesterol level that was 40 mg per deciliter (1.03 mmol per liter) lower than the value in the placebo group and that was accompanied by a 25 percent reduction in cardiovascular events. In our study, the LDL cholesterol level was 33 mg per deciliter (0.85 mmol per liter) lower in the atorvastatin group than in the pravastatin group. This difference should translate into a 20 percent reduction in clinical events, which is very similar to the 16 percent reduction we observed and suggests that much of the benefit is attributable to the difference in the degree of LDL cholesterol lowering. However, we cannot exclude the possibility that the difference in clinical outcomes may be due in part to non–lipid-related pleiotropic effects, which may differ between the two statins we used.15 Future trials involving different doses of a single statin should help address this possibility.
Intensive therapy with high-dose atorvastatin had a consistent beneficial effect on cardiac events, including a significant 29 percent reduction in the risk of recurrent unstable angina and a 14 percent reduction in the need for revascularization. The reduction in the rate of death from any cause was of borderline significance (28 percent, P=0.07), suggesting that more aggressive lipid lowering is important not only to reduce the risk of recurrent ischemia, but possibly also to decrease the risk of fatal events.
The reduction in clinical events with the more intensive lipid-lowering therapy was apparent as early as 30 days after the start of therapy. This rapid time frame is similar to that reported with statin treatment in the placebo-controlled Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial16 and in prior observational studies.17,18 We studied patients who had been hospitalized for an acute coronary syndrome and enrolled them immediately after their condition had stabilized. Three quarters of the patients were treated with an early invasive strategy, and the majority were treated with multiple medications for secondary prevention, including antiplatelet therapy, beta-blockers, and angiotensin-converting–enzyme inhibitors (and a statin as part of the trial design). Nonetheless, early and continued separation of the event curves was observed in the more intensive lipid-lowering group. This early reduction in event rates in patients with acute coronary syndromes contrasts with the lag of approximately one to two years in prior studies of statins in patients with chronic atherosclerosis.1-6 These data suggest that this population of patients with acute coronary syndromes, who have a culprit lesion and frequently multiple additional vulnerable plaques as well,19,20 can derive particular benefit from early and intensive lipid lowering with statins. The current guidelines of the American College of Cardiology and American Heart Association recommend instituting lipid-lowering therapy at the time of hospital discharge in patients with acute coronary syndromes, on the theory that it will improve patients' compliance with the use of statins for long-term secondary prevention.21 Our data are evidence that such therapy will also provide protection against early recurrent cardiovascular events.
After the early separation of the clinical-event curves, we also observed a continued benefit of atorvastatin therapy throughout the follow-up period of two and one-half years (Figure 2). It cannot be determined from this study whether this longer-term benefit was due to ongoing intensive lipid-lowering therapy or was the result of an early benefit in stabilizing vulnerable plaques with the early and intensive treatment after the acute event. It also cannot be determined whether other differences between the two statins used explain the observed clinical benefit. Nonetheless, our findings suggest that patients with acute coronary syndromes who receive early and intensive lipid-lowering therapy continue to derive benefit in the chronic phase of atherosclerosis when high-dose statin therapy is maintained.
Our finding of a continued benefit of intensive lipid-lowering therapy during the follow-up phase is consistent with studies showing that such an approach results in a slower rate of progression of atherosclerosis in patients with stable coronary artery disease22 or in those who undergo coronary-artery bypass grafting,23 as well as in greater reductions in carotid intimal–medial thickening.24-26 Although our study documented a benefit for up to an average of two years of follow-up, several large, ongoing trials involving patients with stable atherosclerosis will determine the five-year outcomes of intensive as compared with moderate lipid lowering.27
It is important to note that our safety and efficacy results were obtained in a carefully selected and monitored study population (for example, we excluded patients who were concomitantly receiving strong inhibitors of cytochrome P-450 3A4, because this is integral to the route of metabolism of atorvastatin). Although both drugs were generally well tolerated, there were significantly more liver-related side effects with high-dose atorvastatin than with standard-dose pravastatin. Patients in clinical practice generally have more coexisting conditions than did our patients, and they may not tolerate a high-dose statin regimen as well as our patients did. Thus, clinicians must take these factors into account when applying the results of our trial in clinical practice.
The National Cholesterol Education Program and European guidelines currently recommend that the goal of treatment in patients with established coronary artery disease should be an LDL cholesterol level of less than 100 mg per deciliter.8,9 Although our data provide support for the use of this approach, given the substantially lower LDL cholesterol levels achieved in the group given 80 mg of atorvastatin daily (median, 62 mg per deciliter), our results suggest that after an acute coronary syndrome, the target LDL cholesterol level may be lower than that recommended in the current guidelines.
Supported by Bristol-Myers Squibb and Sankyo.
Drs. Rader and Pfeffer report having received consulting fees and lecture fees from Bristol-Myers Squibb. Drs. Joyal and Belder are employees of Bristol-Myers Squibb and have equity in the company. Dr. Rouleau reports having received consulting fees and lecture fees from Novartis.
This article was published at www.nejm.org on March 8, 2004.
Source Information
From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston (C.P.C., E.B., C.H.M., M.A.P.); the University of Pennsylvania, Philadelphia (D.J.R.); the University of Montreal, Montreal (J.L.R.); Bristol-Myers Squibb, Princeton, N.J. (R.B., S.V.J.); and the Nottingham Clinical Research Group, Nottingham, United Kingdom (K.A.H., A.M.S.).
Address reprint requests to Dr. Cannon at the TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, 75 Francis St., Boston, MA 02115, or at cpcannon@partners.org.
The investigators and research coordinators who participated in the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 (PROVE IT–TIMI 22) study are listed in the Appendix.
Appendix
The following investigators and research coordinators participated in the study (the complete list of investigators and coordinators is available at www.timi.org): Operations Committee — E. Braunwald (Study Chair), C. Cannon (Principal Investigator), T. Grayston, B. Muhlestein, D. Rader, J. Rouleau, and members of the Data Coordinating Center and Sponsor are indicated with an asterisk; Steering Committee — Members of the Operations Committee and R. Byington, A. Castaigne, H. Darius, G. DeFerrari, B. Gersh, D. Gilbert, S. Grundy, G. Jackson, R. Knopp, I. Meredith, E. Ofili, M. Pfeffer, F. Sacks, P. Shah, S. Smith, A. Tonkin, J. Velasco; TIMI Study Group — C. McCabe (Project Director),* S. McHale (Project Manager); Sponsor (Bristol-Myers Squibb, Princeton, N.J., and Wallingford, Conn.) — R. Belder,* J. Breen,* G. Cucinotta, S. Joyal,* C.-S. Lin, K. Natarajan,* S. Nichols; Data Coordinating Center (Nottingham Clinical Research Group, Nottingham, United Kingdom) — A. Skene,* K. Hill; Clinical Events Committee — M. Pfeffer (Chairman), R. Guertin-Mercier; J. Potzka, R. Messing; Physician Reviewers — E. Ascher, P. Finn, R. Giugliano, J. Kirdar, D. Lee, A. Mirza, T. Rocco; Biomarker Core Laboratory (Brigham and Women's Hospital, Boston) — D. Morrow, P. Ridker, E. Danielson, G. Borkowski; Chlamydia/Serology Core Laboratory (Johns Hopkins University, Baltimore) — T. Quinn; C. Gaydos, B. Wood; Electrocardiographic Core Laboratory (eResearch Technology, Philadelphia) — J. Morganroth; Special Lipid Core Laboratory (University of Pennsylvania, Philadelphia) — D. Rader, M. Wolfe; Chemistry Core Laboratory (LabCorp, Raritan, N.J.); Data and Safety Monitoring Board — A. Gotto (Chair), J. Bartlett, D. DeMets, J. Banas, T. Pearson; Clinical Centers Enrolling the Most Patients (in order of enrollment) — Huntsville Hospital, Huntsville, Ala.: W. Haught and K. Griffin; Fremantle Hospital, Fremantle, Western Australia: R. Hendriks and D. Greenwell; Detar Hospital, Victoria, Tex.: H. Chandna and D. Holly; St. Francis Hospital, Tulsa, Okla.: J. Cassidy and N. Ritchie; Advanced Health Institute, Galax, Va.: J. Puma and E. Jones; Michigan Heart, Ypsilanti: J. Bengtson and C. Carulli; North Mississippi Medical Center, Tupelo: B. Bertolet and M. Jones; Wilford Hall Medical Center, Lackland Air Force Base, Lackland, Tex.: R. Krasuski and U. Ward; Queen Elizabeth Hospital, Woodville, Saskatchewan, Canada: J. Horowitz and R. Prideaux; Moses H. Cone Hospital, Greensboro, N.C.: T. Kelly and K. Cochran; Deaconess Medical Center, Spokane Wash.: D. Hollenbaugh and J. Mansfield; Louisiana Cardiology Associates, Baton Rouge: J. McLachlan and A. Yoches; New Mexico Heart Institute, Albuquerque: R. Orchard and S. Justice; River Cities Cardiology, Jeffersonville, Ind.: D. Denny and B. Vanvactor; Laval Hospital, Quebec, Canada: P. Bogaty and L. Boyer; Altru Health System Research Center, Grand Forks, N.D.: A. Ahmed and D. Vold; Iowa Heart Center, Des Moines: W. Wickmeyer and N. Coffman; MetroHealth Medical Center, Cleveland: R. Finkelhor and M. Dettmer; Scarborough Cardiology Research, Scarborough, Ont., Canada: A. Ricci, and B. Bozek; Moses Cone Hospital, Greensboro, N.C.: T. Stuckey and S. Milks; Lake Forest Hospital, Bannockburn, Ill.: J. Alexander and K. Anderson; Centre Hospitalier Universitaire, Fleurimont, Que., Canada: S. LePage and L. Larrivee; Butterworth Hospital, Grand Rapids, Mich.: R. McNamara and B. Van Over; Centre Hospitalier Regional de Lanaudière, Quebec, Canada: S. Kouz and M. Roy; Craigavaon Area Hospital, Portadown, County Armagh, United Kingdom: A. Moriarty and D. McEneaney.
- References
References
1
Scandinavian Simvastatin Survival Study Group
Web of Science | Medline2
Sacks RM ,Pfeffer MA ,Moye LA , et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-1009
Full Text | Web of Science | Medline3
The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
Full Text | Web of Science | Medline4
Heart Protection Study Collaborative Group
CrossRef | Web of Science | Medline5
Shepard J ,Cobbe SM ,Ford I , et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-1307
Full Text | Web of Science | Medline6
Downs JR ,Clearfield M ,Weis S , et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-1622
CrossRef | Web of Science | Medline7
Shepherd J ,Blauw GJ ,Murphy MB , et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-1630
CrossRef | Web of Science | Medline8
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
CrossRef | Web of Science9
De Backer G ,Ambrosioni E ,Borch-Johnsen K , et al. European guidelines on cardiovascular disease and prevention in clinical practice. Atherosclerosis 2003;171:145-155
CrossRef | Web of Science | Medline10
Davidson MH ,Nawrocki JW ,Weiss SR , et al. Effectiveness of atorvastatin for reducing low-density lipoprotein cholesterol to National Cholesterol Education Program treatment goals. Am J Cardiol 1997;80:347-348
CrossRef | Web of Science | Medline11
Cannon CP ,McCabe CH ,Belder R ,Breen J ,Braunwald E . Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial. Am J Cardiol 2002;89:860-861
CrossRef | Web of Science | Medline12
Cannon CP ,McCabe CH ,Wilcox RG , et al. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation 2000;102:149-156
Web of Science | Medline13
Cannon CP ,Battler A ,Brindis RG , et al. American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes: a report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee). J Am Coll Cardiol 2001;38:2114-2130
CrossRef | Web of Science | Medline14
Lachin JM ,Foulkes MA . Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. Biometrics 1986;42:507-519
CrossRef | Web of Science | Medline15
Bonetti PO ,Lerman LO ,Napoli C ,Lerman A . Statin effects beyond lipid lowering -- are they clinically relevant? Eur Heart J 2003;24:225-248
CrossRef | Web of Science | Medline16
Schwartz GG ,Olsson AG ,Ezekowitz MD , et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001;285:1711-1718
CrossRef | Web of Science | Medline17
Stenestrand U ,Wallentin L . Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001;285:430-436
CrossRef | Web of Science | Medline18
Aronow HD ,Topol EJ ,Roe MT , et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet 2001;357:1063-1068
CrossRef | Web of Science | Medline19
Asakura M ,Ueda Y ,Yamaguchi O , et al. Extensive development of vulnerable plaques as a pan-coronary process in patients with myocardial infarction: an angioscopic study. J Am Coll Cardiol 2001;37:1284-1288
CrossRef | Web of Science | Medline20
Goldstein JA ,Demetriou D ,Grines CL ,Pica M ,Shoukfeh M ,O'Neill WW . Multiple complex coronary plaques in patients with acute myocardial infarction. N Engl J Med 2000;343:915-922
Full Text | Web of Science | Medline21
Braunwald E ,Antman EM ,Beasley JW , et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction -- 2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). Circulation 2002;106:1893-1900
CrossRef | Web of Science | Medline22
Nissen SE ,Tuzcu EM ,Schoenhagen P , et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. JAMA 2004;291:1071-1080
CrossRef | Web of Science | Medline23
Campeau L ,Hunninghake DB ,Knatterud GL , et al. Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors: NHLBI post coronary artery bypass graft clinical trial. Circulation 1999;99:3241-3247
Web of Science | Medline24
Taylor AJ ,Kent SM ,Flaherty PJ ,Coyle LC ,Markwood TT ,Vernalis MN . ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 2002;106:2055-2060
CrossRef | Web of Science | Medline25
Kent SM ,Coyle LC ,Flaherty PJ ,Markwood TT ,Taylor AJ . Marked low-density lipoprotein cholesterol reduction below current National Cholesterol Education Program targets provides the greatest reduction in carotid atherosclerosis. Clin Cardiol 2004;27:17-21
CrossRef | Web of Science | Medline26
Smilde TJ ,van Wissen S ,Wollersheim H ,Trip MD ,Kastelein JJ ,Stalenhoef AF . Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001;357:577-581
CrossRef | Web of Science | Medline27
LaRosa JC . New and emerging data from clinical trials of statins. Curr Atheroscler Rep 2004;6:12-19
CrossRef | Medline
- Citing Articles (1296)
Citing Articles
1
Glenn N. Levine, Eric R. Bates, James C. Blankenship, Steven R. Bailey, John A. Bittl, Bojan Cercek, Charles E. Chambers, Stephen G. Ellis, Robert A. Guyton, Steven M. Hollenberg, Umesh N. Khot, Richard A. Lange, Laura Mauri, Roxana Mehran, Issam D. Moussa, Debabrata Mukherjee, Brahmajee K. Nallamothu, Henry H. Ting, Alice K. Jacobs, Jeffrey L. Anderson, Nancy Albert, Mark A. Creager, Steven M. Ettinger, Robert A. Guyton, Jonathan L. Halperin, Judith S. Hochman, Frederick G. Kushner, E. Magnus Ohman, William Stevenson, Clyde W. Yancy. (2012) 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: Executive Summary. Catheterization and Cardiovascular Interventions 79:3, 453-495
CrossRef2
Hideaki Kaneda, Mitsuyasu Terashima, Hiroshi Yamaguchi. (2012) The Role of Intravascular Ultrasound in the Determination of Progression and Regression of Coronary Artery Disease. Current Atherosclerosis Reports
CrossRef3
K. Rahimi, W. Majoni, A. Merhi, J. Emberson. (2012) Effect of statins on ventricular tachyarrhythmia, cardiac arrest, and sudden cardiac death: a meta-analysis of published and unpublished evidence from randomized trials. European Heart Journal
CrossRef4
Christian W. Hamm, Jean-Pierre Bassand, Stefan Agewall, Jeroen Bax, Eric Boersma, Hector Bueno, Pio Caso, Dariusz Dudek, Stephan Gielen, Kurt Huber, Magnus Ohman, Mark C. Petrie, Frank Sonntag, Miguel Sousa Uva, Robert F. Storey, William Wijns, Doron Zahger. (2012) Guía de práctica clínica de la ESC para el manejo del síndrome coronario agudo en pacientes sin elevación persistente del segmento ST. Revista Española de Cardiología 65:2, 173.e1-173.e55
CrossRef5
Fabio Angeli, Gianpaolo Reboldi, Marta Garofoli, Elisa Ramundo, Paolo Verdecchia. (2012) Very early initiation of statin therapy and mortality in patients with acute coronary syndrome. Acute Cardiac Care1-6
CrossRef6
Tsuyoshi Nozue, Shingo Yamamoto, Shinichi Tohyama, Shigeo Umezawa, Tomoyuki Kunishima, Akira Sato, Shogo Miyake, Youichi Takeyama, Yoshihiro Morino, Takao Yamauchi, Toshiya Muramatsu, Kiyoshi Hibi, Takashi Sozu, Mitsuyasu Terashima, Ichiro Michishita. (2012) Statin treatment for coronary artery plaque composition based on intravascular ultrasound radiofrequency data analysis. American Heart Journal 163:2, 191-199.e1
CrossRef7
Vecih Oduncu, Ayhan Erkol, Mustafa Kurt, İbrahim Halil Tanboğa, Can Yücel Karabay, Cihan Şengül, Mustafa Bulut, Olcay Özveren, Hakan Fotbolcu, Taylan Akgün, Erdem Türkyılmaz, Cevat Kırma. (2012) The prognostic value of very low admission LDL-cholesterol levels in ST-segment elevation myocardial infarction compared in statin-pretreated and statin-naive patients undergoing primary percutaneous coronary intervention. International Journal of Cardiology
CrossRef8
Nabel, Elizabeth G., Braunwald, Eugene, . (2012) A Tale of Coronary Artery Disease and Myocardial Infarction. New England Journal of Medicine 366:1, 54-63
Full Text9
Philipp A Gerber, Giatgen A Spinas, Kaspar Berneis. (2012) Small dense low-density lipoprotein particles: priority as a treatment target in Type 2 diabetes?. Diabetes Management 2:1, 65-74
CrossRef10
L. David Hillis, Peter K. Smith, Jeffrey L. Anderson, John A. Bittl, Charles R. Bridges, John G. Byrne, Joaquin E. Cigarroa, Verdi J. DiSesa, Loren F. Hiratzka, Adolph M. Hutter, Michael E. Jessen, Ellen C. Keeley, Stephen J. Lahey, Richard A. Lange, Martin J. London, Michael J. Mack, Manesh R. Patel, John D. Puskas, Joseph F. Sabik, Ola Selnes, David M. Shahian, Jeffrey C. Trost, Michael D. Winniford, Alice K. Jacobs, Jeffrey L. Anderson, Nancy Albert, Mark A. Creager, Steven M. Ettinger, Robert A. Guyton, Jonathan L. Halperin, Judith S. Hochman, Frederick G. Kushner, E. Magnus Ohman, William Stevenson, Clyde W. Yancy. (2012) 2011 ACCF/AHA guideline for coronary artery bypass graft surgery: Executive summary. The Journal of Thoracic and Cardiovascular Surgery 143:1, 4-34
CrossRef11
Cassandra D. Benge, Brandon Markley, Michael Shawn McFarland. (2012) Role of Aggressive LDL Reduction in Patients With Coronary Heart Disease. Southern Medical Journal 105:1, 48-55
CrossRef12
Blas Gil-Extremera. (2012) Lipid Disorders in Elderly Hypertensive Patients. International Journal of Hypertension 2012, 1-3
CrossRef13
Zhijian Lu, Yi-heng Chen, Joann B. Napolitano, Gayle Taylor, Amjad Ali, Milton L. Hammond, Qiaolin Deng, Eugene Tan, Xinchun Tong, Suoyu S. Xu, Melanie J. Latham, Laurence B. Peterson, Matt S. Anderson, Suzanne S. Eveland, Qiu Guo, Sheryl A. Hyland, Denise P. Milot, Ying Chen, Carl P. Sparrow, Samuel D. Wright, Peter J. Sinclair. (2012) SAR studies on the central phenyl ring of substituted biphenyl oxazolidinone-potent CETP inhibitors. Bioorganic & Medicinal Chemistry Letters 22:1, 199-203
CrossRef14
Min Li, Gang Sun, Juan Ding, Li Li, Zhao-hui Peng, Xiang-sen Jiang. (2012) Risk Factors for Non-calcified Plaques in Asymptomatic Population. Academic Radiology
CrossRef15
Jamal S. Rana, S. Matthijs Boekholdt, John J. P. Kastelein, Prediman K. Shah. (2011) The Role of Non-HDL Cholesterol in Risk Stratification for Coronary Artery Disease. Current Atherosclerosis Reports
CrossRef16
The AIM-HIGH Investigators. (2011) Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy. New England Journal of Medicine 365:24, 2255-2267
Full Text17
Pravin Pratap, Sameer Gupta, Michael Berlowtiz. (2011) Routine Invasive Versus Conservative Management Strategies in Acute Coronary Syndrome: Time for a “Hybrid” Approach. Journal of Cardiovascular Translational Research
CrossRef18
(2011) How much of the world do you need for meaningful clinical trials? * Christmas Greetings 2011 * Book review: 'Cardiovascular catheterization and intervention' * A Textbook of Coronary, Peripheral, and Structural Heart Disease * The Brazilian Archives of Cardiology is the only cardiology journal in Latino America and the Southern hemisphere with an impact factor * The Mediterranean Diet, Part II * The TIMI story. European Heart Journal 32:24, 3057-3063
CrossRef19
Pascale M. Ohnsorg, Jean-Luc Mary, Lucia Rohrer, Michael Pech, Jürgen Fingerle, Arnold von Eckardstein. (2011) Trimerized apolipoprotein A-I (TripA) forms lipoproteins, activates lecithin:cholesterol acyltransferase, elicits lipid efflux, and is transported through aortic endothelial cells. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 1811:12, 1115-1123
CrossRef20
Rajesh Krishna, Daria Stypinski, Melissa Ali, Amit Garg, Isaias Noel Gendrano, Andrea Maes, Bruce DeGroot, Yang Liu, Susie Li, Sandra M. Connolly, John A. Wagner, S. Aubrey Stoch. (2011) Lack of an effect of anacetrapib on the pharmacokinetics of digoxin in healthy subjects. Biopharmaceutics & Drug Disposition 32:9, 525-529
CrossRef21
David Preiss, Naveed Sattar. (2011) Statins and the risk of new-onset diabetes. Current Opinion in Lipidology 22:6, 460-466
CrossRef22
Glenn N. Levine, Eric R. Bates, James C. Blankenship, Steven R. Bailey, John A. Bittl, Bojan Cercek, Charles E. Chambers, Stephen G. Ellis, Robert A. Guyton, Steven M. Hollenberg, Umesh N. Khot, Richard A. Lange, Laura Mauri, Roxana Mehran, Issam D. Moussa, Debabrata Mukherjee, Brahmajee K. Nallamothu, Henry H. Ting. (2011) 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary. Journal of the American College of Cardiology 58:24, 2550-2583
CrossRef23
A. Sicras-Mainar, J. Fernández de Bobadilla, R. Navarro-Artieda, I. Martín, C. Varela-Moreno. (2011) Morbimortalidad y consumo de recursos asociados tras síndrome coronario agudo en una población española. Revista Clínica Española 211:11, 560-571
CrossRef24
L. David Hillis, Peter K. Smith, Jeffrey L. Anderson, John A. Bittl, Charles R. Bridges, John G. Byrne, Joaquin E. Cigarroa, Verdi J. DiSesa, Loren F. Hiratzka, Adolph M. Hutter, Michael E. Jessen, Ellen C. Keeley, Stephen J. Lahey, Richard A. Lange, Martin J. London, Michael J. Mack, Manesh R. Patel, John D. Puskas, Joseph F. Sabik, Ola Selnes, David M. Shahian, Jeffrey C. Trost, Michael D. Winniford. (2011) 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: Executive Summary. Journal of the American College of Cardiology 58:24, 2584-2614
CrossRef25
S Schneeweiss, J J Gagne, R J Glynn, M Ruhl, J A Rassen. (2011) Assessing the Comparative Effectiveness of Newly Marketed Medications: Methodological Challenges and Implications for Drug Development. Clinical Pharmacology & Therapeutics 90:6, 777-790
CrossRef26
Joo-Yong Hahn, Hyun-Joong Kim, Yu Jeong Choi, Sang-Ho Jo, Hak Jin Kim, Sahng Lee, Kyoung-Ju Ahn, Young Bin Song, Jin-Ho Choi, Seung-Hyuk Choi, Young-Jin Choi, Kyung-Han Lee, Sang Hoon Lee, Hyeon-Cheol Gwon. (2011) Effects of atorvastatin pretreatment on infarct size in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. American Heart Journal 162:6, 1026-1033
CrossRef27
L. David Hillis, Peter K. Smith, Jeffrey L. Anderson, John A. Bittl, Charles R. Bridges, John G. Byrne, Joaquin E. Cigarroa, Verdi J. DiSesa, Loren F. Hiratzka, Adolph M. Hutter, Michael E. Jessen, Ellen C. Keeley, Stephen J. Lahey, Richard A. Lange, Martin J. London, Michael J. Mack, Manesh R. Patel, John D. Puskas, Joseph F. Sabik, Ola Selnes, David M. Shahian, Jeffrey C. Trost, Michael D. Winniford. (2011) 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. Journal of the American College of Cardiology 58:24, e123-e210
CrossRef28
Glenn N. Levine, Eric R. Bates, James C. Blankenship, Steven R. Bailey, John A. Bittl, Bojan Cercek, Charles E. Chambers, Stephen G. Ellis, Robert A. Guyton, Steven M. Hollenberg, Umesh N. Khot, Richard A. Lange, Laura Mauri, Roxana Mehran, Issam D. Moussa, Debabrata Mukherjee, Brahmajee K. Nallamothu, Henry H. Ting. (2011) 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. Journal of the American College of Cardiology 58:24, e44-e122
CrossRef29
Khalid El-Salem, Bashar Ababneh, Stacy Rudnicki, Ahmad Malkawi, Ali Alrefai, Yousef Khader, Ruba Saadeh, Mohammad Saydam. (2011) Prevalence and risk factors of muscle complications secondary to statins. Muscle & Nerve 44:6, 877-881
CrossRef30
Alexander Mauskop, William B. Borden. (2011) Predictors of Statin Adherence. Current Cardiology Reports 13:6, 553-558
CrossRef31
, C. W. Hamm, J.-P. Bassand, S. Agewall, J. Bax, E. Boersma, H. Bueno, P. Caso, D. Dudek, S. Gielen, K. Huber, M. Ohman, M. C. Petrie, F. Sonntag, M. S. Uva, R. F. Storey, W. Wijns, D. Zahger, , J. J. Bax, A. Auricchio, H. Baumgartner, C. Ceconi, V. Dean, C. Deaton, R. Fagard, C. Funck-Brentano, D. Hasdai, A. Hoes, J. Knuuti, P. Kolh, T. McDonagh, C. Moulin, D. Poldermans, B. A. Popescu, Z. Reiner, U. Sechtem, P. A. Sirnes, A. Torbicki, A. Vahanian, S. Windecker, , S. Windecker, S. Achenbach, L. Badimon, M. Bertrand, H. E. Botker, J.-P. Collet, F. Crea, N. Danchin, E. Falk, J. Goudevenos, D. Gulba, R. Hambrecht, J. Herrmann, A. Kastrati, K. Kjeldsen, S. D. Kristensen, P. Lancellotti, J. Mehilli, B. Merkely, G. Montalescot, F.-J. Neumann, L. Neyses, J. Perk, M. Roffi, F. Romeo, M. Ruda, E. Swahn, M. Valgimigli, C. J. Vrints, P. Widimsky. (2011) ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal 32:23, 2999-3054
CrossRef32
Philip Barter, Kerry-Anne Rye. (2011) Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: where are we now?. Trends in Pharmacological Sciences 32:12, 694-699
CrossRef33
Rodrigo Antonini Ribeiro, Patricia Klarmann Ziegelmann, Bruce Bartholow Duncan, Steffan Frosi Stella, José Luiz da Costa Vieira, Luciane Maria Fabian Restelatto, Emílio Hideyuki Moriguchi, Carisi Anne Polanczyk. (2011) Impact of statin dose on major cardiovascular events: A mixed treatment comparison meta-analysis involving more than 175,000 patients. International Journal of Cardiology
CrossRef34
Julio A. Carbayo Herencia. (2011) Nuevos marcadores de riesgo cardiovascular. ¿Pueden influir en la clasificación del riesgo cardiovascular?. Clínica e Investigación en Arteriosclerosis
CrossRef35
Ana Teresa Timóteo, Ruben Ramos, Alexandra Toste, Ana Lousinha, José Alberto Oliveira, Maria Lurdes Ferreira, Rui Cruz Ferreira. (2011) Impact of age on treatment and outcomes after acute myocardial infarction, particularly in very elderly patients. Revista Portuguesa de Cardiologia (English Edition)
CrossRef36
Uchechukwu K. Sampson, Sergio Fazio, MacRae F. Linton. (2011) Residual Cardiovascular Risk Despite Optimal LDL Cholesterol Reduction with Statins: The Evidence, Etiology, and Therapeutic Challenges. Current Atherosclerosis Reports
CrossRef37
Peter P Toth, Thomas D Dayspring. (2011) Drug safety evaluation of rosuvastatin. Expert Opinion on Drug Safety 10:6, 969-986
CrossRef38
Toktam Faghihi, Mania Radfar, Zohre Mehrabian, Amir Hoshang Ehsani, Mohsen Rezaei Hemami. (2011) Atorvastatin for the Treatment of Plaque-Type Psoriasis. Pharmacotherapy 31:11, 1045-1050
CrossRef39
Sidney C. Smith, Emelia J. Benjamin, Robert O. Bonow, Lynne T. Braun, Mark A. Creager, Barry A. Franklin, Raymond J. Gibbons, Scott M. Grundy, Loren F. Hiratzka, Daniel W. Jones, Donald M. Lloyd-Jones, Margo Minissian, Lori Mosca, Eric D. Peterson, Ralph L. Sacco, John Spertus, James H. Stein, Kathryn A. Taubert. (2011) AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update. Journal of the American College of Cardiology 58:23, 2432-2446
CrossRef40
Vincent E. Friedewald, William E. Boden, Gregg W. Stone, Clyde W. Yancy, William C. Roberts. (2011) The Editor's Roundtable: Role of Percutaneous Coronary Intervention and Drug-Eluting Stents in Patients With Stable Coronary Heart Disease. The American Journal of Cardiology 108:10, 1417-1425
CrossRef41
Stephen D. Wiviott, Willibald Hochholzer. (2011) On-Clopidogrel Platelet Reactivity. Journal of the American College of Cardiology 58:19, 1955-1957
CrossRef42
Yasushi Saito. (2011) Pitavastatin: An overview. Atherosclerosis Supplements 12:3, 271-276
CrossRef43
Philip Barter. (2011) Introduction. Atherosclerosis Supplements 12:3, 265-266
CrossRef44
Ana Teresa Timóteo, Ruben Ramos, Alexandra Toste, Ana Lousinha, José Alberto Oliveira, Maria Lurdes Ferreira, Rui Cruz Ferreira. (2011) Impacto da idade no tratamento e resultados após enfarte agudo do miocárdio em particular nos muito idosos. Revista Portuguesa de Cardiologia
CrossRef45
I. Lazich, P. Sarafidis, E. de Guzman, A. Patel, R. Oliva, G. Bakris. (2011) Effects of combining simvastatin with rosiglitazone on inflammation, oxidant stress and ambulatory blood pressure in patients with the metabolic syndrome: the SIROCO study. Diabetes, Obesity and Metabolismno-no
CrossRef46
Hector M. Garcia-Garcia, Scot Garg, Salvatore Brugaletta, Roberto Diletti, Eun-Seok Shin, Patrick W. Serruys. 2011. Research Utility of Intravascular Ultrasound. , 109-136.
CrossRef47
P. S. Sever, C. L. Chang, A. K. Gupta, A. Whitehouse, N. R. Poulter, . (2011) The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the UK. European Heart Journal 32:20, 2525-2532
CrossRef48
Ryan P. Morrissey, George A. Diamond, Sanjay Kaul. (2011) The JUPITER Trial: Myth or Reality?. Current Atherosclerosis Reports 13:5, 413-421
CrossRef49
Saeko Takahashi, Michail I. Papafaklis, Shingo Sakamoto, Antonios P. Antoniadis, Ahmet U. Coskun, Charles L. Feldman, Peter H. Stone. (2011) The effect of statins on high-risk atherosclerotic plaque associated with low endothelial shear stress. Current Opinion in Lipidology 22:5, 358-364
CrossRef50
Alexander Kulik, Pierre Voisine, Patrick Mathieu, Roy G. Masters, Thierry G. Mesana, Michel R. Le May, Marc Ruel. (2011) Statin Therapy and Saphenous Vein Graft Disease After Coronary Bypass Surgery: Analysis From the CASCADE Randomized Trial. The Annals of Thoracic Surgery 92:4, 1284-1291
CrossRef51
Michael Grabner, Wallace Johnson, Abdulla M. Abdulhalim, Andreas Kuznik, C. Daniel Mullins. (2011) The Value of Atorvastatin Over the Product Life Cycle in the United States. Clinical Therapeutics 33:10, 1433-1443
CrossRef52
Ki Hong Lee, Myung Ho Jeong, Ha Mi Kim, Youngkeun Ahn, Jong Hyun Kim, Shung Chull Chae, Young Jo Kim, Seung Ho Hur, In Whan Seong, Taek Jong Hong, Dong Hoon Choi, Myeong Chan Cho, Chong Jin Kim, Ki Bae Seung, Wook Sung Chung, Yang Soo Jang, Seung Woon Rha, Jang Ho Bae, Jeong Gwan Cho, Seung Jung Park. (2011) Benefit of Early Statin Therapy in Patients With Acute Myocardial Infarction Who Have Extremely Low Low-Density Lipoprotein Cholesterol. Journal of the American College of Cardiology 58:16, 1664-1671
CrossRef53
Diego Vanuzzo. (2011) The epidemiological concept of residual risk. Internal and Emergency Medicine 6:S1, 45-51
CrossRef54
Rowan Flynn, Kun Qian, Chongren Tang, Nagadhara Dronadula, Joshua M Buckler, Bo Jiang, Shan Wen, Helén L Dichek, David A Dichek. (2011) Expression of Apolipoprotein A-I in Rabbit Carotid Endothelium Protects Against Atherosclerosis. Molecular Therapy 19:10, 1833-1841
CrossRef55
Alberto Zambon. (2011) Residual cardiovascular risk in secondary prevention. Internal and Emergency Medicine 6:S1, 61-68
CrossRef56
Aung K Sett, Tom G Robinson, Amit K Mistri. (2011) Current status of statin therapy for stroke prevention. Expert Review of Cardiovascular Therapy 9:10, 1305-1314
CrossRef57
Zahi A Fayad, Venkatesh Mani, Mark Woodward, David Kallend, Markus Abt, Tracy Burgess, Valentin Fuster, Christie M Ballantyne, Evan A Stein, Jean-Claude Tardif, James H F Rudd, Michael E Farkouh, Ahmed Tawakol. (2011) Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. The Lancet 378:9802, 1547-1559
CrossRef58
Jennifer B. Christian, Nancy E. Bourgeois, Kimberly A. Lowe. (2011) Prevalence, clinical characteristics and treatment patterns of low high-density lipoprotein cholesterol in the US population. Journal of Cardiovascular Medicine 12:10, 714-722
CrossRef59
Nivee P. Amin, Michael J. Blaha, Grant V. Chow, Roger S. Blumenthal, Dominique Ashen. (2011) Comprehensive Lipid Management in the Coronary Artery Disease Patient. Current Cardiovascular Risk Reports 5:5, 399-406
CrossRef60
Karen E. Porter, Neil A. Turner. (2011) Statins and myocardial remodelling: cell and molecular pathways. Expert Reviews in Molecular Medicine 13,
CrossRef61
Jeffrey C. Trost, Richard A. Lange. (2011) Treatment of acute coronary syndrome: Part 1: Non-ST-segment acute coronary syndrome. Critical Care Medicine 39:10, 2346-2353
CrossRef62
Jennifer R. Shiu, Glen J. Pearson, Theresa L. Charrois, Gabor Gyenes, Sheri L. Koshman. (2011) Frequency of Intensive Statin Therapy in Patients With Acute Coronary Syndrome Admitted to a Tertiary Care Center. The American Journal of Cardiology
CrossRef63
Hyo-Bum Kwak, Anna Thalacker-Mercer, Ethan J. Anderson, Chien-Te Lin, Daniel A. Kane, Nam-Sihk Lee, Ronald N. Cortright, Marcas M. Bamman, P. Darrell Neufer. (2011) Simvastatin impairs ADP-stimulated respiration and increases mitochondrial oxidative stress in primary human skeletal myotubes. Free Radical Biology and Medicine
CrossRef64
E. Braunwald. (2011) Creating controversy where none exists: the important role of C-reactive protein in the CARE, AFCAPS/TexCAPS, PROVE IT, REVERSAL, A to Z, JUPITER, HEART PROTECTION, and ASCOT trials. European Heart Journal
CrossRef65
A I Kanaki, P A Sarafidis, P I Georgianos, P C Stafylas, K Kanavos, I M Tziolas, A N Lasaridis. (2011) Low-dose atorvastatin reduces ambulatory blood pressure in patients with mild hypertension and hypercholesterolaemia: a double-blind, randomized, placebo-controlled study. Journal of Human Hypertension
CrossRef66
Michael H. Davidson, Christie M. Ballantyne, Terry A. Jacobson, Vera A. Bittner, Lynne T. Braun, Alan S. Brown, W.Virgil Brown, William C. Cromwell, Ronald B. Goldberg, James M. McKenney, Alan T. Remaley, Allan D. Sniderman, Peter P. Toth, Sotirios Tsimikas, Paul E. Ziajka, Kevin C. Maki, Mary R. Dicklin. (2011) Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists. Journal of Clinical Lipidology 5:5, 338-367
CrossRef67
Liang Fang, Zheng Su. (2011) A hybrid approach to predicting events in clinical trials with time-to-event outcomes. Contemporary Clinical Trials 32:5, 755-759
CrossRef68
Teresa Padró, Maisa García-Arguinzonis, Lina Badimon. (2011) Effects of rosuvastatin on the coordinated proteomic response of human coronary smooth muscle cells to low density lipoproteins. Clínica e Investigación en Arteriosclerosis 23:5, 191-200
CrossRef69
Jesús Millán Núñez-Cortés, Juan Pedro-Botet Montoya, Xavier Pintó Sala. (2011) Riesgo residual vascular de origen lipídico. Estrategias para el tratamiento del riesgo residual por dislipidemia aterogénica. Clínica e Investigación en Arteriosclerosis 23:5, 230-239
CrossRef70
Nageswara Rao Pilli, Ramesh Mullangi, Jaswanth Kuamr Inamadugu, Indira Kumari Nallapati, J. V. L. N Seshagiri Rao. (2011) Simultaneous determination of simvastatin, lovastatin and niacin in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. Biomedical Chromatographyn/a-n/a
CrossRef71
D. K. Y. Chan, F. O’Rourke, Q. Shen, J. C. S. Mak, W. T. Hung. (2011) Meta-analysis of the cardiovascular benefits of intensive lipid lowering with statins. Acta Neurologica Scandinavica 124:3, 188-195
CrossRef72
Mayurkumar D Bhakta, Farouk Mookadam, Susan Wilansky. (2011) Cardiovascular disease in women. Future Cardiology 7:5, 613-627
CrossRef73
Jonathan R. Murrow, Salman Sher, Sarfraz Ali, Irina Uphoff, Riyaz Patel, Marcus Porkert, Ngoc-Anh Le, Dean Jones, Arshed A. Quyyumi. (2011) The differential effect of statins on oxidative stress and endothelial function: Atorvastatin versus pravastatin. Journal of Clinical Lipidology
CrossRef74
Philip Joseph, Koon Teo. (2011) Optimal Medical Therapy, Lifestyle Intervention, and Secondary Prevention Strategies for Cardiovascular Event Reduction in Ischemic Heart Disease. Current Cardiology Reports 13:4, 287-295
CrossRef75
Sergio Martinez-Hervas, Rafael Carmena, Juan F Ascaso. (2011) Significance of LDL-C lowering therapy in diabetic patients. Clinical Lipidology 6:4, 389-399
CrossRef76
Chang Hee Kwon, Byung Jin Kim, Bum Soo Kim, Jin Ho Kang. (2011) Low-density lipoprotein cholesterol to apolipoprotein B ratio is independently associated with metabolic syndrome in Korean men. Metabolism 60:8, 1136-1141
CrossRef77
Laurie L. Yee, Eric A. Wright. (2011) Pitavastatin Calcium: Clinical Review of a New Antihyperlipidemic Medication. Clinical Therapeutics 33:8, 1023-1042
CrossRef78
J.-D. R. Schwalm, S. Yusuf. (2011) Commentary: 'The end of clinical freedom': relevance in the era of evidence-based medicine. International Journal of Epidemiology 40:4, 855-858
CrossRef79
Anetta Undas, Andrzej Machnik, Daniel P Potaczek, Ewa Wypasek, Krzysztof Zmudka, Wieslawa Tracz. (2011) Ezetimibe Combined With Simvastatin Compared With Simvastatin Alone Results in a Greater Suppression of Oxidative Stress and Enhanced Fibrinolysis in Patients After Acute Coronary Events. Journal of Cardiovascular Pharmacology 58:2, 167-172
CrossRef80
P. S. Sever, N. R. Poulter, C. L. Chang, A. Hingorani, S. A. Thom, A. D. Hughes, P. Welsh, N. Sattar, . (2011) Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial. European Heart Journal
CrossRef81
Ana Jover, Emili Corbella, Anna Muñoz, Jesús Millán, Xavier Pintó, Alipio Mangas, Manuel Zúñiga, Juan Pedro-Botet, Antonio Hernández-Mijares. (2011) Prevalence of Metabolic Syndrome and its Components in Patients With Acute Coronary Syndrome. Revista Española de Cardiología (English Edition) 64:7, 579-586
CrossRef82
Edward O. McFalls, Greg Larsen, Gary R. Johnson, Fred S. Apple, Steven Goldman, Andrew Arai, Brahmajee K. Nallamothu, Robert Jesse, Scott T. Holmstrom, Patricia L. Sinnott. (2011) Outcomes of Hospitalized Patients with Non-Acute Coronary Syndrome and Elevated Cardiac Troponin Level. The American Journal of Medicine 124:7, 630-635
CrossRef83
Ana Jover, Emili Corbella, Anna Muñoz, Jesús Millán, Xavier Pintó, Alipio Mangas, Manuel Zúñiga, Juan Pedro-Botet, Antonio Hernández-Mijares. (2011) Prevalencia del síndrome metabólico y de sus componentes en pacientes con síndrome coronario agudo. Revista Española de Cardiología 64:7, 579-586
CrossRef84
Updesh Bedi, Mukesh Singh, Param Singh, Janos Molnar, Sandeep Khosla, Rohit Arora. (2011) Effects of Statins on Progression of Coronary Artery Disease as Measured by Intravascular Ultrasound. The Journal of Clinical Hypertension 13:7, 492-496
CrossRef85
Elmar W. Kuhn, Oliver J. Liakopoulos, Yeong H. Choi, Thorsten Wahlers. (2011) Current Evidence for Perioperative Statins in Cardiac Surgery. The Annals of Thoracic Surgery 92:1, 372-379
CrossRef86
Loukianos S Rallidis, Christos Kotakos, Vassilios Sourides, Christos Varounis, Athanasios Charalampopoulos, Maria Zolindaki, Nikolaos Dagres, Costas Papadopoulos, Maria Anastasiou-Nana. (2011) Attainment of optional low-density lipoprotein cholesterol goal of less than 70 mg/dl and impact on prognosis of very high risk stable coronary patients: a 3-year follow-up. Expert Opinion on Pharmacotherapy 12:10, 1481-1489
CrossRef87
Vimal Ramjee, Laurence S. Sperling, Terry A. Jacobson. (2011) Non–High-Density Lipoprotein Cholesterol Versus Apolipoprotein B in Cardiovascular Risk Stratification. Journal of the American College of Cardiology 58:5, 457-463
CrossRef88
Noah Vale, Alain J Nordmann, Gregory G Schwartz, James de Lemos, Furio Colivicchi, Frank den Hartog, Petr Ostadal, Stella M Macin, Anho H Liem, Edward Mills, Neera Bhatnagar, Heiner C Bucher, Matthias Briel, Matthias Briel. 2011. Statins for acute coronary syndrome. .
CrossRef89
Yuji Takahashi, Mamoru Satoh, Tsuyoshi Tabuchi, Motoyuki Nakamura. (2011) Prospective, randomized, single-blind comparison of effects of 6 months' treatment with atorvastatin versus pravastatin on leptin and angiogenic factors in patients with coronary artery disease. Heart and Vessels
CrossRef90
B. Nazer, K. K. Ray, S. Sloan, B. Scirica, D. A. Morrow, C. P. Cannon, E. Braunwald. (2011) Prognostic utility of neopterin and risk of heart failure hospitalization after an acute coronary syndrome. European Heart Journal 32:11, 1390-1397
CrossRef91
E. J. Mills, C. O'Regan, O. Eyawo, P. Wu, F. Mills, O. Berwanger, M. Briel. (2011) Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta-analysis of >40 000 patients. European Heart Journal 32:11, 1409-1415
CrossRef92
Stephen J. Nicholls, Marilyn Borgman, Steven E. Nissen, Joel S. Raichlen, Christie Ballantyne, Philip Barter, M. John Chapman, Raimund Erbel, Peter Libby. (2011) Impact of statins on progression of atherosclerosis: rationale and design of SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: Effect of Rosuvastatin versus AtorvastatiN). Current Medical Research and Opinion 27:6, 1119-1129
CrossRef93
Jean-Pierre Déry. (2011) Controlling lipids after acute coronary syndromes: what is the best strategy?. Clinical Lipidology 6:3, 253-255
CrossRef94
Sean R. Wilson, Marc S. Sabatine, Stephen D. Wiviott, Kausik K. Ray, James A. De Lemos, Shanggen Zhou, Nader Rifai, Christopher P. Cannon, David A. Morrow. (2011) Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: Observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial–Thrombolysis in Myocardial Infarction 22 (PROVE IT–TIMI 22). American Heart Journal 161:6, 1147-1155.e1
CrossRef95
G.P. Carnevale Schianca, R. Pedrazzoli, S. Onolfo, E. Colli, E. Cornetti, L. Bergamasco, G.P. Fra, E. Bartoli. (2011) ApoB/apoA-I ratio is better than LDL-C in detecting cardiovascular risk. Nutrition, Metabolism and Cardiovascular Diseases 21:6, 406-411
CrossRef96
Therese M Heinonen, Donald M Black. (2011) New considerations in the design of clinical trials for anti-atherosclerotic drugs. Clinical Investigation 1:6, 795-803
CrossRef97
Chang-Wook Nam, Seung-Ho Hur, Yun-Kyeong Cho, Hyoung-Seob Park, Hyuck-Jun Yoon, Hyungseop Kim, In-Sung Chung, Yoon-Nyun Kim, Kwon-Bae Kim, Joon-Hyung Doh, Bon-Kwon Koo, Seung-Jea Tahk, William F. Fearon. (2011) Relation of Fractional Flow Reserve After Drug-Eluting Stent Implantation to One-Year Outcomes. The American Journal of Cardiology 107:12, 1763-1767
CrossRef98
Carlos G. Santos-Gallego, Chiara Giannarelli, Juan José Badimón. (2011) Experimental Models for the Investigation of High-Density Lipoprotein–Mediated Cholesterol Efflux. Current Atherosclerosis Reports 13:3, 266-276
CrossRef99
Tarek AN Ahmed, Ioannis Karalis, J Wouter Jukema. (2011) Emerging drugs for coronary artery disease. From past achievements and current needs to clinical promises. Expert Opinion on Emerging Drugs 16:2, 203-233
CrossRef100
Gissette Reyes-Soffer, Carlos Rondon-Clavo, Henry N Ginsberg. (2011) Combination therapy with statin and fibrate in patients with dyslipidemia associated with insulin resistance, metabolic syndrome and type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy 12:9, 1429-1438
CrossRef101
Paulus Kirchhof, Larissa Fabritz. (2011) High-Density Lipoprotein Shortens the Ventricular Action Potential. Journal of the American College of Cardiology 58:1, 45-47
CrossRef102
M. Noutsias, B. Maisch. (2011) Treatment of cardiovascular diseases in cancer patients. Herz 36:4, 340-345
CrossRef103
Ankur Rohilla, Seema Rohilla, Ashok Kumar, M.U. Khan, Aakash Deep. (2011) Pleiotropic effects of statins: A boulevard to cardioprotection. Arabian Journal of Chemistry
CrossRef104
Cheng-cheng YI, WEN-wen LIU, Ying-qiu ZHANG, Zhi-jun GUO, Xiang-yun WANG, Zhi-zhong YUAN, Chang-lin ZHOU, Ren-fu YIN. (2011) Relationship of low- and high-density lipoprotein cholesterol with atherosclerosis. Academic Journal of Second Military Medical University 31:2, 224-226
CrossRef105
Peter Libby, Paul M Ridker, Göran K. Hansson. (2011) Progress and challenges in translating the biology of atherosclerosis. Nature 473:7347, 317-325
CrossRef106
Israel F. Charo, Rebecca Taub. (2011) Anti-inflammatory therapeutics for the treatment of atherosclerosis. Nature Reviews Drug Discovery 10:5, 365-376
CrossRef107
R. Scott Wright, Jeffrey L. Anderson, Cynthia D. Adams, Charles R. Bridges, Donald E. Casey, Steven M. Ettinger, Francis M. Fesmire, Theodore G. Ganiats, Hani Jneid, A. Michael Lincoff, Eric D. Peterson, George J. Philippides, Pierre Theroux, Nanette K. Wenger, James Patrick Zidar. (2011) 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology 57:19, e215-e367
CrossRef108
D. John Betteridge. (2011) Lipid control in patients with diabetes mellitus. Nature Reviews Cardiology 8:5, 278-290
CrossRef109
Jeffrey S. Berger, Christie M. Ballantyne, Michael H. Davidson, Joel L. Johnson, Elizabeth A. Tarka, Denise Lawrence, Trupti Trivedi, Andrew Zalewski, Emile R. Mohler. (2011) Peripheral artery disease, biomarkers, and darapladib. American Heart Journal 161:5, 972-978
CrossRef110
Shao Hong, -Quan Chen Li, Xu Jun. (2011) Treatment of dyslipidemia in the elderly. Journal of Geriatric Cardiology 8:1, 55-64
CrossRef111
Areli Gutiérrez-Pérez, Christian Cortés-Rojo, Ruth Noriega-Cisneros, Elizabeth Calderón-Cortés, Salvador Manzo-Avalos, Mónica Clemente-Guerrero, Daniel Godínez-Hernández, Istvan Boldogh, Alfredo Saavedra-Molina. (2011) Protective effects of resveratrol on calcium-induced oxidative stress in rat heart mitochondria. Journal of Bioenergetics and Biomembranes 43:2, 101-107
CrossRef112
D. S. H. Bell, F. Al Badarin, J. H. O’Keefe. (2011) Therapies for diabetic dyslipidaemia. Diabetes, Obesity and Metabolism 13:4, 313-325
CrossRef113
Amanda N. Long, Samuel Dagogo-Jack. (2011) Comorbidities of Diabetes and Hypertension: Mechanisms and Approach to Target Organ Protection. The Journal of Clinical Hypertension 13:4, 244-251
CrossRef114
M. Hartmann, J. Huisman, D. Bose, L. O. Jensen, P. Schoenhagen, G. S. Mintz, R. Erbel, C. von Birgelen. (2011) Serial intravascular ultrasound assessment of changes in coronary atherosclerotic plaque dimensions and composition: an update. European Journal of Echocardiography 12:4, 313-321
CrossRef115
Vimal Ramjee, Terry A Jacobson. (2011) Intensifying statin therapy to maximize cardiovascular risk reduction: is 50 the new 70? Goals are getting old. Clinical Lipidology 6:2, 131-136
CrossRef116
Anselm K. Gitt, Claus Jünger, Christina Jannowitz, Barbara Karmann, Jochen Senges, Kurt Bestehorn. (2011) Adherence of hospital-based cardiologists to lipid guidelines in patients at high risk for cardiovascular events (2L registry). Clinical Research in Cardiology 100:4, 277-287
CrossRef117
Carlos G Santos-Gallego, Francisco Torres, Juan José Badimón. (2011) The beneficial effects of HDL-C on atherosclerosis: rationale and clinical results. Clinical Lipidology 6:2, 181-208
CrossRef118
Ibrahim Al-Zakwani, Kadhim Sulaiman, Khalid Al-Rasadi, Dimitri P. Mikhailidis. (2011) Prevalence of low high-density lipoprotein cholesterol (HDL-C) as a marker of residual cardiovascular risk among acute coronary syndrome patients from Oman. Current Medical Research and Opinion 27:4, 879-885
CrossRef119
Alejandro de la Sierra, Eduardo Alegría, Alberto Martínez-Castelao, Carlos Morillas, Diego González-Segura. (2011) Características de los pacientes con hipertensión y síndrome metabólico atendidos por diferentes especialistas. Medicina Clínica
CrossRef120
Shlomi Matetzky, Paul Fefer, Boris Shenkman, Michael Shechter, Ilia Novikov, Naphtali Savion, David Varon, Hanoch Hod. (2011) Statins have an early antiplatelet effect in patients with acute myocardial infarction. Platelets 22:2, 103-110
CrossRef121
(2011) The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol. American Heart Journal 161:3, 471-477.e2
CrossRef122
Anne Holbrook, Mitchell Wright, Melani Sung, Christine Ribic, Steven Baker. (2011) Statin-Associated Rhabdomyolysis: Is There a Dose-Response Relationship?. Canadian Journal of Cardiology 27:2, 146-151
CrossRef123
Leonidas Duntas, Genovefa Kolovou. (2011) Options for the treatment of hyperlipidemia in Type 2 diabetes mellitus and hypothyroidism: lowering the cardiovascular risk. Future Cardiology 7:2, 137-144
CrossRef124
Inge De Meyer, Wim Martinet, Cor E Van Hove, Dorien M Schrijvers, Vicky Y Hoymans, Luc Van Vaeck, Paul Fransen, Hidde Bult, Guido RY De Meyer. (2011) Inhibition of inositol monophosphatase by lithium chloride induces selective macrophage apoptosis in atherosclerotic plaques. British Journal of Pharmacology 162:6, 1410-1423
CrossRef125
D. Allan Butterfield. (2011) Atorvastatin and Aβ(1–40): Not as Simple as Cholesterol Reduction in Brain and Relevance to Alzheimer Disease. Experimental Neurology 228:1, 15-18
CrossRef126
Kenneth J. Colley, Robert L. Wolfert, Michael E. Cobble. (2011) Lipoprotein associated phospholipase A2: role in atherosclerosis and utility as a biomarker for cardiovascular risk. The EPMA Journal 2:1, 27-38
CrossRef127
Ariel Brautbar, Christie M. Ballantyne. (2011) Pharmacological strategies for lowering LDL cholesterol: statins and beyond. Nature Reviews Cardiology
CrossRef128
Michael Clearfield. (2011) Statins in Combinations: From ARBITER-6 HALTS to ACCORD—What Works?. Current Atherosclerosis Reports 13:1, 4-8
CrossRef129
C. L. Meek, J. D. Reston, T. Ramsbottom, H. Pathmanathan, A. Viljoen. (2011) Use of high-intensity statin therapy with simvastatin 80 mg and atorvastatin 80 mg in primary care. International Journal of Clinical Practice 65:2, 120-126
CrossRef130
Usman Javed, Prakash C. Deedwania, Deepak L. Bhatt, Christopher P. Cannon, David Dai, Adrian F. Hernandez, Eric D. Peterson, Gregg C. Fonarow. (2011) Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: An analysis of 65,396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG). American Heart Journal 161:2, 418-424.e3
CrossRef131
Antonio Eduardo P. Pesaro, Carlos V. Serrano, Juliano L. Fernandes, Alexandre B. Cavalcanti, Alexandre H. Campos, Herlon S. Martins, Raul C. Maranhão, James A. de Lemos, Heraldo P. Souza, José C. Nicolau. (2011) Pleiotropic effects of ezetimibe/simvastatin vs. high dose simvastatin. International Journal of Cardiology
CrossRef132
Howard S. Friedman, Srinivasan Rajagopalan, Jaime P. Barnes, Hal Roseman. (2011) Combination Therapy With Ezetimibe/Simvastatin Versus Statin Monotherapy for Low-Density Lipoprotein Cholesterol Reduction and Goal Attainment in a Real-World Clinical Setting. Clinical Therapeutics 33:2, 212-224
CrossRef133
A. G. Semb, I. Holme, T. K. Kvien, T. R. Pedersen. (2011) Intensive lipid lowering in patients with rheumatoid arthritis and previous myocardial infarction: an explorative analysis from the incremental decrease in endpoints through aggressive lipid lowering (IDEAL) trial. Rheumatology 50:2, 324-329
CrossRef134
Yasuhiro Izumiya, Sunao Kojima, Shinobu Kojima, Satoshi Araki, Hiroki Usuku, Junichi Matsubara, Kenji Sakamoto, Kenichi Tsujita, Yasuhiro Nagayoshi, Koichi Kaikita, Seigo Sugiyama, Hisao Ogawa. (2011) Long-term use of oral nicorandil stabilizes coronary plaque in patients with stable angina pectoris. Atherosclerosis 214:2, 415-421
CrossRef135
Rai Ajit K. Srivastava, Shirley He, Roger S. Newton. (2011) Differential regulation of human apolipoprotein AI and high-density lipoprotein by fenofibrate in hapoAI and hapoAI–CIII–AIV transgenic mice. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 1811:2, 76-83
CrossRef136
Stone, Gregg W., Maehara, Akiko, Lansky, Alexandra J., de Bruyne, Bernard, Cristea, Ecaterina, Mintz, Gary S., Mehran, Roxana, McPherson, John, Farhat, Naim, Marso, Steven P., Parise, Helen, Templin, Barry, White, Roseann, Zhang, Zhen, Serruys, Patrick W., . (2011) A Prospective Natural-History Study of Coronary Atherosclerosis. New England Journal of Medicine 364:3, 226-235
Full Text137
Yonghong Li, Marc S. Sabatine, Carmen H. Tong, Ian Ford, Todd G. Kirchgessner, Christopher J. Packard, Michele Robertson, Charles M. Rowland, Lance A. Bare, James Shepherd, James J. Devlin, Olga A. Iakoubova. (2011) Genetic variants in the KIF6 region and coronary event reduction from statin therapy. Human Genetics 129:1, 17-23
CrossRef138
Jesús Millán Núñez-Cortés, Juan Pedro-Botet Montoya, Xavier Pintó Salas, Antonio Hernández Mijares, Vincent J. Carey, Michel P. Hermans, Frank M. Sacks, Jean-Charles Fruchart. (2011) The REALIST (REsiduAl risk, LIpids and Standard Therapies) study: an analysis of residual risk attributable to lipid profile in acute coronary syndrome. Endocrinología y Nutrición (English Edition) 58:1, 38-47
CrossRef139
William L. Baker, Rupangi Datta. (2011) Pitavastatin: a New 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor for the treatment of hyperlipidemia. Advances in Therapy 28:1, 13-27
CrossRef140
A. Mekontso Dessap. (2011) Nouvelles pistes dans le traitement du sepsis — Place des statines. Réanimation 20:S2, 437-440
CrossRef141
Yoshiaki Kawagoe, Yoshiyuki Hattori, Ayuko Nakano, Chie Aoki, Seiichi Tanaka, Satoshi Ohta, Toshie Iijima, Atsuko Tomizawa, Teruo Jojima, Hiroyuki Kase, Kikuo Kasai. (2011) Comparative study between high-dose fluvastatin and low-dose fluvastatin and ezetimibe with regard to the effect on endothelial function in diabetic patients. Endocrine Journal 58:3, 171-175
CrossRef142
Takahide Kohro, Tsutomu Yamazaki, Tohru Izumi, Hiroyuki Daida, Masahiko Kurabayashi, Katsumi Miyauchi, Taiki Tojo, Ryozo Nagai, JCADII Investigators. (2011) Intensively Lowering Both Low-Density Lipoprotein Cholesterol and Blood Pressure Does Not Reduce Cardiovascular Risk in Japanese Coronary Artery Disease Patients. Circulation Journal 75:9, 2062-2070
CrossRef143
Tomotaka Dohi, Katsumi Miyauchi, Shinya Okazaki, Takayuki Yokoyama, Naotake Yanagisawa, Hiroshi Tamura, Takahiko Kojima, Ken Yokoyama, Takeshi Kurata, Hiroyuki Daida. (2011) Higher Baseline LDL-C Levels Amplify the Short-Term Benefit of Early Intensive Statin Treatment in Acute Coronary Syndrome. Journal of Atherosclerosis and Thrombosis 18:1, 42-48
CrossRef144
Simran D.S. Maggo, Martin A. Kennedy, David W.J. Clark. (2011) Clinical Implications of Pharmacogenetic Variation on the Effects of Statins. Drug Safety 34:1, 1-19
CrossRef145
Yasuki Kihara. (2011) After the Triumph of Cardiovascular Medicine Over Acute Myocardial Infarction at the End of the 20th Century. Circulation Journal 75:8, 2019-2026
CrossRef146
Peng Liu, Jie Jiang, Jianping Li, Tao Hong, Yan Zhang, Ronghui Yu, Jia Jia, Yong Huo. (2011) Intensive statin therapy for Chinese patients with coronary artery disease undergoing percutaneous coronary intervention (ISCAP study). Catheterization and Cardiovascular Interventionsn/a-n/a
CrossRef147
Xian-Zhi He, Sheng-Hua Zhou, Xin-Hong Wan, Hai-Yu Wang, Qing-Hua Zhong, Jian-Fang Xue. (2011) The Effect of Early and Intensive Statin Therapy on Ventricular Premature Beat or Nonsustained Ventricular Tachycardia in Patients With Acute Coronary Syndrome. Clinical Cardiology 34:1, 59-63
CrossRef148
T. A. Jacobson. (2011) ‘Trig-onometry’: non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia. International Journal of Clinical Practice 65:1, 82-101
CrossRef149
Takao Maruyama, Masanori Takada, Yoshiharu Nishibori, Kouichi Fujita, Koujirou Miki, Shigeki Masuda, Tetsuo Horimatsu, Toshiaki Hasuike. (2011) Comparison of Preventive Effect on Cardiovascular Events With Different Statins. Circulation Journal 75:8, 1951-1959
CrossRef150
Finn Akerström, Luis Rodríguez-Padial. (2011) The IMPROVE-IT trial: current status and potential clinical implications of ezetimibe. Clinical Investigation 1:1, 137-144
CrossRef151
Min Chul Kim, Youngkeun Ahn, Kyung Hun Cho, Min Goo Lee, Jum Suk Ko, Keun Ho Park, Doo Sun Sim, Nam Sik Yoon, Hyun Ju Yoon, Kye Hun Kim, Young Joon Hong, Hyung Wook Park, Ju Han Kim, Myung Ho Jeong, Jeong Gwan Cho, Jong Chun Park, Jung Chaee Kang. (2011) Early Statin Therapy Within 48 Hours Decreased One-Year Major Adverse Cardiac Events in Patients With Acute Myocardial Infarction. International Heart Journal 52:1, 1-6
CrossRef152
Yasuhiko Sakata. (2011) Is "Strict" Conventional Therapy Enough for the Treatment of Coronary Artery Disease?. Circulation Journal 75:9, 2046-2047
CrossRef153
S. Ylä-Herttuala, J. F. Bentzon, M. Daemen, E. Falk, H. M. Garcia-Garcia, J. Herrmann, I. Hoefer, J. W. Jukema, R. Krams, B. R. Kwak, N. Marx, M. Naruszewicz, A. Newby, G. Pasterkamp, P. W. J. C. Serruys, J. Waltenberger, C. Weber, L. Tokgözoglu. (2011) Stabilisation of atherosclerotic plaques. Thrombosis and Haemostasis 106:1, 1-19
CrossRef154
Enrique C. Morales-Villegas, Germano Di Sciascio, Carlo Briguori. (2011) Statins: Cardiovascular Risk Reduction in Percutaneous Coronary Intervention—Basic and Clinical Evidence of Hyperacute Use of Statins. International Journal of Hypertension 2011, 1-12
CrossRef155
Victor L. Serebruany. (2011) Extreme All-Cause Mortality in JUPITER Requires Reexamination of Vital Records. Cardiology 120:2, 84-88
CrossRef156
Lina Badimon, Gemma Vilahur. (2011) Beneficio clínico de las estatinas: ¿hemos cubierto todo el espectro?. Revista Española de Cardiología Suplementos 11, 3-13
CrossRef157
Glenn N. Levine, Eric R. Bates, James C. Blankenship, Steven R. Bailey, John A. Bittl, Bojan Cercek, Charles E. Chambers, Stephen G. Ellis, Robert A. Guyton, Steven M. Hollenberg, Umesh N. Khot, Richard A. Lange, Laura Mauri, Roxana Mehran, Issam D. Moussa, Debabrata Mukherjee, Brahmajee K. Nallamothu, Henry H. Ting, Alice K. Jacobs, Jeffrey L. Anderson, Nancy Albert, Mark A. Creager, Steven M. Ettinger, Robert A. Guyton, Jonathan L. Halperin, Judith S. Hochman, Frederick G. Kushner, E. Magnus Ohman, William Stevenson, Clyde W. Yancy. (2011) 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. Catheterization and Cardiovascular Interventionsn/a-n/a
CrossRef158
Jang Hoon Lee, Sun Hee Park, Dong Heon Yang, Hun Sik Park, Yongkeun Cho, Won Kee Lee, Myung Ho Jeong, Young Jo Kim, Jae Eun Jun, Shung Chull Chae, . (2011) Threshold Level of Low-Density Lipoprotein Cholesterol for the Short-Term Benefit of Statin Therapy in the Acute Phase of Myocardial Infarction. Clinical Cardiologyn/a-n/a
CrossRef159
Christoph Wanner, Vera Krane. (2011) Recent Advances in the Treatment of Atherogenic Dyslipidemia in Type 2 Diabetes Mellitus. Kidney and Blood Pressure Research 34:4, 209-217
CrossRef160
Young Joon Hong, Myung Ho Jeong, Daisuke Hachinohe, Khurshid Ahmed, Yun Ha Choi, Sook Hee Cho, Seung Hwan Hwang, Jum Suk Ko, Min Goo Lee, Keun Ho Park, Doo Sun Sim, Nam Sik Yoon, Hyun Ju Yoon, Kye Hun Kim, Hyung Wook Park, Ju Han Kim, Youngkeun Ahn, Jeong Gwan Cho, Jong Chun Park, Jung Chaee Kang. (2011) Comparison of Effects of Rosuvastatin and Atorvastatin on Plaque Regression in Korean Patients With Untreated Intermediate Coronary Stenosis. Circulation Journal 75:2, 398-406
CrossRef161
Yun-Kyeong Cho, Seung-Ho Hur, Chun-Duk Han, Hyoung-Seob Park, Hyuck-Jun Yoon, Hyungseop Kim, Chang-Wook Nam, Yoon-Nyun Kim, Kwon-Bae Kim, Nam-Hee Park, Hee-Jun Park. (2011) Comparison of Ezetimibe/Simvastatin 10/20 mg Versus Atorvastatin 20 mg in Achieving a Target Low Density Lipoprotein-Cholesterol Goal for Patients With Very High Risk. Korean Circulation Journal 41:3, 149
CrossRef162
Min Chul Kim, Youngkeun Ahn, Su Young Jang, Kyung Hoon Cho, Seung Hwan Hwang, Min Goo Lee, Jum Suk Ko, Keun Ho Park, Doo Sun Sim, Nam Sik Yoon, Hyun Ju Yoon, Kye Hun Kim, Young Joon Hong, Hyung Wook Park, Ju Han Kim, Myung Ho Jeong, Jeong Gwan Cho, Jong Chun Park, Jung Chaee Kang. (2011) Comparison of Clinical Outcomes of Hydrophilic and Lipophilic Statins in Patients with Acute Myocardial Infarction. The Korean Journal of Internal Medicine 26:3, 294
CrossRef163
Antonio García-Ríos, Javier Delgado-Lista, Pablo Pérez Martínez, Francisco Fuentes-Jiménez, Francisco Pérez-Jiménez, José López-Miranda. (2011) Eficacia de las estatinas en el manejo de la dislipemia. Un paso adelante. Revista Española de Cardiología Suplementos 11, 14-20
CrossRef164
Ángel Brea Hernando. (2011) Tratamiento de la dislipemia en grupos especiales: ancianos y embarazadas. Clínica e Investigación en Arteriosclerosis 23:1, 31-39
CrossRef165
Jerome L. Fleg, Wilbert S. Aronow, William H. Frishman. (2011) Cardiovascular drug therapy in the elderly: benefits and challenges. Nature Reviews Cardiology 8:1, 13-28
CrossRef166
Vivencio Barrios Alonso, Carlos Escobar Cervantes. (2011) Valor de la dislipemia en el conjunto de los factores de riesgo cardiovascular. Revista Española de Cardiología Suplementos 11, 29-35
CrossRef167
Kuo-Liong Chien, Hung-Ju Lin, Hsiu-Ching Hsu, Ming-Fong Chen. (2011) Lipid-related residual risk and renal function for occurrence and prognosis among patients with first-event acute coronary syndrome and normal LDL cholesterol. Lipids in Health and Disease 10:1, 215
CrossRef168
Antonio Pérez, Cintia González Blanco, Miguel Ángel Hernández-Presa, José Chaves. (2011) Therapeutic approach to dyslipidemia and goal achievement in a Spanish population with type 2 diabetes without cardiovascular disease. Endocrinología y Nutrición (English Edition) 58:6, 283-290
CrossRef169
Cannon, Christopher P., Shah, Sukrut, Dansky, Hayes M., Davidson, Michael, Brinton, Eliot A., Gotto, Antonio M. Jr., Stepanavage, Michael, Liu, Sherry Xueyu, Gibbons, Patrice, Ashraf, Tanya B., Zafarino, Jennifer, Mitchel, Yale, Barter, Philip, . (2010) Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease. New England Journal of Medicine 363:25, 2406-2415
Full Text170
Guy De Backer. (2010) Efficacy and benefits of lipid-lowering drug therapy. The new European guidelines for cardiovascular disease prevention. Clínica e Investigación en Arteriosclerosis 22, 48-51
CrossRef171
D. Soonawala, R. A. Middelburg, M. Egger, J. P. Vandenbroucke, O. M. Dekkers. (2010) Efficacy of experimental treatments compared with standard treatments in non-inferiority trials: a meta-analysis of randomized controlled trials. International Journal of Epidemiology 39:6, 1567-1581
CrossRef172
Gregory A Sgueglia, Filippo Crea. (2010) The risks of a new hypothesis: why did JUPITER patients have almost twice the predicted event rate of reduction?. Journal of Cardiovascular Medicine1
CrossRef173
Chiara Melloni, Bimal R. Shah, Fang-Shu Ou, Matthew T. Roe, Sidney C. Smith, Charles V. Pollack, Magnus Ohman, W. Brian Gibler, Eric D. Peterson, Karen P. Alexander. (2010) Lipid-lowering intensification and low-density lipoprotein cholesterol achievement from hospital admission to 1-year follow-up after an acute coronary syndrome event: Results from the Medications ApplIed aNd SusTAINed Over Time (MAINTAIN) registry. American Heart Journal 160:6, 1121-1129.e1
CrossRef174
Erick Alexanderson, Leonardo García-Rojas, Moisés Jiménez, Rodrigo Jácome, Rodrigo Calleja, Alfonso Martínez, Juan M. Ochoa, Aloha Meave, Graciela Alexanderson. (2010) Effect of ezetimibe–simvastatine over endothelial dysfunction in dyslipidemic patients: Assessment by 13N-ammonia positron emission tomography. Journal of Nuclear Cardiology 17:6, 1015-1022
CrossRef175
Luigi Marzio Biasucci, Gina Biasillo, Antonella Stefanelli. (2010) Inflammatory markers, cholesterol and statins: pathophysiological role and clinical importance. Clinical Chemistry and Laboratory Medicine 48:12, 1685-1691
CrossRef176
Usman Javed, Prakash C. Deedwania, Deepak L. Bhatt, Christopher P. Cannon, David Dai, Adrian F. Hernandez, Eric D. Peterson, Gregg C. Fonarow. (2010) Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: An analysis of 65,396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG). American Heart Journal 160:6, 1130-1136.e3
CrossRef177
Zhijian Lu, Joann B. Napolitano, Ashleigh Theberge, Amjad Ali, Milton L. Hammond, Eugene Tan, Xinchun Tong, Suoyu S. Xu, Melanie J. Latham, Laurence B. Peterson, Matt S. Anderson, Suzanne S. Eveland, Qiu Guo, Sheryl A. Hyland, Denise P. Milot, Ying Chen, Carl P. Sparrow, Samuel D. Wright, Peter J. Sinclair. (2010) Design of a novel class of biphenyl CETP inhibitors. Bioorganic & Medicinal Chemistry Letters 20:24, 7469-7472
CrossRef178
Eric A. Osborn, Farouc A. Jaffer. (2010) The Year in Molecular Imaging. JACC: Cardiovascular Imaging 3:11, 1181-1195
CrossRef179
Paul Frey, David D. Waters. (2010) Statins before stents: Does an ounce of prevention improve outcomes?. Canadian Journal of Cardiology 26:9, 486-487
CrossRef180
Andrew Friedrich, Tarek Helmy. (2010) Prevention of Perioperative Myocardial Infarction. International Anesthesiology Clinics 47:4, 13-36
CrossRef181
Yujiao Sun, Guoxian Qi, Yuan Gao, Haishan Zhang, Xuefeng Pang, Weihua Zhao, Zixin Zhang. (2010) Effect of different loading doses of atorvastatin on percutaneous coronary intervention for acute coronary syndromes. Canadian Journal of Cardiology 26:9, 481-485
CrossRef182
Andrew L Mammen, Anthony A Amato. (2010) Statin myopathy: a review of recent progress. Current Opinion in Rheumatology 22:6, 644-650
CrossRef183
Jamal S Rana, S Matthijs Boekholdt. (2010) Should we change our lipid management strategies to focus on non-high-density lipoprotein cholesterol?. Current Opinion in Cardiology 25:6, 622-626
CrossRef184
J. E. Deanfield, P. Sellier, E. Thaulow, J. Bultas, C. Yunis, H. Shi, J. Buch, B. Beckerman. (2010) Potent anti-ischaemic effects of statins in chronic stable angina: incremental benefit beyond lipid lowering?. European Heart Journal 31:21, 2650-2659
CrossRef185
Kenia Pedrosa Nunes, Christine S. Rigsby, R. Clinton Webb. (2010) RhoA/Rho-kinase and vascular diseases: what is the link?. Cellular and Molecular Life Sciences 67:22, 3823-3836
CrossRef186
Adie Viljoen, Anthony S Wierzbicki. (2010) Colesevelam: an improved bile acid sequestrant for treating hypercholesterolemia and improving diabetes. Expert Review of Endocrinology & Metabolism 5:6, 825-834
CrossRef187
, , W. Wijns, P. Kolh, N. Danchin, C. Di Mario, V. Falk, T. Folliguet, S. Garg, K. Huber, S. James, J. Knuuti, J. Lopez-Sendon, J. Marco, L. Menicanti, M. Ostojic, M. F. Piepoli, C. Pirlet, J. L. Pomar, N. Reifart, F. L. Ribichini, M. J. Schalij, P. Sergeant, P. W. Serruys, S. Silber, M. Sousa Uva, D. Taggart, , A. Vahanian, A. Auricchio, J. Bax, C. Ceconi, V. Dean, G. Filippatos, C. Funck-Brentano, R. Hobbs, P. Kearney, T. McDonagh, B. A. Popescu, Z. Reiner, U. Sechtem, P. A. Sirnes, M. Tendera, P. E. Vardas, P. Widimsky, , P. Kolh, O. Alfieri, J. Dunning, S. Elia, P. Kappetein, U. Lockowandt, G. Sarris, P. Vouhe, , P. Kearney, L. von Segesser, S. Agewall, A. Aladashvili, D. Alexopoulos, M. J. Antunes, E. Atalar, A. Brutel de la Riviere, A. Doganov, J. Eha, J. Fajadet, R. Ferreira, J. Garot, J. Halcox, Y. Hasin, S. Janssens, K. Kervinen, G. Laufer, V. Legrand, S. A. M. Nashef, F.-J. Neumann, K. Niemela, P. Nihoyannopoulos, M. Noc, J. J. Piek, J. Pirk, Y. Rozenman, M. Sabate, R. Starc, M. Thielmann, D. J. Wheatley, S. Windecker, M. Zembala. (2010) Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal 31:20, 2501-2555
CrossRef188
H. M. Garcia-Garcia, M. A. Costa, P. W. Serruys. (2010) Imaging of coronary atherosclerosis: intravascular ultrasound. European Heart Journal 31:20, 2456-2469
CrossRef189
Tahir Haque, Bobby V Khan. (2010) Atorvastatin: a review of its pharmacological properties and use in familial hypercholesterolemia. Clinical Lipidology 5:5, 615-625
CrossRef190
C.H. Saely, H. Drexel, K. Huber. (2010) Hochdosierte Statintherapie für kardiovaskuläre Risikopatienten. Herz 35:7, 497-502
CrossRef191
Jacek Lewandowski, Maciej Siński, Joanna Bidiuk, Piotr Abramczyk, Anna Dobosiewicz, Agnieszka Ciarka, Zbigniew Gaciong. (2010) Simvastatin reduces sympathetic activity in men with hypertension and hypercholesterolemia. Hypertension Research 33:10, 1038-1043
CrossRef192
Jonathan D. Rich, Christopher P. Cannon, Sabina A. Murphy, Jie Qin, Robert P. Giugliano, Eugene Braunwald. (2010) Prior Aspirin Use and Outcomes in Acute Coronary Syndromes. Journal of the American College of Cardiology 56:17, 1376-1385
CrossRef193
Yonghong Li, Olga A. Iakoubova, Dov Shiffman, James J. Devlin, James S. Forrester, H. Robert Superko. (2010) KIF6 Polymorphism as a Predictor of Risk of Coronary Events and of Clinical Event Reduction by Statin Therapy. The American Journal of Cardiology 106:7, 994-998
CrossRef194
Giuseppe Boriani, Igor Diemberger, Cinzia Valzania, Mauro Biffi, Cristian Martignani, Emanuel Raschi, Valentina Mantovani, Matteo Ziacchi, Matteo Bertini, Fabrizio De Ponti, Angelo Branzi. (2010) Role of drugs and devices in patients at risk of sudden cardiac death. Fundamental & Clinical Pharmacology 24:5, 575-594
CrossRef195
F. D. R. Hobbs, J. W. Jukema, P. M. Da Silva, T. McCormack, A. L. Catapano. (2010) Barriers to cardiovascular disease risk scoring and primary prevention in Europe. QJM 103:10, 727-739
CrossRef196
Natalie D. Muth, Gail A. Laughlin, Denise von Mühlen, Sidney C. Smith, Elizabeth Barrett-Connor. (2010) High-density lipoprotein subclasses are a potential intermediary between alcohol intake and reduced risk of cardiovascular disease: The Rancho Bernardo Study. British Journal of Nutrition 104:07, 1034-1042
CrossRef197
Ioannis K. Karalis, Sandrin C. Bergheanu, Ron Wolterbeek, Geesje M. Dallinga-Thie, Hiroaki Hattori, Arie van Tol, Anho H. Liem, J. Wouter Jukema. (2010) Effect of increasing doses of Rosuvastatin and Atorvastatin on apolipoproteins, enzymes and lipid transfer proteins involved in lipoprotein metabolism and inflammatory parameters. Current Medical Research and Opinion 26:10, 2301-2313
CrossRef198
Benjamin M. Meador, Kimberly A. Huey. (2010) Statin-associated myopathy and its exacerbation with exercise. Muscle & Nerve 42:4, 469-479
CrossRef199
Mukesh Singh, Shui Hao Chin, Paul D. Giles, David Crothers, Karim Al-Allaf, Jawad M. Khan. (2010) Controlling lipids in a high-risk population with documented coronary artery disease for secondary prevention: are we doing enough?. European Journal of Cardiovascular Prevention & Rehabilitation 17:5, 556-561
CrossRef200
Subroto Acharjee, Christopher P. Cannon. (2010) Office-based Global Cardiometabolic Risk Assessment. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 9:3, 156-159
CrossRef201
Justin A. Ezekowitz, Padma Kaul. (2010) The epidemiology and management of elderly patients with myocardial infarction or heart failure. Heart Failure Reviews 15:5, 407-413
CrossRef202
Vasilios G. Athyros, Konstantinos Tziomalos, Asterios Karagiannis, Dimitri P. Mikhailidis. (2010) Statin-fibrate combination for mixed dyslipidaemia: a limited option?. Current Medical Research and Opinion 26:9, 2137-2140
CrossRef203
David E. Winchester, Xuerong Wen, Lola Xie, Anthony A. Bavry. (2010) Evidence of Pre-Procedural Statin Therapy. Journal of the American College of Cardiology 56:14, 1099-1109
CrossRef204
Annunziata Nusca, Rosetta Melfi, Giuseppe Patti, Germano Di Sciascio. (2010) Statin loading before percutaneous coronary intervention: proposed mechanisms and applications. Future Cardiology 6:5, 579-589
CrossRef205
Deeptankar DeMazumder, Rani K. Hasan, Roger S. Blumenthal, Erin D. Michos, Steven Jones. (2010) Should Statin Therapy Be Allocated on the Basis of Global Risk or on the Basis of Randomized Trial Evidence?. The American Journal of Cardiology 106:6, 905-909
CrossRef206
John Reckless, Glenn Davies, Kaan Tunceli, X. Henry Hu, Philippe Brudi. (2010) Projected Cost-Effectiveness of Ezetimibe/Simvastatin Compared with Doubling the Statin Dose in the United Kingdom: Findings from the INFORCE Study. Value in Health 13:6, 726-734
CrossRef207
John R Guyton. (2010) Combination regimens with statin, niacin, and intestinally active LDL-lowering drugs: alternatives to high-dose statin therapy?. Current Opinion in Lipidology 21:4, 372-377
CrossRef208
Heidi T. May, Xiaoming Sheng, A. Peter Catinella, Benjamin D. Horne, John F. Carlquist, Elizabeth Joy. (2010) Antilipidemic adherence post-coronary artery disease diagnosis among those with and without an ICD-9 diagnosis of depression. Journal of Psychosomatic Research 69:2, 169-174
CrossRef209
Justin A. Ezekowitz, Paul W. Armstrong, Christopher B. Granger, Pierre Theroux, Amanda Stebbins, Raymond J. Kim, Manesh R. Patel. (2010) Predicting chronic left ventricular dysfunction 90 days after ST-segment elevation myocardial infarction: An Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Substudy. American Heart Journal 160:2, 272-278
CrossRef210
Parag H. Joshi, Eric Krivitsky, Zhen Qian, Gustavo Vazquez, Szilard Voros, Joseph Miller. (2010) Do We Know When and How to Lower Lipoprotein(a)?. Current Treatment Options in Cardiovascular Medicine 12:4, 396-407
CrossRef211
Amit V. Khera, Megan L. Wolfe, Christopher P. Cannon, Jie Qin, Daniel J. Rader. (2010) On-Statin Cholesteryl Ester Transfer Protein Mass and Risk of Recurrent Coronary Events (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 [PROVE IT-TIMI 22] Study). The American Journal of Cardiology 106:4, 451-456
CrossRef212
Lorenzo Arnaboldi, Alberto Corsini. (2010) Do structural differences in statins correlate with clinical efficacy?. Current Opinion in Lipidology 21:4, 298-304
CrossRef213
Robert A. O'Rourke. (2010) Alternative Strategies for the Management of Chronic Stable Angina. Current Problems in Cardiology 35:8, 384-446
CrossRef214
Terje R. Pedersen, Nilo B. Cater, Ole Faergeman, John J.P. Kastelein, Anders G. Olsson, Matti J. Tikkanen, Ingar Holme, Mogens Lytken Larsen, Christina Lindahl, Michael Szarek. (2010) Comparison of Atorvastatin 80 mg/day Versus Simvastatin 20 to 40 mg/day on Frequency of Cardiovascular Events Late (Five Years) After Acute Myocardial Infarction (from the Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] Trial). The American Journal of Cardiology 106:3, 354-359
CrossRef215
Harvey White. (2010) Darapladib and its potential for plaque stabilization and prevention of cardiac events. Clinical Lipidology 5:4, 465-476
CrossRef216
Nesan Shanmugam, Ana Román-Rego, Peter Ong, Juan Carlos Kaski. (2010) Atherosclerotic Plaque Regression: Fact or Fiction?. Cardiovascular Drugs and Therapy 24:4, 311-317
CrossRef217
Harvey White. (2010) Editorial: why inhibition of lipoprotein-associated phospholipase A2 has the potential to improve patient outcomes. Current Opinion in Cardiology 25:4, 299-301
CrossRef218
Cathy Jeon, Susana C. Candia, John C. Wang, Elizabeth M. Holper, Michelle Ammerer, Richard E. Kuntz, Laura Mauri. (2010) Relative spatial distributions of coronary artery bypass graft insertion and acute thrombosis: A model for protection from acute myocardial infarction. American Heart Journal 160:1, 195-201
CrossRef219
Erika M. Felix-Getzik, Jeffrey T. Kuvin, Richard H. Karas. (2010) Nonoptimal high-density lipoprotein cholesterol levels are highly prevalent in patients presenting with acute coronary syndromes and well-controlled low-density lipoprotein cholesterol levels. Journal of Clinical Lipidology 4:4, 265-271
CrossRef220
Annunziata Nusca, Rosetta Melfi, Giuseppe Patti, Germano Di Sciascio. (2010) Statin loading for acute coronary syndromes. Current Opinion in Cardiology 25:4, 373-378
CrossRef221
Xavier Pintó, Jesús Millán, Anna Muñoz, Emili Corbella, Antonio Hernández-Mijares, Manuel Zuñiga, Alipio Mangas, Juan Pedro-Botet. (2010) A Very High Prevalence of Low HDL Cholesterol in Spanish Patients With Acute Coronary Syndromes. Clinical Cardiology 33:7, 418-423
CrossRef222
G.F. Gensini, A.M. Gori, B. Dilaghi, C. Rostagno, A. Gaw, L.M. Blanco-Colio, E. de Teresa, J. Egido, C. Farsang, L.A. Leiter, P. Martineau, A. Nozza, A. Langer. (2010) Effect of atorvastatin on circulating hsCRP concentrations: A sub-study of the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) study. International Journal of Cardiology 142:3, 257-264
CrossRef223
Helena Vaverkova, Michel Farnier, Maurizio Averna, Luc Missault, Margus Viigimaa, Qian Dong, Arvind Shah, Amy O. Johnson-Levonas, Philippe Brudi. (2010) Lipid-Altering Efficacy of Ezetimibe/Simvastatin 10/20 mg Compared to Rosuvastatin 10 mg in High-Risk Patients with and without Type 2 Diabetes Mellitus Inadequately Controlled Despite Prior Statin Monotherapy. Cardiovascular Therapeuticsno-no
CrossRef224
Derek J Hausenloy, Lionel Opie, Derek M Yellon. (2010) Dissociating HDL cholesterol from cardiovascular risk. The Lancet 376:9738, 305-306
CrossRef225
Peter P. Toth. (2010) Drug Treatment of Hyperlipidaemia. Drugs 70:11, 1363-1379
CrossRef226
Petter Quist-Paulsen. (2010) Statins and inflammation: an update. Current Opinion in Cardiology 25:4, 399-405
CrossRef227
Kausik K. Ray, Babak Nazer, Richard Cairns, C. Michael Gibson, Christopher P. Cannon. (2010) Association between percutaneous coronary intervention and long-term C-reactive protein levels in patients with acute coronary syndromes. Journal of Thrombosis and Thrombolysis 30:1, 10-13
CrossRef228
Haseeb Jafri, Alawi A. Alsheikh-Ali, Richard H. Karas. (2010) Baseline and On-Treatment High-Density Lipoprotein Cholesterol and the Risk of Cancer in Randomized Controlled Trials of Lipid-Altering Therapy. Journal of the American College of Cardiology 55:25, 2846-2854
CrossRef229
T. Sathyapalan, S. L. Atkin, E. S. Kilpatrick. (2010) Low density lipoprotein-cholesterol variability in patients with type 2 diabetes taking atorvastatin compared to simvastatin: justification for direct measurement?. Diabetes, Obesity and Metabolism 12:6, 540-544
CrossRef230
Eli M. Roth, James M. McKenney, Maureen T. Kelly, Carolyn M. Setze, Dawn M. Carlson, Alex Gold, James C. Stolzenbach, Laura A. Williams, Peter H. Jones. (2010) Efficacy and Safety of Rosuvastatin and Fenofibric Acid Combination Therapy versus Simvastatin Monotherapy in Patients with Hypercholesterolemia and Hypertriglyceridemia. American Journal Cardiovascular Drugs 10:3, 175-186
CrossRef231
Stephanie Cham, Marcella A Evans, Julie O Denenberg, Beatrice A Golomb. (2010) Statin-Associated Muscle-Related Adverse Effects: A Case Series of 354 Patients. Pharmacotherapy 30:6, 541-553
CrossRef232
Jennifer Villa, Richard E. Pratley. (2010) Ezetimibe/Simvastatin or Atorvastatin for the Treatment of Hypercholesterolemia in Patients with the Metabolic Syndrome: The VYMET Study. Current Diabetes Reports 10:3, 173-175
CrossRef233
Lluís Masana, Núria Plana. (2010) Actualización de las tablas de planificación terapéutica de la hipercolesterolemia. Medicina Clínica 135:3, 120-123
CrossRef234
Giuseppe Derosa, Pamela Maffioli. (2010) Effects of amlodipine plus atorvastatin association in hypertensive hypercholesterolemic patients. Expert Review of Cardiovascular Therapy 8:6, 835-843
CrossRef235
Ryan S. Stolcpart, Kari L. Olson, Thomas Delate, Jon Rasmussen, Thomas F. Rehring, John A. Merenich. (2010) The Risk for Significant Creatine Kinase Elevation with Statins. American Journal Cardiovascular Drugs 10:3, 187-192
CrossRef236
Ozgur Bayturan, Samir Kapadia, Stephen J. Nicholls, E. Murat Tuzcu, Mingyuan Shao, Kiyoko Uno, Ajai Shreevatsa, Andrea J. Lavoie, Kathy Wolski, Paul Schoenhagen, Steven E. Nissen. (2010) Clinical Predictors of Plaque Progression Despite Very Low Levels of Low-Density Lipoprotein Cholesterol. Journal of the American College of Cardiology 55:24, 2736-2742
CrossRef237
James P. Corsetti, Ron T. Gansevoort, Charles E. Sparks, Robin P. F. Dullaart. (2010) Inflammation reduces HDL protection against primary cardiac risk. European Journal of Clinical Investigation 40:6, 483-489
CrossRef238
M. John Chapman, Jan S. Redfern, Mark E. McGovern, Philippe Giral. (2010) Niacin and fibrates in atherogenic dyslipidemia: Pharmacotherapy to reduce cardiovascular risk. Pharmacology & Therapeutics 126:3, 314-345
CrossRef239
H. B. Sager, P. Linsel-Nitschke, B. Mayer, W. Lieb, B. Franzel, U. Elsasser, H. Schunkert. (2010) Physicians' perception of guideline-recommended low-density lipoprotein target values: characteristics of misclassified patients. European Heart Journal 31:10, 1266-1273
CrossRef240
Amy B. Kauffman, Kari L. Olson, Morgan L. Youngblood, Emily B. Zadvorny, Thomas Delate, John A. Merenich. (2010) Attainment of low-density lipoprotein cholesterol goals in coronary artery disease. Journal of Clinical Lipidology 4:3, 173-180
CrossRef241
Germán Gómez Briseño, Dolores Mino-León. (2010) Cost-effectiveness of rosuvastatin versus ezetimibe/simvastatin in managing dyslipidemic patients in Mexico. Current Medical Research and Opinion 26:5, 1075-1081
CrossRef242
Mauricio G. Cohen, Mario Pascual, Benjamin M. Scirica, E. Magnus Ohman. (2010) Metas terapéuticas en pacientes con angina refractaria crónica. Revista Española de Cardiología 63:5, 571-582
CrossRef243
Venkata M. Alla, Manu Kaushik, Aryan Mooss. (2010) Targeting Residual Risk: The Rationale for the Use of Non-HDL Cholesterol. Southern Medical Journal 103:5, 434-439
CrossRef244
Wilbert S. Aronow, William H. Frishman. (2010) Management of Hypercholesterolemia in Older Persons for the Prevention of Cardiovascular Disease. Cardiology in Review 18:3, 132-140
CrossRef245
Byeong-Keuk Kim, Dong Whan Kim, Seungjin Oh, Se-Jung Yoon, Sungha Park, Dong Woon Jeon, Joo Young Yang. (2010) Impact of the attainment of current recommended low-density lipoprotein cholesterol goal of less than 70 mg/dl on clinical outcomes in very high-risk patients treated with drug-eluting stents. Coronary Artery Disease 21:3, 182-188
CrossRef246
Maciej Pastuszczak, Agnieszka Kotlarz, Magdalena Mostowik, Jaroslaw Zalewski, Krzysztof Zmudka, Anetta Undas. (2010) Prior simvastatin treatment is associated with reduced thrombin generation and platelet activation in patients with acute ST-segment elevation myocardial infarction. Thrombosis Research 125:5, 382-386
CrossRef247
Makiko Tamada, Shinji Makita, Akihiko Abiko, Yujirou Naganuma, Mizuyoshi Nagai, Motoyuki Nakamura. (2010) Low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio as a useful marker for early-stage carotid atherosclerosis. Metabolism 59:5, 653-657
CrossRef248
S. M. Haldar, Y. Lu, D. Jeyaraj, D. Kawanami, Y. Cui, S. J. Eapen, C. Hao, Y. Li, Y. Q. Doughman, M. Watanabe, K. Shimizu, H. Kuivaniemi, J. Sadoshima, K. B. Margulies, T. P. Cappola, M. K. Jain. (2010) Klf15 Deficiency Is a Molecular Link Between Heart Failure and Aortic Aneurysm Formation. Science Translational Medicine 2:26, 26ra26-26ra26
CrossRef249
Cheol Whan Lee, Sang-Hong Baek, Taek-Jong Hong, Young-Jin Choi, Young-Jo Kim, Tae-Hoon Ahn, Sang-Hyun Ihm, Jang-Ho Bae, Soon-Jun Hong, Doo-Il Kim, Young-Keun Ahn, Seung-Ho Hur, Dae-Gyun Park, Dong-Ju Choi, Seung-Uk Lee, Bum-Soo Kim, Kyu-Hyung Ryu, Yang-Soo Jang, Sang-Hoon Lee, Ki-Bae Seung, Hyo-Soo Kim. (2010) A Multicenter, Eight-Week Treatment, Single-Step Titration, Open-Label Study Assessing the Percentage of Korean Dyslipidemic Patients Achieving LDL Cholesterol Target with Atorvastatin Starting Doses of 10 mg, 20 mg and 40 mg. Cardiovascular Drugs and Therapy 24:2, 181-188
CrossRef250
Francisco M. Gomez-Soto, Sotero P. Romero, Jose A. Bernal, Miguel A. Escobar, Jose L. Puerto, Jose L. Andrey, Pedro Ruiz, Francisco Gomez. (2010) Mortality and morbidity of newly diagnosed heart failure treated with statins. International Journal of Cardiology 140:2, 210-218
CrossRef251
R. J. Jaumdally, P. K. Y. Goon, C. Varma, A. D. Blann, G. Y. H. Lip. (2010) Effects of atorvastatin on circulating CD34+/CD133+/ CD45− progenitor cells and indices of angiogenesis (vascular endothelial growth factor and the angiopoietins 1 and 2) in atherosclerotic vascular disease and diabetes mellitus. Journal of Internal Medicine 267:4, 385-393
CrossRef252
Yuri B Pride, C Michael Gibson. (2010) Intensive statin therapy: a goal worth targeting. Interventional Cardiology 2:2, 103-105
CrossRef253
Vasilios G. Athyros, Konstantinos Tziomalos, Matilda Florentin, Asterios Karagiannis, Dimitri P. Mikhailidis. (2010) Statin loading in patients undergoing percutaneous coronary intervention for acute coronary syndromes: a new pleiotropic effect?. Current Medical Research and Opinion 26:4, 839-842
CrossRef254
T.-C. Weng, Y.-H. Kao Yang, S.-J. Lin, S.-H. Tai. (2010) A systematic review and meta-analysis on the therapeutic equivalence of statins. Journal of Clinical Pharmacy and Therapeutics 35:2, 139-151
CrossRef255
Karl Wegscheider. 2010. Phase IV: Postmarketing Trials. .
CrossRef256
Philip R. Liebson. (2010) ARBITER-6 HALTS and Lipid Concentrations and Heart Failure Incidence: Framingham Heart Study. Preventive Cardiology
CrossRef257
Hans J. Avis, Barbara A. Hutten, Claude Gagné, Gisle Langslet, Brian W. McCrindle, Albert Wiegman, Judith Hsia, John J.P. Kastelein, Evan A. Stein. (2010) Efficacy and Safety of Rosuvastatin Therapy for Children With Familial Hypercholesterolemia. Journal of the American College of Cardiology 55:11, 1121-1126
CrossRef258
Pradeep Natarajan, Kausik K. Ray, Christopher P. Cannon. (2010) High-Density Lipoprotein and Coronary Heart Disease. Journal of the American College of Cardiology 55:13, 1283-1299
CrossRef259
Rosana Gambogi, Marcela Baldizzoni, Henry Albornoz, Carlos Ketzoian, Mariana Cabrera, Gustavo Saona, Abayubá Perna. (2010) Prevención secundaria en pacientes revascularizados coronarios en Uruguay: descripción de un programa, evaluación del control de los factores de riesgo y efecto en la mortalidad. Clínica e Investigación en Arteriosclerosis 22:2, 59-69
CrossRef260
Robert B. Schonberger, Ala S. Haddadin. (2010) The Anesthesia Patient with Acute Coronary Syndrome. Anesthesiology Clinics 28:1, 55-66
CrossRef261
Frederick J Raal, Raul D Santos, Dirk J Blom, A David Marais, Min-Ji Charng, William C Cromwell, Robin H Lachmann, Daniel Gaudet, Ju L Tan, Scott Chasan-Taber, Diane L Tribble, JoAnn D Flaim, Stanley T Crooke. (2010) Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. The Lancet 375:9719, 998-1006
CrossRef262
Yiannis S. Chatzizisis, Konstantinos C. Koskinas, Gesthimani Misirli, Christos Vaklavas, Apostolos Hatzitolios, George D. Giannoglou. (2010) Risk Factors and Drug Interactions Predisposing to Statin-Induced Myopathy. Drug Safety 33:3, 171-187
CrossRef263
David J. Maron, William E. Boden, Robert A. O'Rourke, Pamela M. Hartigan, Karen J. Calfas, G.B. John Mancini, John A. Spertus, Marcin Dada, William J. Kostuk, Merril Knudtson, Crystal L. Harris, Steven P. Sedlis, Robert G. Zoble, Lawrence M. Title, Gilbert Gosselin, Shah Nawaz, Gerald T. Gau, Alvin S. Blaustein, Eric R. Bates, Leslee J. Shaw, Daniel S. Berman, Bernard R. Chaitman, William S. Weintraub, Koon K. Teo. (2010) Intensive Multifactorial Intervention for Stable Coronary Artery Disease. Journal of the American College of Cardiology 55:13, 1348-1358
CrossRef264
Simona Mega, Giuseppe Patti, Christopher P. Cannon, Germano Di Sciascio. (2010) Preprocedural Statin Therapy to Prevent Myocardial Damage in Percutaneous Coronary Intervention. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 9:1, 19-22
CrossRef265
Subroto Acharjee, Jie Qin, Sabina A. Murphy, Carolyn McCabe, Christopher P. Cannon. (2010) Distribution of Traditional and Novel Risk Factors and Their Relation to Subsequent Cardiovascular Events in Patients With Acute Coronary Syndromes (from the PROVE IT-TIMI 22 Trial). The American Journal of Cardiology 105:5, 619-623
CrossRef266
L. Nherera, N.W. Calvert, K. DeMott, S.E. Humphries, H.A.W. Neil, R. Minhas, M. Thorogood. (2010) Cost-effectiveness analysis of the use of a high-intensity statin compared to a low-intensity statin in the management of patients with familial hypercholesterolaemia. Current Medical Research and Opinion 26:3, 529-536
CrossRef267
Juan José Badimón, Borja Ibáñez. (2010) Incremento de las HDL como arma terapéutica en la aterotrombosis. Revista Española de Cardiología 63:3, 323-333
CrossRef268
Andrea Lavoie, Kiyoko Uno, Ozgur Bayturan, Stephen J. Nicholls. (2010) Findings of clinical trials that evaluate the impact of medical therapies on progression of atherosclerosis. Current Medical Research and Opinion 26:3, 745-751
CrossRef269
A.H. Pijlman, R. Huijgen, S.N. Verhagen, B.P.M. Imholz, A.H. Liem, J.J.P. Kastelein, E.J. Abbink, A.F.H. Stalenhoef, F.L.J. Visseren. (2010) Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. Atherosclerosis 209:1, 189-194
CrossRef270
Hakan Ozornek, Elif Ergin, Rajasingam S. Jeyendran, Alev T. Ozay, Delanie Pillai, Carolyn Coulam. (2010) Is Apolipoprotien E codon 112 Polymorphisms Associated with Recurrent Pregnancy Loss?. American Journal of Reproductive Immunology
CrossRef271
Wayne N. Burton, Chin-Yu Chen, Alyssa B. Schultz, Dee W. Edington. (2010) The Association Between Achieving Low-Density Lipoprotein Cholesterol (LDL-C) Goal and Statin Treatment in an Employee Population. Population Health Management 13:1, 1-8
CrossRef272
Carl J. Pepine. (2010) Residual risk for secondary ischemic events in patients with atherothrombotic disease: Opportunity for future improvements in patient care. Annals of Medicine 42:1, 19-35
CrossRef273
F. Schiele, N. Meneveau, M. F. Seronde, R. Chopard, V. Descotes-Genon, J. Dutheil, J.-P. Bassand, . (2010) C-reactive protein improves risk prediction in patients with acute coronary syndromes. European Heart Journal 31:3, 290-297
CrossRef274
Terry K.W. Ma, Yat-Yin Lam, Victoria P. Tan, Thomas J. Kiernan, Bryan P. Yan. (2010) Impact of genetic and acquired alteration in cytochrome P450 system on pharmacologic and clinical response to clopidogrel. Pharmacology & Therapeutics 125:2, 249-259
CrossRef275
Pierre-Frédéric Keller, Marco Roffi. 2010. Acute Coronary Syndromes. , 1-22.
CrossRef276
M. J. Chapman, W. Le Goff, M. Guerin, A. Kontush. (2010) Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. European Heart Journal 31:2, 149-164
CrossRef277
Hideaki Kaneda, Ji Ma, Toshihiro Morita. (2010) Noninferiority of Pitavastatin in Intravascular Ultrasound Findings. Journal of the American College of Cardiology 55:3, 262-263
CrossRef278
Kiyoko Uno, Stephen J. Nicholls. (2010) Statin Effects on Both Low-Density Lipoproteins and High-Density Lipoproteins: Is There a Dual Benefit?. Current Atherosclerosis Reports 12:1, 14-19
CrossRef279
Kazuhisa Kodama, Sei Komatsu, Yasunori Ueda, Tadateru Takayama, Jyunji Yajima, Shinsuke Nanto, Hiroshi Matsuoka, Satoshi Saito, Atsushi Hirayama. (2010) Stabilization and Regression of Coronary Plaques Treated With Pitavastatin Proven by Angioscopy and Intravascular Ultrasound. Circulation Journal 74:9, 1922-1928
CrossRef280
L. Spencer Krane, Sanjeev A. Kaul, Hans J. Stricker, James O. Peabody, Mani Menon, Piyush K. Agarwal. (2010) Men Presenting for Radical Prostatectomy on Preoperative Statin Therapy Have Reduced Serum Prostate Specific Antigen. The Journal of Urology 183:1, 118-125
CrossRef281
Young Joon Hong, Myung Ho Jeong, Yun Ha Choi, Eun Hye Ma, Jum Suk Ko, Min Goo Lee, Keun Ho Park, Doo Sun Sim, Nam Sik Yoon, Hyun Ju Youn, Kye Hun Kim, Hyung Wook Park, Ju Han Kim, Youngkeun Ahn, Jeong Gwan Cho, Jong Chun Park, Jung Chaee Kang. (2010) Usual Dose of Simvastatin Does Not Inhibit Plaque Progression and Lumen Loss at the Peri-Stent Reference Segments after Bare-Metal Stent Implantation: A Serial Intravascular Ultrasound Analysis. The Korean Journal of Internal Medicine 25:4, 356
CrossRef282
Juan José Badimón, Carlos G. Santos-Gallego, Lina Badimón. (2010) Importancia del colesterol HDL en la aterotrombosis. ¿De dónde venimos? ¿Hacia dónde vamos?. Revista Española de Cardiología 63, 20-35
CrossRef283
N. K. Wenger, S. J. Lewis. (2010) Use of Statin Therapy to Reduce Cardiovascular Risk in Older Patients. Current Gerontology and Geriatrics Research 2010, 1-9
CrossRef284
Michel de Lorgeri, Patricia Salen. (2010) Recent cholesterol-lowering drug trials: New data, new questions. Journal of Lipid Nutrition 19:1, 65-92
CrossRef285
Hae Chang Jeong, Youngkeun Ahn, Myung Ho Jeong, Shung Chull Chae, Seung Ho Hur, Taek Jong Hong, Young Jo Kim, In Whan Seong, Jei Keon Chae, Jay Young Rhew, In Ho Chae, Myeong Chan Cho, Jang Ho Bae, Seung Woon Rha, Chong Jin Kim, Donghoon Choi, Yang Soo Jang, Junghan Yoon, Wook Sung Chung, Jeong Gwan Cho, Ki Bae Seung, Seung Jung Park, . (2010) Long-Term Clinical Outcomes according to Initial Management and Thrombolysis In Myocardial Infarction Risk Score in Patients with Acute Non-ST-Segment Elevation Myocardial Infarction. Yonsei Medical Journal 51:1, 58
CrossRef286
Michael Clearfield. (2010) New Evidence Extending the Benefit of Treating LDL-C Beyond the Current Guidelines. Current Atherosclerosis Reports 12:1, 1-4
CrossRef287
Susan W. Miller, Edress Darsey, Thomas J. Heard, Jill Williams, Maureen Kelly, Arnisha Norman, Linh B. ter Riet. (2010) Outcomes of a Multidisciplinary Partnership to Improve Cardiac Wellness: An Opportunity for Pharmacists. The Consultant Pharmacist 25:2, 105-116
CrossRef288
Derek P. Chew, Robert Carter, Bree Rankin, Andrew Boyden, Helen Egan. (2010) Cost effectiveness of a general practice chronic disease management plan for coronary heart disease in Australia. Australian Health Review 34:2, 162
CrossRef289
Joan F. Hilton. (2010) Noninferiority trial designs for odds ratios and risk differences. Statistics in Medicinen/a-n/a
CrossRef290
Hidenori Arai, Takafumi Hiro, Takeshi Kimura, Takeshi Morimoto, Katsumi Miyauchi, Yoshihisa Nakagawa, Masakazu Yamagishi, Yukio Ozaki, Kazuo Kimura, Satoshi Saito, Tetsu Yamaguchi, Hiroyuki Daida, Masunori Matsuzaki. (2010) More Intensive Lipid Lowering is Associated with Regression of Coronary Atherosclerosis in Diabetic Patients with Acute Coronary Syndrome –Sub-Analysis of JAPAN-ACS Study. Journal of Atherosclerosis and Thrombosis 17:10, 1096-1107
CrossRef291
Shepard D. Weiner, LeRoy E. Rabbani. (2010) Secondary prevention strategies for coronary heart disease. Journal of Thrombosis and Thrombolysis 29:1, 8-24
CrossRef292
Monique P. Curran. (2010) Amlodipine/Atorvastatin. Drugs 70:2, 191-213
CrossRef293
James H.F. Rudd, Fabien Hyafil, Silvia Aguiar, Zahi A. Fayad. 2010. Atherosclerotic Plaque Imaging. , 341-350.
CrossRef294
Ryan J. Chauffe, Robert L. Wilensky, Emile R. Mohler. (2010) Recent Developments with Lipoprotein-Associated Phospholipase A2 Inhibitors. Current Atherosclerosis Reports 12:1, 43-47
CrossRef295
José Luis Pérez-Castrillón, Laura Abad Manteca, Gemma Vega, Javier del Pino Montes, Daniel de Luis, Antonio Dueňas Laita. (2010) Vitamin D Levels and Lipid Response to Atorvastatin. International Journal of Endocrinology 2010, 1-4
CrossRef296
Takafumi Hiro, Takeshi Kimura, Takeshi Morimoto, Katsumi Miyauchi, Yoshihisa Nakagawa, Masakazu Yamagishi, Yukio Ozaki, Kazuo Kimura, Satoshi Saito, Tetsu Yamaguchi, Hiroyuki Daida, Masunori Matsuzaki, The JAPAN-ACS Investigators. (2010) Diabetes Mellitus Is a Major Negative Determinant of Coronary Plaque Regression During Statin Therapy in Patients With Acute Coronary Syndrome. Circulation Journal 74:6, 1165-1174
CrossRef297
Pawan D Patel, Rohit R Arora. (2010) Practical Implications of ACC/AHA 2007 Guidelines for the Management of Unstable Angina/Non-ST Elevation Myocardial Infarction. American Journal of Therapeutics 17:1, e24-e40
CrossRef298
Vijay S. Ramanath, David F. Armstrong, Mary Grzybowski, Sahand Rahnama-Mohagdam, Umesh U. Tamhane, Kelly Gordon, James B. Froehlich, Kim A. Eagle, Elizabeth A. Jackson. (2010) Receipt of Cardiac Medications Upon Discharge Among Men and Women With Acute Coronary Syndrome and Nonobstructive Coronary Artery Disease. Clinical Cardiology 33:1, 36-41
CrossRef299
Jung Sun Cho, Myung Ho Jeong, Doo Sun Sim, Young Joon Hong, Kyung Seob Lim, Jung Ha Kim, Hyoung Doo Kim, Ju Yeal Baek, Hee Jeoung Yoon, Sung-Ho Her, Seung Won Jin, Ju Han Kim, Youngkeun Ahn, Jeong Gwan Cho, Jong Chun Park, Jung Chaee Kang. (2010) Effects of Combined Therapy with Ezetimibe Plus Simvastatin After Drug-Eluting Stent Implantation in a Porcine Coronary Restenosis Model. Journal of Korean Medical Science 25:5, 716
CrossRef300
Tomohiro Sakamoto, Hisao Ogawa. (2010) "Just Make It Lower" Is an Alternative Strategy of Lipid-Lowering Therapy With Statins in Japanese Patients. Circulation Journal 74:8, 1731-1741
CrossRef301
Stephen J. Nicholls, Gunnar Brandrup-Wognsen, Mike Palmer, Philip J. Barter. (2010) Meta-analysis of Comparative Efficacy of Increasing Dose of Atorvastatin Versus Rosuvastatin Versus Simvastatin on Lowering Levels of Atherogenic Lipids (from VOYAGER). The American Journal of Cardiology 105:1, 69-76
CrossRef302
Chul Min Ahn, Soon Jun Hong, Seung Cheol Choi, Jae Hyung Park, Jae Sang Kim, Do-Sun Lim. (2010) Red ginseng extract improves coronary flow reserve and increases absolute numbers of various circulating angiogenic cells in patients with first ST-segment elevation acute myocardial infarction. Phytotherapy Researchn/a-n/a
CrossRef303
William L. Baker, Ripple Talati, C. Michael White, Craig I. Coleman. (2010) Differing effect of statins on insulin sensitivity in non-diabetics: A systematic review and meta-analysis. Diabetes Research and Clinical Practice 87:1, 98-107
CrossRef304
Takafumi Hiro, Takeshi Kimura, Takeshi Morimoto, Katsumi Miyauchi, Yoshihisa Nakagawa, Masakazu Yamagishi, Yukio Ozaki, Kazuo Kimura, Satoshi Saito, Tetsu Yamaguchi, Hiroyuki Daida, Masunori Matsuzaki. (2010) Reply. Journal of the American College of Cardiology 55:3, 263
CrossRef305
Kavita Sharma, Christian D. Nagy, Roger S. Blumenthal. 2010. Dyslipidemia Management in Women and MenExploring Potential Gender Differences. , 175-185.
CrossRef306
Helene Glassberg. (2009) Statins in the prevention of heart failure after myocardial infarction. Current Heart Failure Reports 6:4, 215-219
CrossRef307
Carl J. Lavie, Richard V. Milani, Anil Verma, James H. OʼKeefe. (2009) C-Reactive Protein and Cardiovascular Diseases—Is it Ready for Primetime?. The American Journal of the Medical Sciences 338:6, 486-492
CrossRef308
Heinz Drexel. (2009) Statins, fibrates, nicotinic acid, cholesterol absorption inhibitors, anion-exchange resins, omega-3 fatty acids: which drugs for which patients?. Fundamental & Clinical Pharmacology 23:6, 687-692
CrossRef309
Peter Henke. (2009) What is the Optimum Perioperative Drug Therapy Following Lower-Extremity Vein Bypass Surgery?. Seminars in Vascular Surgery 22:4, 245-251
CrossRef310
Andrea Brassard. (2009) Identification of patients at risk of ischemic events for long-term secondary prevention. Journal of the American Academy of Nurse Practitioners 21:12, 677-689
CrossRef311
Alistair S. Hall, Beryl M. Jackson, Amanda J. Farrin, Maria Efthymiou, Julian H. Barth, Joanne Copeland, Kristian M. Bailey, Simon P. R. Romaine, Anthony J. Balmforth, Terry McCormack, Andrew Whitehead, Marcus D. Flather, Jane Nixon. (2009) A randomized, controlled trial of simvastatin versus rosuvastatin in patients with acute myocardial infarction: the Secondary Prevention of Acute Coronary Events – Reduction of Cholesterol to Key European Targets Trial. European Journal of Cardiovascular Prevention & Rehabilitation 16:6, 712-721
CrossRef312
Matthew A. Cavender, Karen P. Alexander, Samuel Broderick, Linda K. Shaw, Charles B. McCants, Judith Kempf, E. Magnus Ohman. (2009) Long-term morbidity and mortality among medically managed patients with angina and multivessel coronary artery disease. American Heart Journal 158:6, 933-940
CrossRef313
E.V. Corp, S. Antoniou, P.G. Wright, H. Khachi, S. Vercaeren, D.S. Wald. (2009) Use and cost of branded and generic drugs in patients with coronary heart disease--results from a prospective survey of 1008 patients in two London hospitals. QJM 102:12, 843-849
CrossRef314
Stephen J Nicholls. (2009) Relationship between LDL, HDL, blood pressure and atheroma progression in the coronaries. Current Opinion in Lipidology 20:6, 491-496
CrossRef315
Adam B. Polis, Nicola Abate, Alberico L. Catapano, Christie M. Ballantyne, Michael H. Davidson, Steven S. Smugar, Andrew M. Tershakovec. (2009) Low-Density Lipoprotein Cholesterol Reduction and Goal Achievement With Ezetimibe/Simvastatin Versus Atorvastatin or Rosuvastatin in Patients With Diabetes, Metabolic Syndrome, or Neither Disease, Stratified by National Cholesterol Education Program Risk Category. Metabolic Syndrome and Related Disorders 7:6, 601-610
CrossRef316
Gregory G. Schwartz, Anders G. Olsson, Christie M. Ballantyne, Phillip J. Barter, Ingar M. Holme, David Kallend, Lawrence A. Leiter, Eran Leitersdorf, John J.V. McMurray, Prediman K. Shah, Jean-Claude Tardif, Bernard R. Chaitman, Regina Duttlinger-Maddux, John Mathieson. (2009) Rationale and design of the dal-OUTCOMES trial: Efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. American Heart Journal 158:6, 896-901.e3
CrossRef317
C. Michael Gibson, Yuri B. Pride, Claudia P. Hochberg, Sarah Sloan, Marc S. Sabatine, Christopher P. Cannon. (2009) Effect of Intensive Statin Therapy on Clinical Outcomes Among Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome. Journal of the American College of Cardiology 54:24, 2290-2295
CrossRef318
Sabina A. Murphy, Christopher P. Cannon, Stephen D. Wiviott, Carolyn H. McCabe, Eugene Braunwald. (2009) Reduction in Recurrent Cardiovascular Events With Intensive Lipid-Lowering Statin Therapy Compared With Moderate Lipid-Lowering Statin Therapy After Acute Coronary Syndromes. Journal of the American College of Cardiology 54:25, 2358-2362
CrossRef319
Stephen P. Motsko, Stefan Russmann, Eileen E. Ming, Varinder P. Singh, Ruby M. Vendiola, Judith K. Jones. (2009) Effectiveness of rosuvastatin compared to other statins for the prevention of cardiovascular eventsâa cohort study in 395â039 patients from clinical practice. Pharmacoepidemiology and Drug Safety 18:12, 1214-1222
CrossRef320
Mark Helfand, Sergio A. Aguilar-Gaxiola, Harry P. Selker. (2009) Comparative Effectiveness Research: An Approach to Avoiding âOvergeneralized Medicineâ. Clinical and Translational Science 2:6, 444-445
CrossRef321
László Márk, András Katona. (2009) A lipidcélértékektől a JUPITER vizsgálatig. Az irányelvekben előírt lipidszintek elérésének jelentősége és a gyakorlat hiányosságai. Orvosi Hetilap 150:44, 2012-2018
CrossRef322
Madhan Shanmugasundaram, Joseph S. Alpert. (2009) Acute Coronary Syndrome in the Elderly. Clinical Cardiology 32:11, 608-613
CrossRef323
Raul D. Santos, David D. Waters, Lisa Tarasenko, Michael Messig, J. Wouter Jukema, Jean Ferrières, Juan Verdejo, Cheng-Wen Chiang. (2009) Low- and high-density lipoprotein cholesterol goal attainment in dyslipidemic women: The Lipid Treatment Assessment Project (L-TAP) 2. American Heart Journal 158:5, 860-866
CrossRef324
Riccardo Candido, Stella Bernardi, Terri J Allen. (2009) Linking diabetes and atherosclerosis. Expert Review of Endocrinology & Metabolism 4:6, 603-624
CrossRef325
Monique A. Ford, Joseph P. McConnell, Shahar Lavi, Charanjit S. Rihal, Abhiram Prasad, Gurpreet S. Sandhu, Stacy J. Hartman, Lilach O. Lerman, Amir Lerman. (2009) Coronary artery endothelial dysfunction is positively correlated with low density lipoprotein and inversely correlated with high density lipoprotein subclass particles measured by nuclear magnetic resonance spectroscopy. Atherosclerosis 207:1, 111-115
CrossRef326
Konstantinos C Koskinas, Yiannis S Chatzizisis, Aaron B Baker, Elazer R Edelman, Peter H Stone, Charles L Feldman. (2009) The role of low endothelial shear stress in the conversion of atherosclerotic lesions from stable to unstable plaque. Current Opinion in Cardiology 24:6, 580-590
CrossRef327
Christine T. Cigolle, Caroline S. Blaum, Jeffrey B. Halter. (2009) Diabetes and Cardiovascular Disease Prevention in Older Adults. Clinics in Geriatric Medicine 25:4, 607-641
CrossRef328
Michael H. Davidson. (2009) AURORA and JUPITER trials: Recognizing the limitations and expanding the benefits of statin treatment. Current Cardiology Reports 11:6, 401-403
CrossRef329
Kae Nakamura, Takeshi Sasaki, Xian Wu Cheng, Akihisa Iguchi, Kohji Sato, Masafumi Kuzuya. (2009) Statin prevents plaque disruption in apoE-knockout mouse model through pleiotropic effect on acute inflammation. Atherosclerosis 206:2, 355-361
CrossRef330
Maurizio Paciaroni, Julien Bogousslavsky. (2009) Statins and stroke prevention. Expert Review of Cardiovascular Therapy 7:10, 1231-1243
CrossRef331
Richard H. Chapman, Allison A. Petrilla, Lance Berman, Joshua S. Benner, Simon S.K. Tang. (2009) Are High-Risk Hypertensive Patients being Prescribed Concomitant Statin Therapy?. American Journal Cardiovascular Drugs 9:5, 299-308
CrossRef332
Yuri B. Pride, John G. Canto, Paul D. Frederick, C. Michael Gibson. (2009) Outcomes Among Patients With Non–ST-Segment Elevation Myocardial Infarction Presenting to Interventional Hospitals With and Without On-Site Cardiac Surgery. JACC: Cardiovascular Interventions 2:10, 944-952
CrossRef333
Jacques Genest, Ruth McPherson, Jiri Frohlich, Todd Anderson, Norm Campbell, André Carpentier, Patrick Couture, Robert Dufour, George Fodor, Gordon A. Francis, Steven Grover, Milan Gupta, Robert A. Hegele, David C. Lau, Lawrence Leiter, Gary F. Lewis, Eva Lonn, G.B. John Mancini, Dominic Ng, Glen J. Pearson, Allan Sniderman, James A. Stone, Ehud Ur. (2009) 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations. Canadian Journal of Cardiology 25:10, 567-579
CrossRef334
David D. Waters, Ivy Ku. (2009) Early Statin Therapy in Acute Coronary Syndromes. Journal of the American College of Cardiology 54:15, 1434-1437
CrossRef335
J.A. Costa, E. Rodilla, F. Pérez-Lahiguera, A. Miralles, C. González, J.M. Pascual. (2009) Objetivos terapéuticos del colesterol LDL y cambios de la proteína C reactiva en pacientes de alto riesgo coronario. Revista Clínica Española 209:9, 415-423
CrossRef336
Claudio Borghi, Arrigo F.G. Cicero, Stefano Bacchelli, Daniela Degli Esposti, Ettore Ambrosioni, . (2009) Serum cholesterol levels on admission and survival in patients with acute myocardial infarction treated with zofenopril: a post hoc analysis of the Survival of Myocardial Infarction Long-term Evaluation trial. Fundamental & Clinical Pharmacology 23:5, 641-648
CrossRef337
Matthew R. Weir, Fawn Yeh, Angela Silverman, Richard B. Devereux, James M. Galloway, Jeffrey A. Henderson, William J. Howard, Marie Russell, Charlton Wilson, Robert Ratner, John Sorkin, Jason G. Umans, Jerome L. Fleg, Mario Stylianou, Elisa Lee, Barbara V. Howard. (2009) Safety and Feasibility of Achieving Lower Systolic Blood Pressure Goals in Persons With Type 2 Diabetes: The SANDS Trial. The Journal of Clinical Hypertension 11:10, 540-548
CrossRef338
Ryan P. Morrissey, George A. Diamond, Sanjay Kaul. (2009) Statins in Acute Coronary Syndromes. Journal of the American College of Cardiology 54:15, 1425-1433
CrossRef339
Alexandre Ouattara, Hamina Benhaoua, Yannick Le Manach, Nejma Mabrouk-Zerguini, Omar Itani, Amer Osman, Marc Landi, Bruno Riou, Pierre Coriat. (2009) Perioperative Statin Therapy Is Associated With a Significant and Dose-Dependent Reduction of Adverse Cardiovascular Outcomes After Coronary Artery Bypass Graft Surgery. Journal of Cardiothoracic and Vascular Anesthesia 23:5, 633-638
CrossRef340
Roberta Ara, Rachid Rafia, Sue E Ward, Anthony S Wierzbicki, Tim M Reynolds, Angie Rees, Abdullah Pandor. (2009) Are intensive lipid-lowering regimens an optimal economic strategy in patients with ACS? An acute and chronic perspective. Expert Review of Pharmacoeconomics & Outcomes Research 9:5, 423-433
CrossRef341
Christopher P. Cannon, Hayes M. Dansky, Michael Davidson, Antonio M. Gotto, Eliot A. Brinton, A. Lawrence Gould, Michael Stepanavage, Sherry Xueyu Liu, Sukrut Shah, Joseph Rubino, Patrice Gibbons, Anne Hermanowski-Vosatka, Bruce Binkowitz, Yale Mitchel, Philip Barter. (2009) Design of the DEFINE trial: Determining the EFficacy and Tolerability of CETP INhibition with AnacEtrapib. American Heart Journal 158:4, 513-519.e3
CrossRef342
Shui-ping Zhao, Dao-quan Peng, Bi-lian Yu, Yong Huo. (2009) Rationale and design of China intensive lipid lowering with statins in acute coronary syndrome: The CHILLAS study. American Heart Journal 158:4, 509-512.e1
CrossRef343
Deepak Voora, Svati H. Shah, Ivan Spasojevic, Shazia Ali, Carol R. Reed, Benjamin A. Salisbury, Geoffrey S. Ginsburg. (2009) The SLCO1B1*5 Genetic Variant Is Associated With Statin-Induced Side Effects. Journal of the American College of Cardiology 54:17, 1609-1616
CrossRef344
A. Kumar, C. P. Cannon. (2009) Acute Coronary Syndromes: Diagnosis and Management, Part I. Mayo Clinic Proceedings 84:10, 917-938
CrossRef345
Roberto Manfredini, Raffaella Salmi, Benedetta Boari, Fabio Manfredini. (2009) Seasonal Variation in Lipids: Should We Consider It More?. The American Journal of Cardiology 104:5, 739-740
CrossRef346
D. Baldassarre, B. Porta, M. Camera, M. Amato, M. Arquati, B. Brusoni, C. Fiorentini, P. Montorsi, S. Romano, F. Veglia, E. Tremoli, M. Cortellaro. (2009) Markers of inflammation, thrombosis and endothelial activation correlate with carotid IMT regression in stable coronary disease after atorvastatin treatment. Nutrition, Metabolism and Cardiovascular Diseases 19:7, 481-490
CrossRef347
Terje R. Pedersen. (2009) Lipid-lowering drugs and risk for cancer. Current Atherosclerosis Reports 11:5, 350-357
CrossRef348
Deborah Gleeson, Deborah L. Crabbe. (2009) Emerging concepts in cardiovascular disease risk assessment: Where do women fit in?. Journal of the American Academy of Nurse Practitioners 21:9, 480-487
CrossRef349
C. Noel Bairey Merz, Mark J. Alberts, Gary J. Balady, Christie M. Ballantyne, Kathy Berra, Henry R. Black, Roger S. Blumenthal, Michael H. Davidson, Sara B. Fazio, Keith C. Ferdinand, Lawrence J. Fine, Vivian Fonseca, Barry A. Franklin, Patrick E. McBride, George A. Mensah, Geno J. Merli, Patrick T. O'Gara, Paul D. Thompson, James A. Underberg. (2009) ACCF/AHA/ACP 2009 Competence and Training Statement: A Curriculum on Prevention of Cardiovascular Disease. Journal of the American College of Cardiology 54:14, 1336-1363
CrossRef350
Tracy Y. Wang, L. Kristin Newby, Anita Y. Chen, Jyotsna Mulgund, Matthew T. Roe, Ali F. Sonel, Deepak L. Bhatt, Elizabeth R. DeLong, E. Magnus Ohman, W. Brian Gibler, Eric D. Peterson. (2009) Hypercholesterolemia Paradox in Relation to Mortality in Acute Coronary Syndrome. Clinical Cardiology 32:9, E22-E28
CrossRef351
Oliver J. Liakopoulos, Yeong-Hoon Choi, Elmar W. Kuhn, Thorsten Wittwer, Michal Borys, Navid Madershahian, Gernot Wassmer, Thorsten Wahlers. (2009) Statins for prevention of atrial fibrillation after cardiac surgery: A systematic literature review. The Journal of Thoracic and Cardiovascular Surgery 138:3, 678-686.e1
CrossRef352
Josep Rodés-Cabau, Jean-Claude Tardif, Mariève Cossette, Olivier F. Bertrand, Reda Ibrahim, Eric Larose, Jean Grégoire, Philippe L. L'Allier, Marie-Claude Guertin. (2009) Acute Effects of Statin Therapy on Coronary Atherosclerosis Following an Acute Coronary Syndrome. The American Journal of Cardiology 104:6, 750-757
CrossRef353
Xinwei Jia, Meng Wei, Xianghua Fu, Xinshun Gu, Weize Fan, Jing Zhang, Ling Xue. (2009) Intensive cholesterol-lowering therapy improves large artery elasticity in acute myocardial infarction patients. Heart and Vessels 24:5, 340-346
CrossRef354
Derek J Hausenloy, Derek M Yellon. (2009) Enhancing cardiovascular disease risk reduction: raising high-density lipoprotein levels. Current Opinion in Cardiology 24:5, 473-482
CrossRef355
John Farmer. (2009) The Vytorin on Carotid–Media Thickness and Overall Arterial Rigidity (VYCTOR) study. Expert Review of Cardiovascular Therapy 7:9, 1057-1060
CrossRef356
Therese Heinonen, David D. Waters, Peter Libby, Jean-Claude Tardif. (2009) A winter’s tale: Report from the First Annual Canadian Biomarkers and Surrogate Endpoints Symposium. Canadian Journal of Cardiology 25:9, 527-532
CrossRef357
Jill S. Burkiewicz, Kathy E. Komperda. (2009) An Elective Course on Landmark Trials to Improve Pharmacy Students' Literature Evaluation and Therapeutic Application Skills. American Journal of Pharmaceutical Education 73:2, 31
CrossRef358
A. S. Wierzbicki. (2009) Storms, tea cups and the adverse effects of statins. International Journal of Clinical Practice 63:9, 1268-1270
CrossRef359
Raphael See, Robert N. Piana. (2009) Achieving optimum lipid-lowering goals in patients with vascular disease. Current Cardiovascular Risk Reports 3:5, 323-330
CrossRef360
M. Miller. (2009) Dyslipidemia and cardiovascular risk: the importance of early prevention. QJM 102:9, 657-667
CrossRef361
Yuichiro Kashima, Atsushi Izawa, Kazunori Aizawa, Megumi Koshikawa, Hiroki Kasai, Takeshi Tomita, Setsuo Kumazaki, Hiroshi Tsutsui, Jun Koyama, Uichi Ikeda. (2009) Rationale and design of assessment of lipophilic vs. hydrophilic statin therapy in acute myocardial infarction (the ALPS-AMI) study. Journal of Cardiology 54:1, 76-79
CrossRef362
Jia Xinwei, Fu Xianghua, Zhang Jing, Gu Xinshun, Xue Ling, Fan Weize, Hao Guozhen, Jiang Yunfa, Wu Weili, Li Shiqiang. (2009) Comparison of Usefulness of Simvastatin 20 mg Versus 80 mg in Preventing Contrast-Induced Nephropathy in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. The American Journal of Cardiology 104:4, 519-524
CrossRef363
DAVID E. DAWE, VIGNENDRA ARIYARAJAH, ALIASGHAR KHADEM. (2009) Is There a Role for Statins in Atrial Fibrillation?. Pacing and Clinical Electrophysiology 32:8, 1063-1072
CrossRef364
Louai Razzouk, Michael E. Farkouh. (2009) Imaging outcomes in cardiovascular clinical trials. Nature Reviews Cardiology 6:8, 524-531
CrossRef365
Karen J McConnell, Kari L Olson, Thomas Delate, John A Merenich. (2009) Factors Associated with Recurrent Coronary Events Among Patients with Cardiovascular Disease. Pharmacotherapy 29:8, 906-913
CrossRef366
Anju Nohria, Adnan Prsic, Ping-Yen Liu, Ryuji Okamoto, Mark A. Creager, Andrew Selwyn, James K. Liao, Peter Ganz. (2009) Statins inhibit Rho kinase activity in patients with atherosclerosis. Atherosclerosis 205:2, 517-521
CrossRef367
Habib Samady, Michael C. McDaniel. (2009) Can Statins Alter Coronary Plaque Composition Assessed by Radiofrequency Backscatter Intravascular Ultrasound?
Editorials published in JACC: Cardiovascular Interventions reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Interventions or the American College of Cardiology.. JACC: Cardiovascular Interventions 2:7, 697-700
CrossRef368
Miriam Jacob, Leslie Cho. (2009) Lipid reduction in acute coronary syndrome: How much, when, and how?. Current Cardiology Reports 11:4, 276-281
CrossRef369
Stephen D. Wiviott, Satishkumar Mohanavelu, Joel S. Raichlen, Valerie A. Cain, Steven E. Nissen, Peter Libby. (2009) Safety and Efficacy of Achieving Very Low Low-Density Lipoprotein Cholesterol Levels With Rosuvastatin 40 mg Daily (from the ASTEROID Study). The American Journal of Cardiology 104:1, 29-35
CrossRef370
Myeong-Ki Hong, Duk-Woo Park, Cheol-Whan Lee, Seung-Whan Lee, Young-Hak Kim, Duk-Hyun Kang, Jae-Kwan Song, Jae-Joong Kim, Seong-Wook Park, Seung-Jung Park. (2009) Effects of Statin Treatments on Coronary Plaques Assessed by Volumetric Virtual Histology Intravascular Ultrasound Analysis. JACC: Cardiovascular Interventions 2:7, 679-688
CrossRef371
Peter Sleight. (2009) Clinical evidence from ONTARGET: the value of an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor. Journal of Hypertension 27:Suppl 5, S23-S29
CrossRef372
Takafumi Hiro, Takeshi Kimura, Takeshi Morimoto, Katsumi Miyauchi, Yoshihisa Nakagawa, Masakazu Yamagishi, Yukio Ozaki, Kazuo Kimura, Satoshi Saito, Tetsu Yamaguchi, Hiroyuki Daida, Masunori Matsuzaki. (2009) Effect of Intensive Statin Therapy on Regression of Coronary Atherosclerosis in Patients With Acute Coronary Syndrome. Journal of the American College of Cardiology 54:4, 293-302
CrossRef373
Douglas C. A. Taylor, Ankur Pandya, David Thompson, Paula Chu, Jennifer Graff, James Shepherd, Nanette Wenger, Heiner Greten, Rafael Carmena, Michael Drummond, Milton C. Weinstein. (2009) Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study. The European Journal of Health Economics 10:3, 255-265
CrossRef374
Ingar Holme, Michael Szarek, Nilo B. Cater, Ole Faergeman, John J.P. Kastelein, Anders G. Olsson, Matti J. Tikkanen, Mogens Lytken Larsen, Christina Lindahl, Terje R. Pedersen. (2009) Adherence-adjusted efficacy with intensive versus standard statin therapy in patients with acute myocardial infarction in the IDEAL study. European Journal of Cardiovascular Prevention & Rehabilitation 16:3, 315-320
CrossRef375
Xiankai Li, Yawei Xu, Jue Li, Dayi Hu. (2009) The Gender Differences in Baseline Characteristics and Statin Intervention Among Outpatients with Coronary Heart Disease in China: The China Cholesterol Education Program. Clinical Cardiology 32:6, 308-314
CrossRef376
Jean Ferrières, Vincent Bataille, Florence Leclercq, Philippe Geslin, Jean-Bernard Ruidavets, Gilles Grollier, Paul Bernard, Jean-Pierre Cambou, Tabassome Simon, Nicolas Danchin. (2009) Patterns of statin prescription in acute myocardial infarction. Atherosclerosis 204:2, 491-496
CrossRef377
Fabrizio Montecucco, François Mach. (2009) Update on statin-mediated anti-inflammatory activities in atherosclerosis. Seminars in Immunopathology 31:1, 127-142
CrossRef378
Michael J. Koren, Theodore Feldman, Robert A. Mendes. (2009) Impact of High-Dose Atorvastatin in Coronary Heart Disease Patients Age 65 to 78 Years. Clinical Cardiology 32:5, 256-263
CrossRef379
William Clifford Roberts. (2009) Evaluating Lipid-Lowering Trials in the Twenty-First Century. The American Journal of Cardiology 103:9, 1325-1328
CrossRef380
David D. Waters. (2009) Clinical Insights From the Treating to New Targets Trial. Progress in Cardiovascular Diseases 51:6, 487-502
CrossRef381
Ralph AH Stewart. (2009) Predicting benefit from statins by C-reactive protein, LDL-cholesterol or absolute cardiovascular risk. Future Cardiology 5:3, 231-236
CrossRef382
Frank R. Lichtenberg. (2009) Have newer cardiovascular drugs reduced hospitalization? Evidence from longitudinal country-level data on 20 OECD countries, 1995-2003. Health Economics 18:5, 519-534
CrossRef383
Robert Zeiser, Kristina Maas, Sawsan Youssef, Christoph Dürr, Lawrence Steinman, Robert S. Negrin. (2009) Regulation of different inflammatory diseases by impacting the mevalonate pathway. Immunology 127:1, 18-25
CrossRef384
Zhuo Zhao, Jing Geng, Zhi-Ming Ge, Wei Wang, Yun Zhang, Wei-Qiang Kang. (2009) EFFICACY AND SAFETY OF ATORVASTATIN DURING EARLY HOSPITALIZATION IN ELDERLY PATIENTS WITH UNSTABLE ANGINA. Clinical and Experimental Pharmacology and Physiology 36:5-6, 554-558
CrossRef385
Pierre Amarenco, Julien Labreuche. (2009) Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. The Lancet Neurology 8:5, 453-463
CrossRef386
Gianna Fabbri, Aldo Pietro Maggioni. (2009) Cardiovascular risk reduction: What do recent trials with rosuvastatin tell us?. Advances in Therapy 26:5, 469-487
CrossRef387
Joseph P. Vande Griend, Joseph J. Saseen. (2009) Low-density lipoprotein cholesterol goal attainment in high-risk family medicine patients. Journal of Clinical Lipidology 3:3, 195-200
CrossRef388
José Paulo Araújo, Patricia Lourenço, Ana Azevedo, Fernando Friões, Francisco Rocha-Gonçalves, António Ferreira, Paulo Bettencourt. (2009) Prognostic Value of High-Sensitivity C-Reactive Protein in Heart Failure: A Systematic Review. Journal of Cardiac Failure 15:3, 256-266
CrossRef389
Paul M Ridker, Eleanor Danielson, Francisco AH Fonseca, Jacques Genest, Antonio M Gotto, John JP Kastelein, Wolfgang Koenig, Peter Libby, Alberto J Lorenzatti, Jean G MacFadyen, Børge G Nordestgaard, James Shepherd, James T Willerson, Robert J Glynn. (2009) Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. The Lancet 373:9670, 1175-1182
CrossRef390
Khalid Alwaili, Khalid Alrasadi, Zuhier Awan, Jacques Genest. (2009) Approach to the diagnosis and management of lipoprotein disorders. Current Opinion in Endocrinology, Diabetes and Obesity 16:2, 132-140
CrossRef391
Anthony Keech, John D. Horowitz. (2009) Cost-effectiveness Considerations of Cardiovascular Therapeutics. Heart, Lung and Circulation 18:2, 118-122
CrossRef392
Patricia Tung, Stephen D. Wiviott, Christopher P. Cannon, Sabina A. Murphy, Carolyn H. McCabe, C. Michael Gibson. (2009) Seasonal Variation in Lipids in Patients Following Acute Coronary Syndrome on Fixed Doses of Pravastatin (40 mg) or Atorvastatin (80 mg) (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction 22 [PROVE IT-TIMI 22] Study). The American Journal of Cardiology 103:8, 1056-1060
CrossRef393
Andrew Ludman, Vinod Venugopal, Derek M. Yellon, Derek J. Hausenloy. (2009) Statins and cardioprotection — More than just lipid lowering?. Pharmacology & Therapeutics 122:1, 30-43
CrossRef394
Stefan N. Willich, Heike Englert, Frank Sonntag, Heinz Völler, Wolfgang Meyer-Sabellek, Karl Wegscheider, Eberhard Windler, Hugo Katus, Jacqueline Müller-Nordhorn. (2009) Impact of a compliance program on cholesterol control: results of the randomized ORBITAL study in 8108 patients treated with rosuvastatin. European Journal of Cardiovascular Prevention & Rehabilitation 16:2, 180-187
CrossRef395
Tara L. Dall, Harold Bays. (2009) Addressing Lipid Treatment Targets Beyond Cholesterol: A Role for Prescription Omega-3 Fatty Acid Therapy. Southern Medical Journal 102:4, 390-396
CrossRef396
M. Farnier, M. Averna, L. Missault, H. Vaverkova, M. Viigimaa, R. Massaad, K. Vandormael, A. O. Johnson-Levonas, P. Brudi. (2009) Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study. International Journal of Clinical Practice 63:4, 547-559
CrossRef397
María G. Barderas, José Tuñón, Verónica M. Dardé, Fernando De la Cuesta, José J. Jiménez-Nácher, Nieves Tarín, Lorenzo López-Bescós, Jesús Egido, Fernando Vivanco. (2009) Atorvastatin modifies the protein profile of circulating human monocytes after an acute coronary syndrome. PROTEOMICS 9:7, 1982-1993
CrossRef398
Dean G. Karalis. (2009) Intensive Lowering of Low-Density Lipoprotein Cholesterol Levels for Primary Prevention of Coronary Artery Disease. Mayo Clinic Proceedings 84:4, 345-352
CrossRef399
Evan A. Stein. (2009) Low-Density Lipoprotein Cholesterol Reduction and Prevention of Cardiovascular Disease. Mayo Clinic Proceedings 84:4, 307-309
CrossRef400
E. A. Stein. (2009) Low-Density Lipoprotein Cholesterol Reduction and Prevention of Cardiovascular Disease. Mayo Clinic Proceedings 84:4, 307-309
CrossRef401
D. G. Karalis. (2009) Intensive Lowering of Low-Density Lipoprotein Cholesterol Levels for Primary Prevention of Coronary Artery Disease. Mayo Clinic Proceedings 84:4, 345-352
CrossRef402
Paul Hamilton. (2009) Role of ezetimibe in the management of patients with atherosclerosis. Coronary Artery Disease 20:2, 169-174
CrossRef403
D. N. Orken, G. Kenangil, M. Celik, Z. Mail, H. Kayaalp, E. Erginoz, H. Forta. (2009) Association of low cholesterol with primary intracerebral haemorrhage: a case control study. Acta Neurologica Scandinavica 119:3, 151-154
CrossRef404
Runhua Hou, Anne Carol Goldberg. (2009) Lowering Low-Density Lipoprotein Cholesterol: Statins, Ezetimibe, Bile Acid Sequestrants, and Combinations: Comparative Efficacy and Safety. Endocrinology & Metabolism Clinics of North America 38:1, 79-97
CrossRef405
Adnan K. Chhatriwalla, Stephen J. Nicholls, Thomas H. Wang, Kathy Wolski, Ilke Sipahi, Tim Crowe, Paul Schoenhagen, Samir Kapadia, E. Murat Tuzcu, Steven E. Nissen. (2009) Low Levels of Low-Density Lipoprotein Cholesterol and Blood Pressure and Progression of Coronary Atherosclerosis. Journal of the American College of Cardiology 53:13, 1110-1115
CrossRef406
Evan A. Stein. (2009) Other Therapies for Reducing Low-Density Lipoprotein Cholesterol: Medications in Development. Endocrinology & Metabolism Clinics of North America 38:1, 99-119
CrossRef407
Philip R. Liebson. (2009) JUPITER and ACCOMPLISH. Preventive Cardiology 12:2, 114-119
CrossRef408
Ajith P. Nair, Bruce Darrow. (2009) Lipid Management in the Geriatric Patient. Endocrinology & Metabolism Clinics of North America 38:1, 185-206
CrossRef409
Subramaniam Tavintharan, Su Chi Lim, Chee Fang Sum. (2009) Effects of Niacin on Cell Adhesion and Early Atherogenesis: Biochemical and Functional Findings in Endothelial Cells. Basic & Clinical Pharmacology & Toxicology 104:3, 206-210
CrossRef410
Venkateshwar R. Polsani, Salim S. Virani, Vijay Nambi. (2009) Lipid management: Considerations in acute coronary syndrome. Current Atherosclerosis Reports 11:2, 149-156
CrossRef411
Terri Montague, Barbara Murphy. (2009) Lipid Management in Chronic Kidney Disease, Hemodialysis, and Transplantation. Endocrinology & Metabolism Clinics of North America 38:1, 223-234
CrossRef412
Sreenivasa RK Seshasai, Kausik K Ray. (2009) Intensive statin therapy in coronary artery disease: is lower cholesterol better and safe?. Future Cardiology 5:2, 129-139
CrossRef413
Mark Rosenberg, Martin Urbansky, Markus Haass. (2009) Insufficient Statin Therapy in Coronary Heart Disease Is Related to the Time of the Last Coronary Angiography. Journal of Cardiovascular Pharmacology 53:3, 215-222
CrossRef414
Alawi A. Alsheikh-Ali, Richard H. Karas. (2009) The relationship of statins to rhabdomyolysis, malignancy, and hepatic toxicity: Evidence from clinical trials. Current Atherosclerosis Reports 11:2, 100-104
CrossRef415
S. J. Lester, M. F. Eleid, B. K. Khandheria, R. T. Hurst. (2009) Carotid Intima-Media Thickness and Coronary Artery Calcium Score as Indications of Subclinical Atherosclerosis. Mayo Clinic Proceedings 84:3, 229-233
CrossRef416
Alberico L. Catapano. (2009) Perspectives on low-density lipoprotein cholesterol goal achievement. Current Medical Research and Opinion 25:2, 431-447
CrossRef417
Nenad Lakusic, Darija Granec. (2009) Improvement in lipid profile of patients referred to a cardiac rehabilitation program: is the effect of regular exercise underestimated because of the antilipid drugs?. European Journal of Cardiovascular Prevention & Rehabilitation 16:1, 114-116
CrossRef418
Helmut Gohlke, Christian Albus, Detlef Bernd Gysan, Harry W. Hahmann, Peter Mathes. (2009) Cardiovascular Prevention in Clinical Practice (ESC and German Guidelines 2007). Herz 34:1, 4-14
CrossRef419
Annapoorna S. Kini, Paul Muntner, Pedro R. Moreno, Devin Mann, Prakash Krishnan, Michael C. Kim, Oana C. Rafael, Michael E. Farkouh, Samin K. Sharma. (2009) Relation of High-Density Lipoprotein Cholesterol to Mortality After Percutaneous Coronary Interventions in Patients With Low-Density Lipoprotein <70 mg/dl. The American Journal of Cardiology 103:3, 350-354
CrossRef420
Jay N. Cohn, Daniel J. Wilson, Joel Neutel, Mark Houston, Myron H. Weinberger, Richard Grimm, David H.G. Smith, William Sun. (2009) Coadministered Amlodipine and Atorvastatin Produces Early Improvements in Arterial Wall Compliance in Hypertensive Patients With Dyslipidemia. American Journal of Hypertension 22:2, 137-144
CrossRef421
A. Corsini, E. Windier, M. Farnier. (2009) Colesevelam hydrochloride: usefulness of a specifically engineered bile acid sequestrant for lowering LDL-cholesterol. European Journal of Cardiovascular Prevention & Rehabilitation 16:1, 1-9
CrossRef422
Philippa J. Delahoy, Dianna J. Magliano, Kate Webb, Mendel Grobler, Danny Liew. (2009) The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: An updated meta-analysis. Clinical Therapeutics 31:2, 236-244
CrossRef423
Hemanth Neeli, Ram Gadi, Daniel J. Rader. (2009) Managing diabetic dyslipidemia: Beyond statin therapy. Current Diabetes Reports 9:1, 11-17
CrossRef424
Robert A. Vogel, Michael Miller. (2009) Cholesterol Goals: Moving from Numbers to Treatment. Clinical Cardiology 32:2, 106-108
CrossRef425
Carol M. Mason. (2009) Preventing coronary heart disease and stroke with aggressive statin therapy in older adults using a team management model. Journal of the American Academy of Nurse Practitioners 21:1, 47-53
CrossRef426
Tsutomu Yamazaki, Masahiko Kurabayashi. (2009) A Randomized Controlled Study to Compare the Effects of Rosuvastatin 5mg and Atorvastatin10mg on the Plasma Lipid Profile in Japanese Patients with Hypercholesterolemia (ASTRO-2). Annals of Vascular Diseases 2:3, 159-173
CrossRef427
Tomohito Hamazaki. (2009) Are the upper limits for serum cholesterol levels necessary?. Journal of Lipid Nutrition 18:1, 33-50
CrossRef428
Peter Baginsky. (2009) Should we treat all patients with coronary heart disease or the equivalent with statins?. Current Atherosclerosis Reports 11:1, 28-35
CrossRef429
Faramarz Tehrani, Ryan Morrissey, Anita Phan, Christopher Chien, Ernst R. Schwarz. (2009) Statin Therapy in Patients with Diastolic Heart Failure. Clinical Cardiologyn/a-n/a
CrossRef430
Kyeong Ho Yun, Ik-Sang Shin, Sang Jae Rhee, Eun Mi Lee, Nam Jin Yoo, Nam-Ho Kim, Seok Kyu Oh, Jin-Won Jeong. (2009) Clinical Significance of On-Treatment Triglyceride Level in Patients Treated by Percutaneous Coronary Intervention for Non-ST-Segment Elevation Acute Coronary Syndrome. The Korean Journal of Internal Medicine 24:4, 330
CrossRef431
Katsunori Ikewaki, Yoshio Terao, Hideki Ozasa, Yoshinobu Nakada, Jun-ichiro Tohyama, Yae Inoue, Michihiro Yoshimura. (2009) Effects of Atorvastatin on Nuclear Magnetic Resonance-Defined Lipoprotein Subclasses and Inflammatory Markers in Patients with Hypercholesterolemia. Journal of Atherosclerosis and Thrombosis 16:1, 51-56
CrossRef432
Christos Vaklavas, Yiannis S. Chatzizisis, Anthony Ziakas, Chrysanthos Zamboulis, George D. Giannoglou. (2009) Molecular basis of statin-associated myopathy. Atherosclerosis 202:1, 18-28
CrossRef433
V. G. Athyros, A. I. Kakafika, A. S. Wierzbicki, A. Karagiannis, D. P. Mikhailidis. (2009) Targeting triglycerides in secondary prevention: should we bother?. International Journal of Clinical Practice 63:1, 15-18
CrossRef434
Babak B. Navi, Alan Z. Segal. (2009) The role of cholesterol and statins in stroke. Current Cardiology Reports 11:1, 4-11
CrossRef435
Kazuto Watanabe, Mriko Harada-Shiba, Akira Suzuki, Yuriko Higuchi, Shigeru Kawakami, Mitsuru Hashida, Risa Gokuden, Ryohsuke Kurihara, Yusuke Sugao, Takeshi Mori, Yoshiki Katayama, Takuro Niidome. (2009) Oligonuleotide Delivery with Dendritic Poly(L-lysine) for Treatments of the Liver Disorders. MRS Proceedings 1237,
CrossRef436
Herbert D. Aronow, Michael P. Dutro, Andreas Kuznik, James Cwengros. (2009) Prevalence of cardiovascular comorbidities and utilization of evidence-based treatment strategies among statin users in a Medicare and commercial health plan*. Current Medical Research and Opinion 25:1, 205-213
CrossRef437
Gary S. Mintz, Akiko Maehara. (2009) Serial Intravascular Ultrasound Assessment of Atherosclerosis Progression and Regression. Circulation Journal 73:9, 1557-1560
CrossRef438
Atsushi Hirayama, Satoshi Saito, Yasunori Ueda, Tadateru Takayama, Junko Honye, Sei Komatsu, Osamu Yamaguchi, Yuxin Li, Junji Yajima, Shinsuke Nanto, Kenji Takazawa, Kazuhisa Kodama. (2009) Qualitative and Quantitative Changes in Coronary Plaque Associated With Atorvastatin Therapy. Circulation Journal 73:4, 718-725
CrossRef439
Borja Ibanez, Giovanni Cimmino, Juan Bénézet-Mazuecos, Carlos G. Santos-Gallego, Antonio Pinero, Susanna Prat-González, Walter S. Speidl, Valentin Fuster, Mario J. García, Javier Sanz, Juan J. Badimon. (2009) Quantification of serial changes in plaque burden using multi-detector computed tomography in experimental atherosclerosis. Atherosclerosis 202:1, 185-191
CrossRef440
Tsuyoshi Nozue, Shingo Yamamoto, Shinichi Tohyama, Shigeo Umezawa, Tomoyuki Kunishima, Akira Sato, Shogo Miyake, Youichi Takeyama, Yoshihiro Morino, Takao Yamauchi, Toshiya Muramatsu, Kiyoshi Hibi, Takashi Sozu, Ichiro Michishita, Kanagawa PTCA Conference Study Grou. (2009) Treatment With Statin on Atheroma Regression Evaluated by Intravascular Ultrasound With Virtual Histology (TRUTH Study). Circulation Journal 73:2, 352-355
CrossRef441
Toru Toi, Isao Taguchi, Shuichi Yoneda, Michiya Kageyama, Akiko Kikuchi, Michiaki Tokura, Tomoaki Kanaya, Shichiro Abe, Ryuko Matsuda, Noboru Kaneko. (2009) Early Effect of Lipid-Lowering Therapy With Pitavastatin on Regression of Coronary Atherosclerotic Plaque. Circulation Journal 73:8, 1466-1472
CrossRef442
Amit Sachdeva, Christopher P. Cannon, Prakash C. Deedwania, Kenneth A. LaBresh, Sidney C. Smith, David Dai, Adrian Hernandez, Gregg C. Fonarow. (2009) Lipid levels in patients hospitalized with coronary artery disease: An analysis of 136,905 hospitalizations in Get With The Guidelines. American Heart Journal 157:1, 111-117.e2
CrossRef443
Gregg C. Fonarow, William J. French, Paul D. Frederick. (2009) Trends in the use of lipid-lowering medications at discharge in patients with acute myocardial infarction: 1998 to 2006. American Heart Journal 157:1, 185-194.e2
CrossRef444
L.M. Dijksman, A. Hirsch, F. Windhausen, F.F. Asselman, J.G.P. Tijssen, M.G.W. Dijkgraaf, R.J. de Winter. (2009) Cost-effectiveness of early versus selectively invasive strategy in patients with acute coronary syndromes without ST-segment elevation. International Journal of Cardiology 131:2, 204-211
CrossRef445
Michael T. McDermott. 2009. Lipid Disorders. , 65-75.
CrossRef446
Takatoshi Kasai, Katsumi Miyauchi, Kan Kajimoto, Naozumi Kubota, Takeshi Kurata, Atsushi Amano, Hiroyuki Daida. (2009) The Impact of Pravastatin Therapy on Long-Term Outcome in Patients With Metabolic Syndrome Undergoing Complete Coronary Revascularization. Circulation Journal 73:11, 2104-2109
CrossRef447
Kazuto Watanabe, Mariko Harada-Shiba, Akira Suzuki, Risa Gokuden, Ryohsuke Kurihara, Yusuke Sugao, Takeshi Mori, Yoshiki Katayama, Takuro Niidome. (2009) In vivo siRNA delivery with dendritic poly(l-lysine) for the treatment of hypercholesterolemia. Molecular BioSystems 5:11, 1306
CrossRef448
Peter Ganz, Priscilla Y. Hsue. (2009) Individualized Approach to the Management of Coronary Heart Disease. Journal of the American College of Cardiology 53:4, 331-333
CrossRef449
Jennifer G. Robinson, Songfeng Wang, Brian J. Smith, Terry A. Jacobson. (2009) Meta-Analysis of the Relationship Between Non–High-Density Lipoprotein Cholesterol Reduction and Coronary Heart Disease Risk. Journal of the American College of Cardiology 53:4, 316-322
CrossRef450
Martin Sénécal, George Fodor, Claude Gagné, Jacques Genest, Marc-André Lavoie, Ruth McPherson, Michael Marentette, Rolf J. Sebaldt. (2009) Limitations of statin monotherapy for the treatment of dyslipidemia: a projection based on the Canadian lipid study – observational. Current Medical Research and Opinion 25:1, 47-55
CrossRef451
Robert S Rosenson, Bertram Pitt. (2008) Triglycerides and cardiovascular events in ACS: the need for combined lipid-altering therapies. Nature Clinical Practice Cardiovascular Medicine 6:2, 98-100
CrossRef452
Lynn Moran, Tyler Fugate, Yufei Xiang, Christopher Cianci, Sherrine Eid, Martin Matsumura. (2008) Statin Pretreatment Is Protective Despite an Association With Greater Coronary Artery Disease Burden in Patients Presenting With a First ST-Elevation Myocardial Infarction. Preventive Cardiology 11:1, 21-25
CrossRef453
Robert L. Ohsfeldt, Sanjay K. Gandhi, Kathleen M. Fox, James M. McKenney. (2008) Statin Cost-Effectiveness Comparisons Using Real-World Effectiveness Data: Formulary Implications. Value in Health 11:7, 1061-1069
CrossRef454
ROBERT L. WILENSKY. (2008) Vulnerable Plaque: Scope of the Problem. Journal of Interventional Cardiology 21:6, 443-451
CrossRef455
D John Betteridge. (2008) Lipid lowering in diabetes mellitus. Current Opinion in Lipidology 19:6, 579-584
CrossRef456
Alastair Matheson. (2008) Corporate Science and the Husbandry of Scientific and Medical Knowledge by the Pharmaceutical Industry. BioSocieties 3:4, 355-382
CrossRef457
M.W. Merx, C. Weber. (2008) Benefits of statins beyond lipid lowering. Drug Discovery Today: Disease Mechanisms 5:3-4, e325-e331
CrossRef458
Jacques Bonnet, R. McPherson, A. Tedgui, D. Simoneau, A. Nozza, P. Martineau, Jean Davignon. (2008) Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: Results of the CAP (Comparative Atorvastatin Pleiotropic effects) study. Clinical Therapeutics 30:12, 2298-2313
CrossRef459
John Strony, Robert Hoffman, Mary Hanson, Enrico Veltri. (2008) Tolerability and effects on lipids of ezetimibe coadministered with pravastatin or simvastatin for twelve months: Results from two open-label extension studies in hypercholesterolemic patients. Clinical Therapeutics 30:12, 2280-2297
CrossRef460
Seung-Hoon Lee, Yoon-Hee Kim, Young-Ju Kim, Byung-Woo Yoon. (2008) Atorvastatin enhances hypothermia-induced neuroprotection after stroke. Journal of the Neurological Sciences 275:1-2, 64-68
CrossRef461
J. Cash, M. E. Callender, N. I. McDougall, I. S. Young, D. P. Nicholls. (2008) Statin safety and chronic liver disease. International Journal of Clinical Practice 62:12, 1831-1835
CrossRef462
Cihan Cevik, Mohammad Otahbachi, Kenneth Nugent, Chokesuwattanaskul Warangkana, Gary Meyerrose. (2008) Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition on serum matrix metalloproteinase-13 and tissue inhibitor matrix metalloproteinase-1 levels as a sign of plaque stabilization. Journal of Cardiovascular Medicine 9:12, 1274-1278
CrossRef463
T. A. Jacobson, D. A. Wertz, T. Hoy, A. Kuznik, D. Grochulski, M. Cziraky. (2008) Comparison of Cardiovascular Event Rates in Patients Without Cardiovascular Disease in Whom Atorvastatin or Simvastatin Was Newly Initiated. Mayo Clinic Proceedings 83:12, 1316-1325
CrossRef464
R. A. Krasuski. (2008) Primary Prevention and Statins: Is It Just About Going to Class?. Mayo Clinic Proceedings 83:12, 1313-1315
CrossRef465
Robert S Rosenson. (2008) Fenofibrate: treatment of hyperlipidemia and beyond. Expert Review of Cardiovascular Therapy 6:10, 1319-1330
CrossRef466
Herbert D. Aronow, A. Michael Lincoff, Martin J. Quinn, A. Thomas McRae, Hitinder S. Gurm, Penny L. Houghtaling, Christopher B. Granger, Robert A. Harrington, Franz Van de Werf, Eric J. Topol, Michael S. Lauer. (2008) Relation Between Previous Lipid-Lowering Therapy and Infarct Size (Creatine Kinase-MB Level) in Patients Presenting With Acute Myocardial Infarction. The American Journal of Cardiology 102:9, 1119-1124
CrossRef467
Aarif Y Khakoo, Edward TH Yeh. (2008) Therapy Insight: management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy. Nature Clinical Practice Oncology 5:11, 655-667
CrossRef468
Edward J. Mills, Beth Rachlis, Ping Wu, Philip J. Devereaux, Paul Arora, Dan Perri. (2008) Primary Prevention of Cardiovascular Mortality and Events With Statin Treatments. Journal of the American College of Cardiology 52:22, 1769-1781
CrossRef469
Melinda J Carrington, Claudia Retegan, Colin I Johnston, Garry L Jennings, Simon Stewart. (2008) Cholesterol complacency in Australia: time to revisit the basics of cardiovascular disease prevention. Journal of Clinical Nursing
CrossRef470
Antonio Maria Leone, Sergio Rutella, Maria Benedetta Giannico, Matteo Perfetti, Vincenzo Zaccone, Salvatore Brugaletta, Barbara Garramone, Giampaolo Niccoli, Italo Porto, Giovanna Liuzzo, Luigi Marzio Biasucci, Silvia Bellesi, Leonarda Galiuto, Giuseppe Leone, Antonio Giuseppe Rebuzzi, Filippo Crea. (2008) Effect of intensive vs standard statin therapy on endothelial progenitor cells and left ventricular function in patients with acute myocardial infarction: Statins for regeneration after acute myocardial infarction and PCI (STRAP) trial. International Journal of Cardiology 130:3, 457-462
CrossRef471
J. H. O'Keefe, K. A. Bybee, C. J. Lavie. (2008) Is Carotid Intima-Media Thickness a Reliable Clinical Predictor?-Reply-I. Mayo Clinic Proceedings 83:11, 1300-1301
CrossRef472
Michael Domanski, Xin Tian, Jerome Fleg, Sean Coady, Christine Gosen, Ruth Kirby, Vandana Sachdev, Genell Knatterud, Eugene Braunwald. (2008) Pleiotropic Effect of Lovastatin, With and Without Cholestyramine, in the Post Coronary Artery Bypass Graft (Post CABG) Trial. The American Journal of Cardiology 102:8, 1023-1027
CrossRef473
Alexander JM Rennings, Anton FH Stalenhoef. (2008) JTT-705: is there still future for a CETP inhibitor after torcetrapib?. Expert Opinion on Investigational Drugs 17:10, 1589-1597
CrossRef474
Richard J. Willke, Steve Zhou, Robert A. Vogel. (2008) Differences in cardiovascular event rates between atorvastatin and simvastatin among new users: managed-care experience. Current Medical Research and Opinion 24:10, 2873-2882
CrossRef475
A. M. Leone, M. Valgimigli, M. B. Giannico, V. Zaccone, M. Perfetti, D. D'Amario, A. G. Rebuzzi, F. Crea. (2008) From bone marrow to the arterial wall: the ongoing tale of endothelial progenitor cells. European Heart Journal 30:8, 890-899
CrossRef476
Kamal Sharma, Mark J. Eisenberg. (2008) Putting the benefits of percutaneous coronary revascularization into perspective: From trials to guidelines. Current Cardiology Reports 10:5, 393-401
CrossRef477
Bart Staels, Michel Maes, Alberto Zambon. (2008) Fibrates and future PPARα agonists in the treatment of cardiovascular disease. Nature Clinical Practice Cardiovascular Medicine 5:9, 542-553
CrossRef478
Albert V.G. Bruschke, J. Wouter Jukema. (2008) Aggressive Therapy Is Not Always the Best Therapy. Journal of the American College of Cardiology 52:11, 921-923
CrossRef479
Caroline Sirois, Paul Poirier, Jocelyne Moisan, Jean-Pierre Grégoire. (2008) The benefit of aspirin therapy in type 2 diabetes: What is the evidence?. International Journal of Cardiology 129:2, 172-179
CrossRef480
Michael Roden, Kurt Huber. (2008) Lipidprofil und Therapiestatus in der Sekundärprävention bei Hochrisiko-Patienten mit klinisch manifester Arteriosklerose und/oder Diabetes mellitus: Das Hospital Screening Projekt (HSP) in Österreich. Wiener klinische Wochenschrift 120:17-18, 558-565
CrossRef481
&NA;. (2008) Which Statin?. Obstetrics & Gynecology 112:3, 696-698
CrossRef482
Henry Fischer, Thomas Mackenzie, Kevin McCullen, Rachel Everhart, Raymond O. Estacio. (2008) Design of a nurse-run, telephone-based intervention to improve lipids in diabetics. Contemporary Clinical Trials 29:5, 809-816
CrossRef483
Claudio Rapezzi, Elena Biagini, Paolo Bellis, Massimo Cafiero, Mario Velussi, Antonio Ceriello, Robin MT Cooke, Carlo Schweiger. (2008) Exploring the gap between National Cholesterol Education Program guidelines and clinical practice in secondary care: results of a cross-sectional study involving over 10 000 patients followed in different specialty settings across Italy. Journal of Cardiovascular Medicine 9:9, 878-887
CrossRef484
Vasilios G. Athyros, Anna I. Kakafika, Asterios Karagiannis, Dimitri P. Mikhailidis. (2008) Do we need to consider inflammatory markers when we treat atherosclerotic disease?. Atherosclerosis 200:1, 1-12
CrossRef485
Hitoshi Ando, Koh-ichi Sugimoto, Hayato Yanagihara, Shuichi Tsuruoka, Tetsuo Saito, Toshinari Takamura, Shuichi Kaneko, Akio Fujimura. (2008) EFFECTS OF ATORVASTATIN AND PRAVASTATIN ON GLUCOSE TOLERANCE, ADIPOKINE LEVELS AND INFLAMMATORY MARKERS IN HYPERCHOLESTEROLAEMIC PATIENTS. Clinical and Experimental Pharmacology and Physiology 35:9, 1012-1017
CrossRef486
Roberto R. Giraldez, Robert P. Giugliano, Satishkumar Mohanavelu, Sabina A. Murphy, Carolyn H. McCabe, Christopher P. Cannon, Eugene Braunwald. (2008) Baseline Low-Density Lipoprotein Cholesterol Is an Important Predictor of the Benefit of Intensive Lipid-Lowering Therapy. Journal of the American College of Cardiology 52:11, 914-920
CrossRef487
Niels Engberding, Nanette K Wenger. (2008) Cardiovascular disease prevention tailored for women. Expert Review of Cardiovascular Therapy 6:8, 1123-1134
CrossRef488
Emmanouil S. Brilakis, James A. de Lemos, Christopher P. Cannon, Stephen D. Wiviott, Sabina A. Murphy, David A. Morrow, Marc S. Sabatine, Subhash Banerjee, Michael A. Blazing, Robert M. Califf, Eugene Braunwald. (2008) Outcomes of Patients With Acute Coronary Syndrome and Previous Coronary Artery Bypass Grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] Trials). The American Journal of Cardiology 102:5, 552-558
CrossRef489
Philippe Couvert, Philippe Giral, Sylvie Dejager, Jessie Gu, Thierry Huby, M John Chapman, Eric Bruckert, Alain Carrié. (2008) Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy. Pharmacogenomics 9:9, 1217-1227
CrossRef490
The SEARCH Collaborative Group. (2008) SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study. New England Journal of Medicine 359:8, 789-799
Full Text491
Jobien K Olijhoek, Gideon R Hajer, Yolanda van der Graaf, Geesje M Dallinga-Thie, Frank L J Visseren. (2008) The Effects of Low-Dose Simvastatin and Ezetimibe Compared to High-Dose Simvastatin Alone on Post-Fat Load Endothelial Function in Patients With Metabolic Syndrome: A Randomized Double-Blind Crossover Trial. Journal of Cardiovascular Pharmacology 52:2, 145-150
CrossRef492
T. Sathyapalan, S. L. Atkin, E. S. Kilpatrick. (2008) Variability of lipids in patients with Type 2 diabetes taking statin treatment: implications for target setting. Diabetic Medicine 25:8, 909-915
CrossRef493
Gilbert J. Zoghbi, Todd A. Dorfman, Ami E. Iskandrian. (2008) The Effects of Medications on Myocardial Perfusion. Journal of the American College of Cardiology 52:6, 401-416
CrossRef494
Fergus McTaggart, Peter Jones. (2008) Effects of Statins on High-Density Lipoproteins: A Potential Contribution to Cardiovascular Benefit. Cardiovascular Drugs and Therapy 22:4, 321-338
CrossRef495
Allan Gaw. (2008) Should we be targeting triglyceride as well as LDL cholesterol in the battle against coronary heart disease?. Nature Clinical Practice Cardiovascular Medicine 5:8, 438-439
CrossRef496
Ameen F. Person, Cam Patterson. (2008) Therapeutic options for premature coronary artery disease. Current Treatment Options in Cardiovascular Medicine 10:4, 294-303
CrossRef497
Michael A. Pacanowski, Reginald F. Frye, Osatohanmen Enogieru, Richard S. Schofield, Issam Zineh. (2008) Plasma coenzyme Q10 predicts lipid-lowering response to high-dose atorvastatin. Journal of Clinical Lipidology 2:4, 289-297
CrossRef498
Goran Gajski, Vera Garaj-Vrhovac, Višnja Oreščanin. (2008) Cytogenetic status and oxidative DNA-damage induced by atorvastatin in human peripheral blood lymphocytes: Standard and Fpg-modified comet assay. Toxicology and Applied Pharmacology 231:1, 85-93
CrossRef499
P. P. Toth. (2008) Subclinical atherosclerosis: what it is, what it means and what we can do about it. International Journal of Clinical Practice 62:8, 1246-1254
CrossRef500
Handrean Soran, Paul Durrington. (2008) Rosuvastatin: efficacy, safety and clinical effectiveness. Expert Opinion on Pharmacotherapy 9:12, 2145-2160
CrossRef501
Mohammad Zubaid, Douraid K Shakir, Nooshin Bazargani, Azan Binbrek, Raj Gopal, Omar Al-Tamimi, Sherif Bakir. (2008) Effect of ezetimibe coadministration with simvastatin in a Middle Eastern population: a prospective, multicentre, randomized, double-blind, placebo-controlled trial. Journal of Cardiovascular Medicine 9:7, 688-693
CrossRef502
JoAnne M. Foody, Amie T. Joyce, Amy E. Rudolph, Larry Z. Liu, Joshua S. Benner. (2008) Persistence of atorvastatin and simvastatin among patients with and without prior cardiovascular diseases: a US managed care study. Current Medical Research and Opinion 24:7, 1987-2000
CrossRef503
T. R. Pedersen. (2008) Overview of clinical trials on calcific aortic stenosis. European Heart Journal Supplements 10:Suppl E, E31-E40
CrossRef504
Christopher P. Cannon, Cong Chen, Sean P. Curtis, John Viscusi, Tuli Ahmed, Peter M. DiBattiste. (2008) A Comparison of Cardiovascular Biomarkers in Patients Treated for Three Months with Etoricoxib, Celecoxib, Ibuprofen, and Placebo. Archives of Drug Information 1:1, 4-13
CrossRef505
Alan B. Jotkowitz, Victor Novack, Gad Rabinowitz, Anat Raskin Segal, Ron Weitzman, Avi Porath. (2008) A national study on lipid management. European Journal of Internal Medicine 19:5, 356-361
CrossRef506
Almudena Gómez-Hernández, Eva Sánchez-Galán, Mónica Ortego, José Luis Martín-Ventura, Luis Miguel Blanco-Colio, Nieves Tarín-Vicente, José Julio Jiménez-Nacher, Lorenzo López-Bescos, Jesús Egido, José Tuñón. (2008) Effect of Intensive Atorvastatin Therapy on Prostaglandin E2 Levels and Metalloproteinase-9 Activity in the Plasma of Patients With Non-ST-Elevation Acute Coronary Syndrome. The American Journal of Cardiology 102:1, 12-18
CrossRef507
Rik Hermanides, Jan Paul Ottervanger. (2008) Treatment of ST-elevation myocardial infarction. Future Cardiology 4:4, 391-397
CrossRef508
Freidy Eid, William E. Boden. (2008) The evolving role of medical therapy for chronic stable angina. Current Cardiology Reports 10:4, 263-271
CrossRef509
Venkateshwar R. Polsani, Salim S. Virani, Vijay Nambi. (2008) Lipid management: Considerations in acute coronary syndrome. Current Cardiology Reports 10:4, 334-341
CrossRef510
T. Geisler, C. Zurn, M. Paterok, K. Gohring-Frischholz, B. Bigalke, K. Stellos, P. Seizer, B. F. Kraemer, J. Dippon, A. E. May, C. Herdeg, M. Gawaz. (2008) Statins do not adversely affect post-interventional residual platelet aggregation and outcomes in patients undergoing coronary stenting treated by dual antiplatelet therapy. European Heart Journal 29:13, 1635-1643
CrossRef511
M. Settergren, F. Bohm, L. Ryden, J. Pernow. (2008) Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease. European Heart Journal 29:14, 1753-1760
CrossRef512
Barry A. Franklin, Peter A. McCullough. (2008) The “Null Effect” of Low-Density Lipoprotein Cholesterol Lowering on a Modest Baseline Intima-Media Thickness: Lessons Learned From the ENHANCE Trial. Preventive Cardiology 11:3, 177-178
CrossRef513
Antonio Iglesias del Sol, Prabath WB Nanayakkara. (2008) Pravastatin: an evidence-based statin?. Expert Opinion on Drug Metabolism & Toxicology 4:6, 821-825
CrossRef514
Shigemasa Tani, Ken Nagao, Takeo Anazawa, Hirofumi Kawamata, Kiyoshi Iida, Michiaki Matsumoto, Yuichi Sato, Atsushi Hirayama. (2008) Association of circulating leukocyte count with coronary atherosclerosis regression after pravastatin treatment. Atherosclerosis 198:2, 360-365
CrossRef515
Pierre Amarenco, Philippa C Lavallée, Mikael Mazighi, Julien Labreuche. (2008) Statins in stroke prevention. Future Lipidology 3:3, 319-325
CrossRef516
Justin M. S. Lee, Alistair C. Lindsay, Ilias Kylintireas, Robin P. Choudhury. (2008) Atherosclerosis regression. Current Treatment Options in Cardiovascular Medicine 10:3, 187-194
CrossRef517
P A Ades, P D Savage, M J Toth, D J Schneider, M C Audelin, J Y Bunn, M Ludlow. (2008) The influence of obesity and consequent insulin resistance on coronary risk factors in medically treated patients with coronary disease. International Journal of Obesity 32:6, 967-974
CrossRef518
Shahar Lavi, Joerg Herrmann, Ronit Lavi, Joseph P. McConnell, Lilach O. Lerman, Amir Lerman. (2008) Role of lipoprotein-associated phospholipase A2 in atherosclerosis. Current Atherosclerosis Reports 10:3, 230-235
CrossRef519
Robin P F Dullaart, Wim J Sluiter. (2008) Common variation in the CETP gene and the implications for cardiovascular disease and its treatment: an updated analysis. Pharmacogenomics 9:6, 747-763
CrossRef520
L. Meloni, M. R. Manca, I. Loddo, G. Cioglia, P. Cocco, A. Schwartz, S. Muntoni, Sa. Muntoni. (2008) Glucose-6-phosphate dehydrogenase deficiency protects against coronary heart disease. Journal of Inherited Metabolic Disease 31:3, 412-417
CrossRef521
Padmini Manghat, Anthony S Wierzbicki. (2008) Colesevelam hydrochloride: a specifically engineered bile acid sequestrant. Future Lipidology 3:3, 237-255
CrossRef522
Rebecca L Pollex, Tisha R Joy, Robert A Hegele. (2008) Emerging antidyslipidemic drugs. Expert Opinion on Emerging Drugs 13:2, 363-381
CrossRef523
M. T. Roe, F.-S. Ou, K. P. Alexander, L. K. Newby, J. M. Foody, W. B. Gibler, W. E. Boden, E. M. Ohman, S. C. Smith, E. D. Peterson. (2008) Patterns and prognostic implications of low high-density lipoprotein levels in patients with non-ST-segment elevation acute coronary syndromes. European Heart Journal 29:20, 2480-2488
CrossRef524
Victor L. Serebruany. (2008) Excess Rates of Nonfatal Myocardial Infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel (Preventing Clinical Events or Chasing Enzymatic Ghosts?†)†Conflict of interest: Dr. Serebruany is listed as an inventor and received compensation for U.S. Patent Application P-17232, “Method for Treating Vascular Diseases With Prasugrel,” assigned to Eli Lilly and Company, Indianapolis, Indiana. He has received funding for research studies with clopidogrel and prasugrel.. The American Journal of Cardiology 101:9, 1364-1366
CrossRef525
John B. Kostis, Andrei Breazna, Prakash C. Deedwania, John C. LaRosa. (2008) The Benefits of Intensive Lipid Lowering in Patients With Stable Coronary Heart Disease With Normal or High Systolic Blood Pressure: An Analysis of the Treating to New Targets (TNT) Study. The Journal of Clinical Hypertension 10:5, 367-376
CrossRef526
Stephen D. Wiviott, Eugene Braunwald, Sabina A. Murphy, Elliott M. Antman. (2008) A Perspective on the Efficacy and Safety of Intensive Antiplatelet Therapy in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38. The American Journal of Cardiology 101:9, 1367-1370
CrossRef527
Eric de Groot, Sander I van Leuven, Raphaël Duivenvoorden, Marijn C Meuwese, Fatima Akdim, Michiel L Bots, John JP Kastelein. (2008) Measurement of carotid intima–media thickness to assess progression and regression of atherosclerosis. Nature Clinical Practice Cardiovascular Medicine 5:5, 280-288
CrossRef528
Matthias Dahm, Nicolás Porteiro. (2008) Informational lobbying under the shadow of political pressure. Social Choice and Welfare 30:4, 531-559
CrossRef529
Amir Lotfi, Marc J. Schweiger, Gregory R. Giugliano, Sabina A. Murphy, Christopher P. Cannon. (2008) High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients—A Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 (PROVE IT–TIMI 22) analysis. American Heart Journal 155:5, 954-958
CrossRef530
JB Warren. (2008) Cholesterol—When Is Lower Better?. Clinical Pharmacology & Therapeutics 83:5, 777-780
CrossRef531
NI Ntukidem, AT Nguyen, V Stearns, M Rehman, A Schott, T Skaar, Y Jin, P Blanche, L Li, S Lemler, J Hayden, RM Krauss, Z Desta, DA Flockhart, DF Hayes. (2008) Estrogen Receptor Genotypes, Menopausal Status, and the Lipid Effects of Tamoxifen. Clinical Pharmacology & Therapeutics 83:5, 702-710
CrossRef532
Nancy M. Albert, Kimberly K. Birtcher, Christopher P. Cannon, David C. Goff, Jyotsna Mulgund, Li Liang, Gregg C. Fonarow. (2008) Factors Associated With Discharge Lipid-Lowering Drug Prescription in Patients Hospitalized for Coronary Artery Disease (from the Get With the Guidelines Database). The American Journal of Cardiology 101:9, 1242-1246
CrossRef533
M-a Kawashiri, A Nohara, H Tada, M Mori, M Tsuchida, S Katsuda, A Inazu, J Kobayashi, J Koizumi, H Mabuchi, M Yamagishi. (2008) Comparison of Effects of Pitavastatin and Atorvastatin on Plasma Coenzyme Q10 in Heterozygous Familial Hypercholesterolemia: Results From a Crossover Study. Clinical Pharmacology & Therapeutics 83:5, 731-739
CrossRef534
Sanjiv J. Shah, David D. Waters, Philip Barter, John J.P. Kastelein, James Shepherd, Nanette K. Wenger, David A. DeMicco, Andrei Breazna, John C. LaRosa. (2008) Intensive Lipid-Lowering With Atorvastatin for Secondary Prevention in Patients After Coronary Artery Bypass Surgery. Journal of the American College of Cardiology 51:20, 1938-1943
CrossRef535
Amy E Miller, Laura B Hansen, Joseph J Saseen. (2008) Switching Statin Therapy Using a Pharmacist-Managed Therapeutic Conversion Program versus Usual Care Conversion Among Indigent Patients. Pharmacotherapy 28:5, 553-561
CrossRef536
Joel C Marrs, Joseph J Saseen. (2008) Dyslipidemia Control in Indigent Patients Receiving Medication Assistance Compared with Insured Patients. Pharmacotherapy 28:5, 562-569
CrossRef537
Kastelein, John J.P., Akdim, Fatima, Stroes, Erik S.G., Zwinderman, Aeilko H., Bots, Michiel L., Stalenhoef, Anton F.H., Visseren, Frank L.J., Sijbrands, Eric J.G., Trip, Mieke D., Stein, Evan A., Gaudet, Daniel, Duivenvoorden, Raphael, Veltri, Enrico P., Marais, A. David, de Groot, Eric, . (2008) Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia. New England Journal of Medicine 358:14, 1431-1443
Full Text538
Bonnie Ky, Anne Burke, Sotirios Tsimikas, Megan L. Wolfe, Mahlet G. Tadesse, Philippe O. Szapary, Joseph L. Witztum, Garret A. FitzGerald, Daniel J. Rader. (2008) The Influence of Pravastatin and Atorvastatin on Markers of Oxidative Stress in Hypercholesterolemic Humans. Journal of the American College of Cardiology 51:17, 1653-1662
CrossRef539
Carter Coberley, Greg Morrow, Matthew McGinnis, Aaron Wells, Sadie Coberley, Patty Orr, Dexter Shurney. (2008) Increased Adherence to Cardiac Standards of Care during Participation in Cardiac Disease Management Programs. Disease Management 11:2, 111-118
CrossRef540
Madiha Abdel-Maksoud, Vasilisa Sazonov, Stephen W Gutkin, John E Hokanson. (2008) Effects of Modifying Triglycerides and Triglyceride-rich Lipoproteins on Cardiovascular Outcomes. Journal of Cardiovascular Pharmacology 51:4, 331-351
CrossRef541
Peter H. Jones, John A. Farmer. (2008) Adjunctive interventions in myocardial infarction: The role of statin therapy. Current Atherosclerosis Reports 10:2, 142-148
CrossRef542
John A. Ambrose. (2008) In Search of the “Vulnerable Plaque”. Journal of the American College of Cardiology 51:16, 1539-1542
CrossRef543
B. G. Choi, G. Vilahur, L. Cardoso, J. C. Fritton, B. Ibanez, M. U. Zafar, D. Yadegar, W. S. Speidl, M. B. Schaffler, V. Fuster, J. J. Badimon. (2008) Ovariectomy increases vascular calcification via the OPG/RANKL cytokine signalling pathway. European Journal of Clinical Investigation 38:4, 211-217
CrossRef544
M. Anselmino, K. Malmberg, J. Ohrvik, L. Ryden, . (2008) Evidence-based medication and revascularization: powerful tools in the management of patients with diabetes and coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart. European Journal of Cardiovascular Prevention & Rehabilitation 15:2, 216-223
CrossRef545
Kevin A. Bybee, John H. Lee, James H. O'Keefe. (2008) Cumulative clinical trial data on atorvastatin for reducing cardiovascular events: the clinical impact of atorvastatin. Current Medical Research and Opinion 24:4, 1217-1229
CrossRef546
Farhan Majeed, Michael Miller. (2008) Low high-density lipoprotein cholesterol: an important consideration in coronary heart disease risk assessment. Current Opinion in Endocrinology, Diabetes and Obesity 15:2, 175-181
CrossRef547
Kumar Rajamani, Seemant Chaturvedi. (2008) New strategies in the medical treatment of carotid artery disease. Current Treatment Options in Cardiovascular Medicine 10:2, 156-163
CrossRef548
Bertram Pitt, Joseph Loscalzo, Joseph Yčas, Joel S. Raichlen. (2008) Lipid Levels After Acute Coronary Syndromes. Journal of the American College of Cardiology 51:15, 1440-1445
CrossRef549
J. P. D. Reckless, P. Henry, T. Pomykaj, S. T. Lim, R. Massaad, K. Vandormael, A. O. Johnson-Levonas, K. Lis, P. Brudi, C. Allen. (2008) Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study. International Journal of Clinical Practice 62:4, 539-554
CrossRef550
Michael Miller. (2008) Lipid Levels in the Post-Acute Coronary Syndrome Setting. Journal of the American College of Cardiology 51:15, 1446-1447
CrossRef551
Emile R. Mohler, Christie M. Ballantyne, Michael H. Davidson, Markolf Hanefeld, Luis M. Ruilope, Joel L. Johnson, Andrew Zalewski. (2008) The Effect of Darapladib on Plasma Lipoprotein-Associated Phospholipase A2 Activity and Cardiovascular Biomarkers in Patients With Stable Coronary Heart Disease or Coronary Heart Disease Risk Equivalent. Journal of the American College of Cardiology 51:17, 1632-1641
CrossRef552
Vincent E. Friedewald, Jennifer C. Cather, Kenneth B. Gordon, Arthur Kavanaugh, Paul M. Ridker, William C. Roberts. (2008) The Editor’s Roundtable: Psoriasis, Inflammation, and Coronary Artery Disease. The American Journal of Cardiology 101:8, 1119-1126
CrossRef553
Amit Kumar, Christopher P. Cannon. (2008) The Role of Statins in the Prevention of Heart Failure After Acute Coronary Syndrome. Heart Failure Clinics 4:2, 129-139
CrossRef554
Tze Vun Liew, Kausik K. Ray. (2008) Intensive statin therapy in acute coronary syndromes. Current Atherosclerosis Reports 10:2, 158-163
CrossRef555
Pablo F. Castro, Rodrigo Miranda, Hugo E. Verdejo, Douglas Greig, Luigi A. Gabrielli, Hernán Alcaino, Mario Chiong, Carlos Bustos, Lorena Garcia, Rosemarie Mellado, José Luis Vukasovic, Ivan Godoy, Sergio Lavandero. (2008) Pleiotropic Effects of Atorvastatin in Heart Failure: Role in Oxidative Stress, Inflammation, Endothelial Function, and Exercise Capacity. The Journal of Heart and Lung Transplantation 27:4, 435-441
CrossRef556
C. P. Cannon. (2008) Combination therapy in the management of mixed dyslipidaemia. Journal of Internal Medicine 263:4, 353-365
CrossRef557
Jean-Claude Tardif, Jean Grégoire, Philippe L. L’Allier, Reda Ibrahim, Todd J. Anderson, François Reeves, Lawrence M. Title, Erick Schampaert, Michel LeMay, Jacques Lespérance, Rob Scott, Marie-Claude Guertin, Marie-Luise Brennan, Stanley L. Hazen, Olivier F. Bertrand. (2008) Effects of the antioxidant succinobucol (AGI-1067) on human atherosclerosis in a randomized clinical trial. Atherosclerosis 197:1, 480-486
CrossRef558
Marc Fisher, Edward Folland. (2008) Acute Ischemic Coronary Artery Disease and Ischemic Stroke: Similarities and Differences. American Journal of Therapeutics 15:2, 137-149
CrossRef559
Xue-Qiao Zhao, B. Greg Brown. (2008) ApoA-IMilano/Phospholipid Complex. Journal of the American College of Cardiology 51:11, 1110-1111
CrossRef560
Soon-Tae Lee, Kon Chu, Jung-Eun Park, Nan Hyung Hong, Woo-Seok Im, Lami Kang, Zhe Han, Keun-Hwa Jung, Min-Wook Kim, Manho Kim. (2008) Atorvastatin attenuates mitochondrial toxin-induced striatal degeneration, with decreasing iNOS/c-Jun levels and activating ERK/Akt pathways. Journal of Neurochemistry 104:5, 1190-1200
CrossRef561
Thomas F. Whayne. (2008) Nonprescription Statins: Not Ready for Prime Time. The American Journal of Cardiology 101:5, 745-746
CrossRef562
Marc A. Pfeffer. (2008) Critical Missing Data on Erythropoiesis-Stimulating Agents in CKD: First Beat Placebo. American Journal of Kidney Diseases 51:3, 366-369
CrossRef563
Mark Y. Chan, Richard C. Becker, Robert A. Harrington, Eric D. Peterson, Paul W. Armstrong, Harvey White, Keith A.A. Fox, E. Magnus Ohman, Matthew T. Roe. (2008) Noninvasive, medical management for non–ST-elevation acute coronary syndromes. American Heart Journal 155:3, 397-407
CrossRef564
Kenneth K.C. Lee, Vivian W.Y. Lee, Wai Kwong Chan, Benjamin S.C. Lee, Agnes C.Y. Chong, Jasper C.L. Wong, Don Yin, Evo Alemao, Brian Tomlinson. (2008) Cholesterol Goal Attainment in Patients with Coronary Heart Disease and Elevated Coronary Risk: Results of the Hong Kong Hospital Audit Study. Value in Health 11, S91-S98
CrossRef565
Roy W. Jones, Miia Kivipelto, Howard Feldman, Larry Sparks, Rachelle Doody, David D. Waters, Judith Hey-Hadavi, Andrei Breazna, Rachel J. Schindler, Harry Ramos. (2008) The Atorvastatin/Donepezil in Alzheimer’s Disease Study (LEADe): Design and baseline characteristics
CrossRef566
François Charbonneau, Todd J. Anderson, Lawrence Title, Jean Jobin, Paul Poirier, Thao Huyhn, Sammy Chan, Ann Walling, Stuart Hutchison, Thang Tran, Eva Lonn, Jean Buithieu, Jacques Genest. (2008) Modulation of arterial reactivity using amlodipine and atorvastatin measured by ultrasound examination (MARGAUX). Atherosclerosis 197:1, 420-427
CrossRef567
William E. Boden, Prediman K. Shah, Vipul Gupta, E. Magnus Ohman. (2008) Contemporary Approach to the Diagnosis and Management of Non–ST-Segment Elevation Acute Coronary Syndromes. Progress in Cardiovascular Diseases 50:5, 311-351
CrossRef568
Pavel Broz, Nadav Ben-Haim, Mariusz Grzelakowski, Stephan Marsch, Wolfgang Meier, Patrick Hunziker. (2008) Inhibition of Macrophage Phagocytotic Activity by a Receptor-targeted Polymer Vesicle-based Drug Delivery Formulation of Pravastatin. Journal of Cardiovascular Pharmacology 51:3, 246-252
CrossRef569
Willeke de Haan, Caroline C. van der Hoogt, Marit Westerterp, Menno Hoekstra, Geesje M. Dallinga-Thie, Hans M.G. Princen, Johannes A. Romijn, J. Wouter Jukema, Louis M. Havekes, Patrick C.N. Rensen. (2008) Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice. Atherosclerosis 197:1, 57-63
CrossRef570
A. K. Meena, D. Venkat Ratnam, G. Chandraiah, D. D. Ankola, P. Rama Rao, M. N. V. Ravi Kumar. (2008) Oral Nanoparticulate Atorvastatin Calcium is More Efficient and Safe in Comparison to Lipicure® in Treating Hyperlipidemia. Lipids 43:3, 231-241
CrossRef571
Lisa R Tannock. (2008) Advances in the management of hyperlipidemia-induced atherosclerosis. Expert Review of Cardiovascular Therapy 6:3, 369-383
CrossRef572
Borja Ibanez, Gemma Vilahur, Giovanni Cimmino, Walter S. Speidl, Antonio Pinero, Brian G. Choi, M. Urooj Zafar, Carlos G. Santos-Gallego, Brian Krause, Lina Badimon, Valentin Fuster, Juan J. Badimon. (2008) Rapid Change in Plaque Size, Composition, and Molecular Footprint After Recombinant Apolipoprotein A-IMilano (ETC-216) Administration. Journal of the American College of Cardiology 51:11, 1104-1109
CrossRef573
Wilbert S Aronow. (2008) Treatment of High-Risk Older Persons With Lipid-Lowering Drug Therapy. American Journal of Therapeutics 15:2, 102-107
CrossRef574
John J. Young, Harry R. Phillips, Steven P. Marso, Juan F. Granada, John A. McPherson, Ron Waksman, Steven R. Steinhubl, Robert S. Schwartz, Gregg W. Stone. (2008) Vulnerable plaque intervention: State of the art. Catheterization and Cardiovascular Interventions 71:3, 367-374
CrossRef575
J. Ferrières. (2008) Statines chez le coronarien : un problème résolu ?. Annales de Cardiologie et d'Angéiologie 57, 16-23
CrossRef576
Antonella Sassano, Leonidas C. Platanias. (2008) Statins in tumor suppression. Cancer Letters 260:1-2, 11-19
CrossRef577
Giampaolo Niccoli, Luigi M. Biasucci, Carmine Biscione, Beatrice Fusco, Italo Porto, Antonio Maria Leone, Roberta Della Bona, Ilaria Dato, Giovanna Liuzzo, Filippo Crea. (2008) Independent prognostic value of C-reactive protein and coronary artery disease extent in patients affected by unstable angina. Atherosclerosis 196:2, 779-785
CrossRef578
Gregory G Schwartz. (2008) Lipid management after acute coronary syndrome. Current Opinion in Internal Medicine 7:1, 75-81
CrossRef579
Brian R. Long, Ferdinand Leya. (2008) The Role of Antiphospholipid Syndrome in Cardiovascular Disease. Hematology/Oncology Clinics of North America 22:1, 79-94
CrossRef580
Helene Glassberg, Daniel J. Rader. (2008) Management of Lipids in the Prevention of Cardiovascular Events. Annual Review of Medicine 59:1, 79-94
CrossRef581
JH Choi, MG Lee, J-Y Cho, J-E Lee, KH Kim, K Park. (2008) Influence of OATP1B1 Genotype on the Pharmacokinetics of Rosuvastatin in Koreans. Clinical Pharmacology & Therapeutics 83:2, 251-257
CrossRef582
H. Sillesen. (2008) What Does ‘Best Medical Therapy’ Really Mean?. European Journal of Vascular and Endovascular Surgery 35:2, 139-144
CrossRef583
Michael Miller, Christopher P. Cannon, Sabina A. Murphy, Jie Qin, Kausik K. Ray, Eugene Braunwald. (2008) Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial. Journal of the American College of Cardiology 51:7, 724-730
CrossRef584
Sergio Fazio. (2008) Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: A role for combination fibrate therapy. Clinical Therapeutics 30:2, 294-306
CrossRef585
William H Frishman, Wilbert S Aronow, Angela Cheng-Lai. 2008. Cardiovascular Drug Therapy in the Elderly. , 99-136.
CrossRef586
Joseph E. Thomas, JoAnne M. Foody. 2008. Disorders of Lipid Metabolism. , 159-178.
CrossRef587
Michael W. Rich. 2008. Therapy of Acute Myocardial Infarction. , 293-326.
CrossRef588
Dalton S. McLean, Shmuel Ravid, Michael Blazing, Bernard Gersh, Amy Shui, Christopher P. Cannon. (2008) Effect of statin dose on incidence of atrial fibrillation: Data from the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 (PROVE IT–TIMI 22) and Aggrastat to Zocor (A to Z) trials. American Heart Journal 155:2, 298-302
CrossRef589
Wilbert S. Aronow. 2008. Management of the Older Patient After Myocardial Infarction. , 327-350.
CrossRef590
Fernando Fabiani, Teresa Arrobas, Reyes de la Iglesia, Juan Manuel de la Vega, Teresa Holgado, Patricia Fernández-Riejos, Miguel Ángel Rico, Antonio Barco, Salomé Hijano, Eva Martínez, Ana I. Oribe, Carmen Cruz. (2008) Cumplimiento de objetivos terapéuticos en pacientes con revascularización miocárdica en el Área Virgen Macarena de Sevilla. Clínica e Investigación en Arteriosclerosis 20:1, 1-7
CrossRef591
Matthias Briel, Alain J Nordmann, Gregory G Schwartz, James de Lemos, Furio Colivicchi, Frank den Hartog, Heiner Bucher, Matthias Briel. 2008. Statins for acute coronary syndrome. .
CrossRef592
F. Cuculi, D. Radovanovic, F.R. Eberli, J.C. Stauffer, O. Bertel, P. Erne. (2008) The Impact of Statin Treatment on Presentation Mode and Early Outcomes in Acute Coronary Syndromes. Cardiology 109:3, 156-162
CrossRef593
Baoshan Xu, Chao Wang, Jie Yang, Guanping Mao, Cheng Zhang, Dan Liu, Ping Tai, Bo Zhou, Guoliang Xia, Meijia Zhang. (2008) Silencing of Mouse Hepatic Lanosterol 14-α Demethylase Down-Regulated Plasma Low-Density Lipoprotein Cholesterol Levels by Short-Term Treatment of siRNA. Biological & Pharmaceutical Bulletin 31:6, 1182-1191
CrossRef594
Hiroshi Sato, Kunihiro Kinjo, Hiroshi Ito, Atsushi Hirayama, Shinsuke Nanto, Masatake Fukunami, Masami Nishino, Young-Jae Lim, Yoshiyuki Kijima, Yukihiro Koretsune, Daisaku Nakatani, Hiroya Mizuno, Masahiko Shimizu, Masatsugu Hori, The Osaka Acute Coronary Insufficie. (2008) Effect of Early Use of Low-Dose Pravastatin on Major Adverse Cardiac Events in Patients With Acute Myocardial Infarction. Circulation Journal 72:1, 17-22
CrossRef595
Kate McKeage, M Asif A Siddiqui. (2008) Amlodipine/Atorvastatin Fixed-Dose Combination. American Journal of Cardiovascular Drugs 8:1, 51-67
CrossRef596
Oliver Wieben, Christopher Francois, Scott B. Reeder. (2008) Cardiac MRI of ischemic heart disease at 3T: Potential and challenges. European Journal of Radiology 65:1, 15-28
CrossRef597
Michel De Lorgeril, Patricia Salen. (2008) Cholesterol lowering, sudden cardiac death and mortality. Scandinavian Cardiovascular Journal 42:4, 264-267
CrossRef598
Luis Rodríguez Padial. (2008) Ezetimibe plus simvastatin cardiovascular outcomes study program. Expert Review of Cardiovascular Therapy 6:1, 17-25
CrossRef599
Chao-Yung Wang, Ping-Yen Liu, James K. Liao. (2008) Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends in Molecular Medicine 14:1, 37-44
CrossRef600
Charles H Hennekens, Wendy R Schneider. (2008) The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease. Expert Review of Cardiovascular Therapy 6:1, 95-107
CrossRef601
Karim El Harchaoui, Fatima Akdim, Erik S G Stroes, Mieke D Trip, John J P Kastelein. (2008) Current and Future Pharmacologic Options for the Management of Patients Unable to Achieve Low-Density Lipoprotein-Cholesterol Goals with Statins. American Journal of Cardiovascular Drugs 8:4, 233-242
CrossRef602
Rainer Hoffmann, Philipp Haager, Hasna Suliman, Philipp Christott, Peter Radke, Rüdiger Blindt, Malte Kelm. (2008) Effect of Statin Therapy Before Q-Wave Myocardial Infarction on Myocardial Perfusion. The American Journal of Cardiology 101:2, 139-143
CrossRef603
Arthur L. Riba. (2008) Evidence-Based Performance and Quality Improvement in the Acute Cardiac Care Setting. Critical Care Clinics 24:1, 201-229
CrossRef604
Hae Chang Jeong, Young Keun Ahn, Myung Ho Jeong, Shung Chull Chae, Jong Hyun Kim, In Whan Seong, Young Jo Kim, Seung Ho Hur, Dong Hoon Choi, Taek Jong Hong, Jung Han Yoon, Jae Young Rhew, Jei Keon Chae, Doo Il Kim, In Ho Chae, Bon Kwon Koo, Byung Ok Kim, Nae Hee Lee, Jin Yong Hwang, Seok Kyu Oh, Myeong Chan Cho, Kee Sik Kim, Kyoung Tae Jeong, Myoung Yong Lee, Chong Jin Kim, Wook Sung Chung, Korea Acute Myocardial Infarction R. (2008) Intensive Pharmacologic Treatment in Patients With Acute Non ST-Segment Elevation Myocardial Infarction Who Did Not Undergo Percutaneous Coronary Intervention. Circulation Journal 72:9, 1403-1409
CrossRef605
B. M. Biccard. (2008) A peri-operative statin update for non-cardiac surgery. Part I: The effects of statin therapy on atherosclerotic disease and lessons learnt from statin therapy in medical (non-surgical) patients. Anaesthesia 63:1, 52-64
CrossRef606
Karol E. Watson. (2008) What is the evidence in favor of low-dose statin therapy in 2008?. Current Atherosclerosis Reports 10:1, 33-38
CrossRef607
Jeffrey A. Pfefferkorn, Scott D. Larsen, Chad Van Huis, Roderick Sorenson, Tom Barton, Thomas Winters, Bruce Auerbach, Chenyan Wu, Thaddeus J. Wolfram, Hongliang Cai, Kathleen Welch, Nadia Esmaiel, JoAnn Davis, Richard Bousley, Karl Olsen, Sandra Bak Mueller, Thomas Mertz. (2008) Substituted oxazolidinones as novel NPC1L1 ligands for the inhibition of cholesterol absorption. Bioorganic & Medicinal Chemistry Letters 18:2, 546-553
CrossRef608
Dayi Hu, Jue Li, Xiankai Li, for the China Cholesterol Education. (2008) Investigation of Blood Lipid Levels and Statin Interventions in Outpatients With Coronary Heart Disease in China. Circulation Journal 72:12, 2040-2045
CrossRef609
Bijesh P Maroo, Carl J Lavie, Richard V Milani. (2008) Secondary Prevention of Coronary Heart Disease in Elderly Patients Following Myocardial Infarction. Drugs & Aging 25:8, 649-664
CrossRef610
Prakash Deedwania, Sundararajan Srikanth. (2008) Diabetes and vascular disease. Expert Review of Cardiovascular Therapy 6:1, 127-138
CrossRef611
Sammy Elmariah, Sidney C Smith, Valentin Fuster. (2008) Late medical versus interventional therapy for stable ST-segment elevation myocardial infarction. Nature Clinical Practice Cardiovascular Medicine 5:1, 42-52
CrossRef612
Michael Clearfield. (2008) Clinical trials report. Current Atherosclerosis Reports 10:1, 5-10
CrossRef613
Olga A. Iakoubova, Marc S. Sabatine, Charles M. Rowland, Carmen H. Tong, Joseph J. Catanese, Koustubh Ranade, Katy L. Simonsen, Todd G. Kirchgessner, Christopher P. Cannon, James J. Devlin, Eugene Braunwald. (2008) Polymorphism in KIF6 Gene and Benefit From Statins After Acute Coronary Syndromes. Journal of the American College of Cardiology 51:4, 449-455
CrossRef614
Brian Eley. (2008) Metabolic complications of antiretroviral therapy in HIV-infected children. Expert Opinion on Drug Metabolism & Toxicology 4:1, 37-49
CrossRef615
Ilke Sipahi, E Murat Tuzcu. (2008) Candidate Mechanisms for Regression of Coronary Atherosclerosis with High-Dose Statins. American Journal of Cardiovascular Drugs 8:6, 365-371
CrossRef616
Yutaka Furukawa, Ryoji Taniguchi, Natsuhiko Ehara, Neiko Ozasa, Yoshisumi Haruna, Naritatsu Saito, Takahiro Doi, Kozo Hoshino, Satoshi Shizuta, Takeshi Morimoto, Yukiko Imai, Satoshi Teramukai, Masanori Fukushima, Toru Kita, Takeshi Kimura, CREDO-Kyoto Investigators. (2008) Better Survival With Statin Administration After Revascularization Therapy in Japanese Patients With Coronary Artery Disease. Circulation Journal 72:12, 1937-1945
CrossRef617
David A. Morrow, Yunmei Wang, Kevin Croce, Masashi Sakuma, Marc S. Sabatine, Huiyun Gao, Aruna D. Pradhan, Aileen M. Healy, Jacki Buros, Carolyn H. McCabe, Peter Libby, Christopher P. Cannon, Eugene Braunwald, Daniel I. Simon. (2008) Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Theraphy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial. American Heart Journal 155:1, 49-55
CrossRef618
Young-Soo Lee, Kee-Sik Kim. (2008) The Short-term Effect of Atorvastatin on Flow-Mediated Vasodilation, Pulse Wave Velocity and Carotid Intima-Media Thickness in Patients With Moderate Cholesterolemia. Korean Circulation Journal 38:3, 144
CrossRef619
Ho Kil, Eun-Young Choi, Won-Yik Lee, Jang-Whan Bae, Kyung-Kuk Whang, Dong-Woon Kim, Myeong-Chan Cho. (2008) The Early Treatment Gap of Dyslipidemia for Patients With Acute Myocardial Infarction. Korean Circulation Journal 38:8, 419
CrossRef620
A. Kaneda, C. J. Wang, R. Cheong, W. Timp, P. Onyango, B. Wen, C. A. Iacobuzio-Donahue, R. Ohlsson, R. Andraos, M. A. Pearson, A. A. Sharov, D. L. Longo, M. S. H. Ko, A. Levchenko, A. P. Feinberg. (2007) Enhanced sensitivity to IGF-II signaling links loss of imprinting of IGF2 to increased cell proliferation and tumor risk. Proceedings of the National Academy of Sciences 104:52, 20926-20931
CrossRef621
Raphael Duivenvoorden, Aart J Nederveen, Eric de Groot, John JP Kastelein. (2007) Atherosclerosis imaging as a benchmark in the development of novel cardiovasular drugs. Current Opinion in Lipidology 18:6, 613-621
CrossRef622
Andrew Moore, Binh An P. Phan, Catherine Challender, Jayne Williamson, Santica Marcovina, Xue-Qiao Zhao. (2007) Effects of adding extended-release niacin and colesevelam to statin therapy on lipid levels in subjects with atherosclerotic disease. Journal of Clinical Lipidology 1:6, 620-625
CrossRef623
AMIT KUMAR, CHRISTOPHER P. CANNON. (2007) Importance of Intensive Lipid Lowering in Acute Coronary Syndrome and Percutaneous Coronary Intervention. Journal of Interventional Cardiology 20:6, 447-457
CrossRef624
Geoffrey C. Schreiner, Loren Laine, Sabina A. Murphy, Christopher P. Cannon. (2007) Evaluation of Proton Pump Inhibitor Use in Patients With Acute Coronary Syndromes Based on Risk Factors for Gastrointestinal Bleed. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 6:4, 169-172
CrossRef625
Martin Duerden. (2007) Absence of policy on how to use statins in England and Wales: do not let JBS2 fill the void. International Journal of Clinical Practice 61:12, 1967-1970
CrossRef626
Tamara B Horwich, W Robb MacLellan. (2007) Atorvastatin and statins in the treatment of heart failure. Expert Opinion on Pharmacotherapy 8:17, 3061-3068
CrossRef627
Mikael Mazighi, Philippa C Lavallée, Julien Labreuche, Pierre Amarenco. (2007) Statin therapy and stroke prevention: what was known, what is new and what is next?. Current Opinion in Lipidology 18:6, 622-625
CrossRef628
John M Galla, Stephen J Nicholls. (2007) Impact of statin therapy on the artery wall in the low-risk patient: implications from the METEOR study. Future Lipidology 2:6, 595-601
CrossRef629
Catherine Y. Campbell, Juan J. Rivera, Roger S. Blumenthal. (2007) Residual risk in statin-treated patients: Future therapeutic options. Current Cardiology Reports 9:6, 499-505
CrossRef630
Christopher M. Rembold. (2007) To statin or to non-statin in coronary disease—considering absolute risk is the answer. Atherosclerosis 195:1, 1-6
CrossRef631
Pierre Amarenco. (2007) Atorvastatin in prevention of stroke and transient ischaemic attack. Expert Opinion on Pharmacotherapy 8:16, 2789-2797
CrossRef632
Annemarie Armani, Peter P. Toth. (2007) SPARCL: The glimmer of statins for stroke risk reduction. Current Atherosclerosis Reports 9:5, 347-351
CrossRef633
Loukianos S. Rallidis, John Lekakis, Dimitrios T. Kremastinos. (2007) Current questions regarding the use of statins in patients with coronary heart disease. International Journal of Cardiology 122:3, 188-194
CrossRef634
Madhavi Koka, Julie Joseph, Wilbert S. Aronow. (2007) Prevalence of Adequate and of Optimal Control of Serum Low-Density Lipoprotein Cholesterol in an Academic Nursing Home. Journal of the American Medical Directors Association 8:9, 604-606
CrossRef635
Petr Ostadal, David Alan, Jiri Vejvoda, Jana Cepova, Jiri Kukacka, Peter Blasko, Lucia Martinkovicova, Jan Vojacek. (2007) Immediate effect of fluvastatin on lipid levels in acute coronary syndrome. Molecular and Cellular Biochemistry 306:1-2, 19-23
CrossRef636
Stanley G. Rockson, Emil M. deGoma, Gregg C. Fonarow. (2007) Reinforcing a Continuum of Care: In-Hospital Initiation of Long-Term Secondary Prevention Following Acute Coronary Syndromes. Cardiovascular Drugs and Therapy 21:5, 375-388
CrossRef637
Lawrence A. Leiter, Robert S. Rosenson, Evan Stein, John P.D. Reckless, Karl-Ludwig Schulte, Margo Schleman, Paul Miller, Michael Palmer, Froukje Sosef. (2007) Efficacy and safety of rosuvastatin 40mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: Results of the POLARIS study. Atherosclerosis 194:2, e154-e164
CrossRef638
James O. Mudd, Barry A. Borlaug, Peter V. Johnston, Brian G. Kral, Rosanne Rouf, Roger S. Blumenthal, Peter O. Kwiterovich. (2007) Beyond Low-Density Lipoprotein Cholesterol. Journal of the American College of Cardiology 50:18, 1735-1741
CrossRef639
K. K. Ray, P. M. Schofield. (2007) Secondary prevention for coronary heart disease in the United Kingdom, low-density lipoprotein cholesterol goals and statin switching-an expression of concern. International Journal of Clinical Practice 61:10, 1608-1611
CrossRef640
Sabina A. Murphy, Christopher P. Cannon, Stephen D. Wiviott, James A. de Lemos, Michael A. Blazing, Carolyn H. McCabe, Robert M. Califf, Eugene Braunwald. (2007) Effect of Intensive Lipid-Lowering Therapy on Mortality After Acute Coronary Syndrome (a Patient-Level Analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction 22 Trials). The American Journal of Cardiology 100:7, 1047-1051
CrossRef641
Scott D. Larsen, Toni-Jo Poel, Kevin J. Filipski, Jeffrey T. Kohrt, Jeffrey A. Pfefferkorn, Roderick J. Sorenson, Bradley D. Tait, Valerie Askew, Lisa Dillon, Jeffrey C. Hanselman, Gina H. Lu, Andrew Robertson, Catherine Sekerke, Mark C. Kowala, Bruce J. Auerbach. (2007) Pyrazole inhibitors of HMG-CoA reductase: An attempt to dramatically reduce synthetic complexity through minimal analog re-design. Bioorganic & Medicinal Chemistry Letters 17:20, 5567-5572
CrossRef642
Hector M. Medina, Deepak L. Bhatt. (2007) Evolution of Anticoagulant and Antiplatelet Therapy: Benefits and Risks of Contemporary Pharmacologic Agents and Their Implications for Myonecrosis and Bleeding in Percutaneous Coronary Intervention. Clinical Cardiology 30:S2, II4-II15
CrossRef643
Juan Ascaso, Pedro Gonzalez Santos, Antonio Hernández Mijares, Alipio Mangas Rojas, Luis Masana Marín, Jesús Millan Nuñez-Cortés, Luis Felipe Pallardo, Juan Pedro-Botet, Francisco Pérez Jimenez, Xavier Pintó, Ignacio Plaza, Juan Rubiés, Manuel Zúñiga. (2007) Dislipemia del síndrome metabólico. Documento sumario del Foro-HDL. Clínica e Investigación en Arteriosclerosis 19:5, 252-263
CrossRef644
Carmen Suárez, Marc Cairols, José Castillo, Enric Esmatjes, Joan Sala, Xavier Llobet, Juan Carlos Palma. (2007) Control de factores de riesgo y tratamiento de la aterotrombosis. Registro REACH España. Medicina Clínica 129:12, 446-450
CrossRef645
Toshio Hayashi, Koutaro Yokote, Yasushi Saito, Akihisa Iguchi. (2007) Pitavastatin: efficacy and safety in intensive lipid lowering. Expert Opinion on Pharmacotherapy 8:14, 2315-2327
CrossRef646
Rohit Bhatheja, Debabrata Mukherjee. (2007) Acute Coronary Syndromes: Unstable Angina/Non-ST Elevation Myocardial Infarction. Critical Care Clinics 23:4, 709-735
CrossRef647
John B. Kostis. (2007) The Importance of Managing Hypertension and Dyslipidemia to Decrease Cardiovascular Disease. Cardiovascular Drugs and Therapy 21:4, 297-309
CrossRef648
Pamela R. Kushner. (2007) Can Intensive Statin Therapy Halt the Progression of Atherosclerosis? Recent Evidence and Potential Implications for Patient Management. Progress in Cardiovascular Nursing 22:4, 207-213
CrossRef649
Frederick A. Spencer, Robert J. Goldberg, Joel M. Gore, Keith A.A. Fox, Alvaro Avezum, Giancarlo Agnelli, Leonard Kritharides, Frederick A. Anderson, Shaun G. Goodman, Gordon FitzGerald, Jeanna Allegrone, David Brieger. (2007) Comparison of Utilization of Statin Therapy at Hospital Discharge and Six-Month Outcomes in Patients With an Acute Coronary Syndrome and Serum Low-Density Lipoprotein ≥100 mg/dl Versus <100 mg/dl. The American Journal of Cardiology 100:6, 913-918
CrossRef650
John C. LaRosa, Scott M. Grundy, John J.P. Kastelein, John B. Kostis, Heiner Greten. (2007) Safety and Efficacy of Atorvastatin-Induced Very Low-Density Lipoprotein Cholesterol Levels in Patients With Coronary Heart Disease (a Post Hoc Analysis of the Treating to New Targets [TNT] Study). The American Journal of Cardiology 100:5, 747-752
CrossRef651
Irene F. Gazi, Stella S. Daskalopoulou, Devaki R. Nair, Dimitri P. Mikhailidis. (2007) Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. Current Medical Research and Opinion 23:9, 2183-2192
CrossRef652
Stephen J. Nicholls, Srinivasa Kalidindi, Steven E. Nissen. (2007) Intensive lipid lowering in the cardiovascular patient: Who, how low, and for how long?. Current Cardiovascular Risk Reports 1:4, 290-295
CrossRef653
Robert M Guthrie, Daniel R Martin. (2007) The safety of rosuvastatin: effects on renal and hepatic function. Expert Opinion on Drug Safety 6:5, 573-581
CrossRef654
&NA;. (2007) FULL TEXT Chapter 1: Introduction. European Journal of Cardiovascular Prevention & Rehabilitation 14:Supplement 2, S2-S113
CrossRef655
Michael H. Davidson. (2007) Targeting High-Density Lipoprotein Cholesterol in the Management of Cardiovascular Disease. The American Heart Hospital Journal 5:4, 210-216
CrossRef656
Maurizio Trevisan, Saverio Stranges. (2007) Reply to Drs Vos, Ravnskov, Mascitelli and Pezzetta. Nutrition, Metabolism and Cardiovascular Diseases 17:7, e21-e23
CrossRef657
Carolyn Jenkins, Maria Lopes-Virella. 2007. Nutrition in Diabetes Mellitus. , 785-813.
CrossRef658
Pinakini K. Shankar, Rama Bhat, Mukhyaprana Prabhu, Bandi Partha Saradhi Reddy, M. Srinivasa Reddy, Mohan Reddy. (2007) Efficacy and tolerability of fixed-dose combination of simvastatin plus ezetimibe in patients with primary hypercholesterolemia: Results of a multicentric trial from India. Journal of Clinical Lipidology 1:4, 264-270
CrossRef659
Tomoyuki Nishimoto, Eiichiro Ishikawa, Hisashi Anayama, Hitomi Hamajyo, Hirofumi Nagai, Masao Hirakata, Ryuichi Tozawa. (2007) Protective effects of a squalene synthase inhibitor, lapaquistat acetate (TAK-475), on statin-induced myotoxicity in guinea pigs. Toxicology and Applied Pharmacology 223:1, 39-45
CrossRef660
Sanjaya Khanal, Omar Obeidat, Michael P. Hudson, Mouaz Al-Mallah, Mary Bloome, Mei Lu, Adam B. Greenbaum, Aaron D. Kugelmass, W. Douglas Weaver. (2007) Active Lipid Management In Coronary Artery Disease (ALMICAD) Study. The American Journal of Medicine 120:8, 734.e11-734.e17
CrossRef661
Aziz Momin, Narbeh Melikian, Stephen B. Wheatcroft, David Grieve, Lindsay C. John, Ahmad El Gamel, Michael T. Marrinan, Jatin B. Desai, Catherine Driver, Roy Sherwood, Ajay M. Shah, Mark T. Kearney. (2007) The association between saphenous vein endothelial function, systemic inflammation, and statin therapy in patients undergoing coronary artery bypass surgery. The Journal of Thoracic and Cardiovascular Surgery 134:2, 335-341
CrossRef662
Fatima Akdim, Karim El Harchaoui, Erik SG Stroes, John JP Kastelein. (2007) Antisense apolipoprotein B-100 as novel treatment for hypercholesterolemia: focus on ISIS 301012. Future Lipidology 2:4, 387-393
CrossRef663
Kosmas I. Paraskevas, George Hamilton, Dimitri P. Mikhailidis. (2007) Statins: An essential component in the management of carotid artery disease. Journal of Vascular Surgery 46:2, 373-386.e9
CrossRef664
Xue-Qiao Zhao, Binh An P. Phan, Baocheng Chu, Frank Bray, Andrew B. Moore, Nayak L. Polissar, J. Theodore Dodge, Colin D. Lee, Thomas S. Hatsukami, Chun Yuan. (2007) Testing the hypothesis of atherosclerotic plaque lipid depletion during lipid therapy by magnetic resonance imaging: Study design of Carotid Plaque Composition Study. American Heart Journal 154:2, 239-246
CrossRef665
Robert C. Block, Thomas A. Pearson. (2007) Organizing services for cardiovascular prevention. Current Treatment Options in Cardiovascular Medicine 9:4, 278-286
CrossRef666
Anne Carol Goldberg. (2007) Combination therapy of dyslipidemia. Current Treatment Options in Cardiovascular Medicine 9:4, 249-258
CrossRef667
F. Cohen Aubart, B. Hansel, J.-S. Hulot, P. Lechat, E. Bruckert. (2007) Avancées récentes et perspectives dans le traitement des dyslipidémies athérogènes. La Revue de Médecine Interne 28:8, 537-544
CrossRef668
Jordan Asher, Mark Houston. (2007) Statins and C-Reactive Protein Levels. The Journal of Clinical Hypertension 9:8, 622-628
CrossRef669
Krista M. Dale, C. Michael White, Nickole N. Henyan, Jeffrey Kluger, Craig I. Coleman. (2007) Impact of Statin Dosing Intensity on Transaminase and Creatine Kinase. The American Journal of Medicine 120:8, 706-712
CrossRef670
Christian R. Dolder, Angie Veverka, Donald S. Nuzum, Jonathan McKinsey. (2007) <b>Cardiovascular Medication Prescribing in Older Adults with Psychiatric Disorders Research and Reports</b>. The Consultant Pharmacist 22:8, 660-668
CrossRef671
Jeffrey A. Pfefferkorn, Yuntao Song, Kuai-Lin Sun, Steven R. Miller, Bharat K. Trivedi, Chulho Choi, Roderick J. Sorenson, Larry D. Bratton, Paul C. Unangst, Scott D. Larsen, Toni-Jo Poel, Xue-Min Cheng, Chitase Lee, Noe Erasga, Bruce Auerbach, Valerie Askew, Lisa Dillon, Jeffrey C. Hanselman, Zhiwu Lin, Gina Lu, Andrew Robertson, Karl Olsen, Thomas Mertz, Catherine Sekerke, Alexander Pavlovsky, Melissa S. Harris, Graeme Bainbridge, Nicole Caspers, Huifen Chen, Matthias Eberstadt. (2007) Design and synthesis of hepatoselective, pyrrole-based HMG-CoA reductase inhibitors. Bioorganic & Medicinal Chemistry Letters 17:16, 4538-4544
CrossRef672
Jeffrey L. Anderson, Cynthia D. Adams, Elliott M. Antman, Charles R. Bridges, Robert M. Califf, Donald E. Casey, William E. Chavey, Francis M. Fesmire, Judith S. Hochman, Thomas N. Levin, A. Michael Lincoff, Eric D. Peterson, Pierre Theroux, Nanette Kass Wenger, R. Scott Wright, Sidney C. Smith, Alice K. Jacobs, Cynthia D. Adams, Jeffrey L. Anderson, Elliott M. Antman, Jonathan L. Halperin, Sharon A. Hunt, Harlan M. Krumholz, Frederick G. Kushner, Bruce W. Lytle, Rick Nishimura, Joseph P. Ornato, Richard L. Page, Barbara Riegel. (2007) ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology 50:7, e1-e157
CrossRef673
Gregory A. Nichols, Carol E. Koro. (2007) Does Statin Therapy Initiation Increase the Risk for Myopathy? An Observational Study of 32,225 Diabetic and Nondiabetic Patients. Clinical Therapeutics 29:8, 1761-1770
CrossRef674
Jeffrey L. Anderson, Cynthia D. Adams, Elliott M. Antman, Charles R. Bridges, Robert M. Califf, Donald E. Casey, William E. Chavey, Francis M. Fesmire, Judith S. Hochman, Thomas N. Levin, A. Michael Lincoff, Eric D. Peterson, Pierre Theroux, Nanette Kass Wenger, R. Scott Wright, Sidney C. Smith, Alice K. Jacobs, Cynthia D. Adams, Jeffrey L. Anderson, Elliot M. Antman, Jonathan L. Halperin, Sharon A. Hunt, Harlan M. Krumholz, Frederick G. Kushner, Bruce W. Lytle, Rick Nishimura, Joseph P. Ornato, Richard L. Page, Barbara Riegel. (2007) ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction—Executive Summary. Journal of the American College of Cardiology 50:7, 652-726
CrossRef675
C. Farsang, V. Athyros, A. Gaw. (2007) A multicentre, open study to assess the effect of individualizing starting doses of atorvastatin according to baseline LDL-C levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST-2) study*. Current Medical Research and Opinion 23:8, 1945-1956
CrossRef676
Derek J. Hausenloy, Derek M. Yellon. (2007) Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Failure Reviews 12:3-4, 217-234
CrossRef677
E. V. Gelfand, C. P. Cannon. (2007) Myocardial infarction: contemporary management strategies. Journal of Internal Medicine 262:1, 59-77
CrossRef678
Sundararajan Srikanth, Prakash Deedwania. (2007) Management of coronary artery disease in patients with type 2 diabetes mellitus. Current Cardiology Reports 9:4, 264-271
CrossRef679
Stephen E. Van Horn, Calin V. Maniu. (2007) Management of non–ST-Segment Elevation Myocardial Infarction. Medical Clinics of North America 91:4, 683-700
CrossRef680
Gema Vega, Silvia Martínez, Pedro A. Jiménez, Amalia Navarro, Fernando Bernad. (2007) Efecto de los factores de riesgo cardiovascular sobre la morbimortalidad a largo plazo después de un infarto agudo de miocardio. Revista Española de Cardiología 60:7, 703-713
CrossRef681
Bernd Genser, Winfried März. (2007) Low density lipoprotein cholesterol, statins and cardiovascular events: a meta–analysis. Clinical Research in Cardiology 96:7, 526-526
CrossRef682
Wilbert S. Aronow, William H. Frishman, Angela Cheng-Lai. (2007) Cardiovascular Drug Therapy in the Elderly. Cardiology in Review 15:4, 195-215
CrossRef683
Stephen J. Nicholls, E. Murat Tuzcu, Steven E. Nissen. (2007) Atherosclerosis regression: Is low-density lipoprotein or high-density lipoprotein the answer?. Current Atherosclerosis Reports 9:4, 266-273
CrossRef684
L. R. Erhardt, F. D. R. Hobbs. (2007) A global survey of physicians’ perceptions on cholesterol management: the From The Heart study. International Journal of Clinical Practice 61:7, 1078-1085
CrossRef685
Tze Vun Liew, BChir, Kausik K Ray. (2007) Aggressive statin therapy for acute coronary syndromes. Current Cardiology Reports 9:4, 298-302
CrossRef686
Eugene Braunwald. (2007) Reducing Myocardial Injury by Minimizing Imbalance between Oxygen Supply and Demand. Anesthesiology 107:1, 161-163
CrossRef687
B. IBANEZ, G. VILAHUR, J. J. BADIMON. (2007) Plaque progression and regression in atherothrombosis. Journal of Thrombosis and Haemostasis 5, 292-299
CrossRef688
R. Todd Hurst, Daniel W.C. Ng, Chris Kendall, Bijoy Khandheria. (2007) Clinical Use of Carotid Intima-Media Thickness: Review of the Literature. Journal of the American Society of Echocardiography 20:7, 907-914
CrossRef689
Alawi A. Alsheikh-Ali, Prasad V. Maddukuri, Hui Han, Richard H. Karas. (2007) Effect of the Magnitude of Lipid Lowering on Risk of Elevated Liver Enzymes, Rhabdomyolysis, and Cancer. Journal of the American College of Cardiology 50:5, 409-418
CrossRef690
Peter P. Toth, Chris J. Cadman. (2007) Implications of recent statin trials for primary care practice. Journal of Clinical Lipidology 1:3, 182-190
CrossRef691
Jarett D. Berry, Donald M. Lloyd-Jones, Daniel B. Garside, Philip Greenland. (2007) Framingham risk score and prediction of coronary heart disease death in young men. American Heart Journal 154:1, 80-86
CrossRef692
Robert J. Straka, Muhammad Mamdani, Joep Damen, C. Erik E. Kuntze, Larry Z. Liu, Marc F. Botteman, Michael J. Koren. (2007) Economic impacts attributable to the early clinical benefit of atorvastatin therapy – a US managed care perspective. Current Medical Research and Opinion 23:7, 1517-1529
CrossRef693
John C. LaRosa. (2007) Low-Density Lipoprotein Cholesterol Reduction: The End Is More Important Than the Means. The American Journal of Cardiology 100:2, 240-242
CrossRef694
Chung-Hua Chen, Ru-Ping Lee, Wen-Tien Wu, Kuang-Wen Liao, Nanly Hsu, Bang-Gee Hsu. (2007) Fluvastatin ameliorates endotoxin induced multiple organ failure in conscious rats. Resuscitation 74:1, 166-174
CrossRef695
Dominick J. Angiolillo, Fernando Alfonso. (2007) Clopidogrel–Statin Interaction. Journal of the American College of Cardiology 50:4, 296-298
CrossRef696
C. Constance, S. Westphal, N. Chung, M. Lund, C. McCrary Sisk, A. O. Johnson-Levonas, R. Massaad, C. Allen. (2007) Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism 9:4, 575-584
CrossRef697
K. K. Ray, C. P. Cannon, E. Braunwald. (2007) Recent trials of lipid lowering. International Journal of Clinical Practice 61:7, 1145-1159
CrossRef698
Irina Buhaescu, Hassane Izzedine. (2007) Mevalonate pathway: A review of clinical and therapeutical implications. Clinical Biochemistry 40:9-10, 575-584
CrossRef699
Ramprasad Gadi, Frederick F. Samaha. (2007) Dyslipidemia in type 2 diabetes mellitus. Current Diabetes Reports 7:3, 228-234
CrossRef700
Yiannis S. Chatzizisis, Ahmet Umit Coskun, Michael Jonas, Elazer R. Edelman, Charles L. Feldman, Peter H. Stone. (2007) Role of Endothelial Shear Stress in the Natural History of Coronary Atherosclerosis and Vascular Remodeling. Journal of the American College of Cardiology 49:25, 2379-2393
CrossRef701
Michitaka Nagashima, Ryo Koyanagi, Hiroshi Kasanuki, Nobuhisa Hagiwara, Jun-ichi Yamaguchi, Nobuhiko Atsuchi, Takashi Honda, Kazuo Haze, Tetsuya Sumiyoshi, Mitsuyoshi Urashima, Hiroshi Ogawa. (2007) Effect of Early Statin Treatment at Standard Doses on Long-Term Clinical Outcomes in Patients With Acute Myocardial Infarction (The Heart Institute of Japan, Department of Cardiology Statin Evaluation Program). The American Journal of Cardiology 99:11, 1523-1528
CrossRef702
S. R. Kalidindi, E. M. Tuzcu, S. J. Nicholls. (2007) Role of imaging end points in atherosclerosis trials: focus on intravascular ultrasound. International Journal of Clinical Practice 61:6, 951-962
CrossRef703
Cesare R Sirtori, James W Anderson, Anna Arnoldi. (2007) Nutritional and nutraceutical considerations for dyslipidemia. Future Lipidology 2:3, 313-339
CrossRef704
J Rumi Jaumdally, Chetan Varma, Gregory YH Lip. (2007) Statin therapy in South-Asian patients: clinical implications beyond lipid lowering?. Expert Opinion on Pharmacotherapy 8:9, 1235-1243
CrossRef705
P. Moulin. (2007) Les traitements à visée métabolique: «de la biochimie à la paroi». La Revue de Médecine Interne 28, S12-S13
CrossRef706
Nancy Albert. (2007) Non?ST segment elevation acute coronary syndromes: Treatment guidelines for the nurse practitioner. Journal of the American Academy of Nurse Practitioners 19:6, 277-289
CrossRef707
Douwe J. Mulder, Paul L. Haelst, Martgriet H. Wobbes, Rijk O. Gans, Felix Zijlstra, Johan F. May, Andries J. Smit, Jan Willem Cohen Tervaert, Jasper J. Doormaal. (2007) The Effect of Aggressive Versus Conventional Lipid-lowering Therapy on Markers of Inflammatory and Oxidative Stress. Cardiovascular Drugs and Therapy 21:2, 91-97
CrossRef708
Jennifer G. Robinson, Helmut Schrott. (2007) Statin Pleiotropy: A Popular Concept but Clinical Significance Unclear. Cardiovascular Drugs and Therapy 21:2, 81-83
CrossRef709
Kwok-Wai Mui, Arend-Jan Woittiez, Gerjan Navis. (2007) Atherosclerotic renovascular disease and renal impairment: Can we predict the effect of intervention?. Current Hypertension Reports 9:2, 140-147
CrossRef710
B. ilerigelen, Y. Üresin, M. Şan, H. KÜltÜrsay, S. GÜneri, O. A. Serdar, S. GÜleç, H. Pençedemir. (2007) Efficacy and safety of extended-release fluvastatin in Turkish patients with hypercholesterolaemia: TULiPS (Turkish Lipid Study). Current Medical Research and Opinion 23:5, 1093-1102
CrossRef711
Hugh F. McIntyre. (2007) Lighting the vascular fuse - late surgical attrition in older patients. International Journal of Clinical Practice 61:5, 718-720
CrossRef712
Jacqueline Suk Danik, Paul M. Ridker. (2007) Genetic determinants of C-reactive protein. Current Atherosclerosis Reports 9:3, 195-203
CrossRef713
Harm H.H. Feringa, Stefanos E. Karagiannis, Virginie H. van Waning, Eric Boersma, Olaf Schouten, Jeroen J. Bax, Don Poldermans. (2007) The effect of intensified lipid-lowering therapy on long-term prognosis in patients with peripheral arterial disease. Journal of Vascular Surgery 45:5, 936-943
CrossRef714
E. Murat Tuzcu, Stephen J. Nicholls. (2007) Statins. Journal of the American College of Cardiology 49:20, 2010-2012
CrossRef715
(2007) Guías de práctica clínica sobre diabetes, prediabetes y enfermedades cardiovasculares: versión resumida. Revista Española de Cardiología 60:5, 525.e1-525.e64
CrossRef716
A. Lawrence Gould, Glenn M. Davies, Evo Alemao, Donald D. Yin, John R. Cook. (2007) Cholesterol reduction yields clinical benefits: meta-analysis including recent trials. Clinical Therapeutics 29:5, 778-794
CrossRef717
Michael H. Davidson, Jennifer G. Robinson. (2007) Safety of Aggressive Lipid Management. Journal of the American College of Cardiology 49:17, 1753-1762
CrossRef718
F. Chenot, P. F. Montant, O. Marcovitch, M. Blaimont, A. de Meester, O. S. Descamps. (2007) Co-administration of ezetimibe and simvastatin in acute myocardial infarction. European Journal of Clinical Investigation 37:5, 357-363
CrossRef719
J. S. Rana, M. Nieuwdorp, J. W. Jukema, J. J. P. Kastelein. (2007) Cardiovascular metabolic syndrome ? an interplay of, obesity, inflammation, diabetes and coronary heart disease. Diabetes, Obesity and Metabolism 9:3, 218-232
CrossRef720
Giuseppe Boriani, Cinzia Valzania, Igor Diemberger, Mauro Biffi, Cristian Martignani, Matteo Bertini, Matteo Ziacchi, Giulia Domenichini, Davide Saporito, Claudio Rapezzi, Angelo Branzi. (2007) Potential of non-antiarrhythmic drugs to provide an innovative upstream approach to the pharmacological prevention of sudden cardiac death. Expert Opinion on Investigational Drugs 16:5, 605-623
CrossRef721
M. C. Kontos, S. E. Joyner, C. S. Roberts, F. P. Anderson, J. P. Ornato, J. L. Tatum, R. L. Jesse. (2007) Implication of the New Low-Density Lipoprotein Goals in Dyslipidemia Management of Patients With Acute Coronary Syndrome. Mayo Clinic Proceedings 82:5, 551-555
CrossRef722
Kastelein, John J.P., van Leuven, Sander I., Burgess, Leslie, Evans, Greg W., Kuivenhoven, Jan A., Barter, Philip J., Revkin, James H., Grobbee, Diederick E., Riley, Ward A., Shear, Charles L., Duggan, William T., Bots, Michiel L., . (2007) Effect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia. New England Journal of Medicine 356:16, 1620-1630
Full Text723
Hochman, Judith S., Steg, P. Gabriel, . (2007) Does Preventive PCI Work?. New England Journal of Medicine 356:15, 1572-1574
Full Text724
N. Danchin, R. Chadarevian, J.-L. Gayet, M. Licour, P. Valensi. (2007) À la dose identique de 10 mg/j, la rosuvastatine est plus efficace que l'atorvastatine pour atteindre l'objectif de LDL-cholestérol<1,00 g/l chez les patients à haut risque cardiovasculaire (étude ARIANE). Annales de Cardiologie et d'Angéiologie 56:2, 82-87
CrossRef725
L. Wei, T. M. MacDonald, A. D. Watson, M. J. Murphy. (2007) Effectiveness of two statin prescribing strategies with respect to adherence and cardiovascular outcomes: observational study. Pharmacoepidemiology and Drug Safety 16:4, 385-392
CrossRef726
Alberico L. Catapano, Terje R. Pedersen, Guy de Backer. (2007) Averting a pandemic health crisis in Europe by 2020: what physicians need to know regarding cholesterol management. European Journal of Cardiovascular Prevention & Rehabilitation 14:2, 340-345
CrossRef727
John J. P. Kastelein, Sander I. van Leuven, Gregory W. Evans, Ward A. Riley, James H. Revkin, Charles L. Shear, Michiel L. Bots. (2007) Designs of RADIANCE 1 and 2:carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis*. Current Medical Research and Opinion 23:4, 885-894
CrossRef728
Nguyen D. Nguyen, Claire Y. Wang, John A. Eisman, Tuan V. Nguyen. (2007) On the association between statin and fracture: A Bayesian consideration. Bone 40:4, 813-820
CrossRef729
Thomas Dayspring, Gregory Pokrywka. (2007) Pharmacotherapeutic decisions in menopausal women with cardiovascular risk. Future Lipidology 2:2, 197-210
CrossRef730
Christopher P. Cannon, Eugene Braunwald. (2007) Reply. Journal of the American College of Cardiology 49:13, 1502-1503
CrossRef731
Allan D Sniderman. (2007) Low-density lipoprotein lowering in type 2 diabetes mellitus: how to know how low to go. Current Opinion in Endocrinology, Diabetes and Obesity 14:2, 116-123
CrossRef732
M. D. Blagden, R. Chipperfield. (2007) Efficacy and safety of ezetimibe co-administered with atorvastatin in untreated patients with primary hypercholesterolaemia and coronary heart disease. Current Medical Research and Opinion 23:4, 767-775
CrossRef733
Jaakko Tuomilehto. (2007) Rosuvastatin: the most efficient treatment option for patients with dyslipidemia. Future Lipidology 2:2, 127-141
CrossRef734
Stephen Y Chen, WH Wilson Tang. (2007) Emerging drugs for acute and chronic heart failure: current and future developments. Expert Opinion on Emerging Drugs 12:1, 75-95
CrossRef735
James M. McKenney. (2007) Effect of drugs on high-density lipoprotein. Journal of Clinical Lipidology 1:1, 74-87
CrossRef736
Stephen J Nicholls, Jordan Andrews, Keon-Woong Moon. (2007) Exploring the natural history of atherosclerosis with intravascular ultrasound. Expert Review of Cardiovascular Therapy 5:2, 295-306
CrossRef737
W. März, T.B. Grammer. (2007) Senkung des LDL-Cholesterins. Der Internist 48:3, 319-326
CrossRef738
Antonio M. Gotto. (2007) Role of C-Reactive Protein in Coronary Risk Reduction: Focus on Primary Prevention. The American Journal of Cardiology 99:5, 718-725
CrossRef739
Navin K Kapur. (2007) Rosuvastatin: a highly potent statin for the prevention and management of coronary artery disease. Expert Review of Cardiovascular Therapy 5:2, 161-175
CrossRef740
Dan Fintel, Amie Joyce, Joan Mackell, Jennifer Graff, Erik Kuntze, Daniel A. Ollendorf. (2007) Reduced Mortality Rates after Intensive Statin Therapy in Managed-Care Patients. Value in Health 10:2, 161-169
CrossRef741
Kathleen M. McCauley. (2007) Modifying Women’s Risk for Cardiovascular Disease. Journal of Obstetric, Gynecologic, & Neonatal Nursing 36:2, 116-124
CrossRef742
José Tuñón, José Luis Martín-Ventura, Luis Miguel Blanco-Colio, Jesús Egido. (2007) Mechanisms of action of statins in stroke. Expert Opinion on Therapeutic Targets 11:3, 273-278
CrossRef743
Herbert Schuster. (2007) The GALAXY Program: an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk. Expert Review of Cardiovascular Therapy 5:2, 177-193
CrossRef744
Christie M. Ballantyne, Robert Weiss, Tiziano Moccetti, Anja Vogt, Bernd Eber, Froukje Sosef, Emma Duffield. (2007) Efficacy and Safety of Rosuvastatin 40 mg Alone or in Combination With Ezetimibe in Patients at High Risk of Cardiovascular Disease (Results from the EXPLORER Study). The American Journal of Cardiology 99:5, 673-680
CrossRef745
P. Martineau, A. Gaw, E. de Teresa, C. Farsang, G.F. Gensini, L.A. Leiter, A. Langer. (2007) Effect of individualizing starting doses of a statin according to baseline LDL-cholesterol levels on achieving cholesterol targets: The Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) study. Atherosclerosis 191:1, 135-146
CrossRef746
Chiara Cuccurullo, Andrea Mezzetti, Francesco Cipollone. (2007) COX-2 and the vasculature: Angel or evil?. Current Hypertension Reports 9:1, 73-80
CrossRef747
Stephen J Nicholls, Adnan K Chhatriwalla, Pia Lundman. (2007) Impact of statins on atherosclerotic plaque. Future Cardiology 3:2, 157-164
CrossRef748
Dirk Böse, Clemens von Birgelen, Raimund Erbel. (2007) Intravascular Ultrasound for the Evaluation of Therapies Targeting Coronary Atherosclerosis. Journal of the American College of Cardiology 49:9, 925-932
CrossRef749
Risa M. Hoffman, Judith S. Currier. (2007) Management of Antiretroviral Treatment–Related Complications. Infectious Disease Clinics of North America 21:1, 103-132
CrossRef750
Linda Van Horn. (2007) Heart Health: Does Diet Still Matter?. Journal of the American Dietetic Association 107:2, 185
CrossRef751
Mihai Gheorghiade, Gregg C. Fonarow. (2007) Management of Post-Myocardial Infarction Patients with Left Ventricular Systolic Dysfunction. The American Journal of Medicine 120:2, 109-120
CrossRef752
Rishi Sukhija, Jawahar L Mehta. (2007) Use of statins in the elderly. Future Lipidology 2:1, 9-13
CrossRef753
Kausik K. Ray, Christopher P. Cannon. (2007) Lipid-independent pleiotropic effects of statins in the management of acute coronary coronary syndromes. Current Treatment Options in Cardiovascular Medicine 9:1, 46-51
CrossRef754
Matthew Silva, Michele L. Matthews, Courtney Jarvis, Nicole M. Nolan, Paul Belliveau, Michael Malloy, Pritesh Gandhi. (2007) Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clinical Therapeutics 29:2, 253-260
CrossRef755
Michael H. Davidson. (2007) Global Risk Management in Patients with Type 2 Diabetes Mellitus. The American Journal of Cardiology 99:4, 41-50
CrossRef756
Robert J. Applegate, Matthew T. Sacrinty, Michael A. Kutcher, Talal T. Baki, Sanjay K. Gandhi, Renato M. Santos, William C. Little. (2007) Comparison of Drug-Eluting Versus Bare Metal Stents on Later Frequency of Acute Myocardial Infarction and Death. The American Journal of Cardiology 99:3, 333-338
CrossRef757
Sophie L. Rogers, Dianna J. Magliano, Dane B. Levison, Kate Webb, Philippa J. Clarke, Mendel P. Grobler, Danny Liew. (2007) A dose-specific meta-analysis of lipid changes in randomized controlled trials of atorvastatin and simvastatin. Clinical Therapeutics 29:2, 242-252
CrossRef758
Daniel J Rader. (2007) Mechanisms of Disease: HDL metabolism as a target for novel therapies. Nature Clinical Practice Cardiovascular Medicine 4:2, 102-109
CrossRef759
Colin Berry, Jean-Claude Tardif, Martial G. Bourassa. (2007) Coronary Heart Disease in Patients With Diabetes. Journal of the American College of Cardiology 49:6, 631-642
CrossRef760
Rakesh K. Mishra, Craig T. Basson. (2007) Treatment goals for the management of lipids and inflammation for patients with coronary artery disease. Current Treatment Options in Cardiovascular Medicine 9:1, 3-10
CrossRef761
Keeley, Ellen C., Hillis, L. David, . (2007) Primary PCI for Myocardial Infarction with ST-Segment Elevation. New England Journal of Medicine 356:1, 47-54
Full Text762
Marcello Arca, Achille Gaspardone. (2007) Atorvastatin Efficacy in the Primary and Secondary Prevention of Cardiovascular Events. Drugs 67:Supplement 1, 29-42
CrossRef763
Juan J. Rivera, Roger S. Blumenthal, Dominique Ashen. (2007) Low-Density Lipoprotein Cholesterol in High-Risk Asymptomatic Individuals. Journal of the CardioMetabolic Syndrome 2:1, 49-52
CrossRef764
Michael H Davidson. (2007) Rosuvastatin in Elderly Patients. Drugs & Aging 24:11, 933-944
CrossRef765
Takashi Yamada, Akihiro Azuma, Susumu Sasaki, Takahisa Sawada, Hiroaki Matsubara, The REACH Study Group. (2007) Randomized Evaluation of Atorvastatin in Patients With Coronary Heart Disease. Circulation Journal 71:12, 1845-1850
CrossRef766
Peter P. Toth. (2007) Reducing cardiovascular risk by targeting high-density lipoprotein cholesterol. Current Atherosclerosis Reports 9:1, 81-88
CrossRef767
Rob Butler, James Wainwright. (2007) Cholesterol lowering in patients with CHD and metabolic syndrome. The Lancet 369:9555, 27
CrossRef768
Wilbert S. Aronow. (2007) Intensive Statin Treatment or Combination Therapy in High-Risk Patients. Preventive Cardiology 10:1, 7-8
CrossRef769
Young Joon Hong, Myung Ho Jeong, Youngkeun Ahn, Jae Youn Moon, Kye Hun Kim, Hyung Wook Park, Ju Han Kim, Jeong Gwan Cho, Jong Chun Park, Jung Chaee Kang. (2007) Effect of Conventional Dose of Simvastatin on Plaque Regression and Vascular Remodeling in the Peristent Reference Segments of Normocholesterolemic Patients: A Serial Intravascular Ultrasound Assessment. Korean Circulation Journal 37:10, 483
CrossRef770
Tracie C. Collins, Peter H. Jones. (2007) Statin therapy: Is the percent reduction or the attained low-density lipoprotein cholesterol level more important?. Current Atherosclerosis Reports 9:1, 10-17
CrossRef771
Cheol-Ho Kim, Kwang-Il Kim, Jae-Hyung Kim, Jae-Eun Jun, Jong-Hwa Bae, Jae-Woo Lee, Kyung-Hoon Choe, Soon-Pyo Hong, Bang-Hun Lee. (2007) Prospective Study to Evaluate the Efficacy and Safety of Pitavastatin in Patients with Risk Factor of Cardiovascular Disease(PEACE Study). Korean Circulation Journal 37:1, 16
CrossRef772
Yi-Heng Li, Hui-Ling Wu, Yea-Huei Kao Yang, Hui-Shan Tsai, Ting-Hsing Chao. (2007) Effect of Early Versus Late In-Hospital Initiation of Statin Therapy on the Clinical Outcomes of Patients With Acute Coronary Syndrome. International Heart Journal 48:6, 677-688
CrossRef773
Maurizio Paciaroni, Michael Hennerici, Giancarlo Agnelli, Julien Bogousslavsky. (2007) Statins and Stroke Prevention. Cerebrovascular Diseases 24:2-3, 170-182
CrossRef774
Michael Clearfield. (2007) Clinical trials report. Current Atherosclerosis Reports 9:1, 5-9
CrossRef775
Vincent E. Friedewald, Ruth McPherson, Robert Roberts, William C. Roberts, David D. Waters. (2007) The Editor’s Roundtable: Statin Therapy in Acute Coronary Syndrome. The American Journal of Cardiology 99:2, 213-221
CrossRef776
Anthony A Bavry, Girish R Mood, Dharam J Kumbhani, Peter P Borek, Arman T Askari, Deepak L Bhatt. (2007) Long-Term Benefit of Statin Therapy Initiated??during Hospitalization for??an??Acute??Coronary Syndrome. American Journal of Cardiovascular Drugs 7:2, 135-141
CrossRef777
Hae-Chang Jeong, Myung Ho Jeong, Young Keun Ahn, Sung Chull Chae, Young Jo Kim, Seung Ho Hur, Dong Hoon Choi, Jung Han Yoon, Jei Keon Chae, Doo Il Kim, Bon Kwon Koo, Jin Yong Hwang, Seok Kyu Oh, Kee Sik Kim, Kyung Tae Jeong, Chong Jin Kim, Wook Sung Chung, Yang Soo Jang, . (2007) In-Hospital Outcome According to the Initial Management and the "Thrombolysis in Myocardial Infarction Risk Score" of Acute Non-ST Segment Elevation Myocardial Infarction. Korean Circulation Journal 37:11, 550
CrossRef778
W.J. Howard. (2007) High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After Myocardial Infarction: The IDEAL Study: A Randomized Controlled Trial. Yearbook of Endocrinology 2007, 106-108
CrossRef779
W.J. Howard. (2007) High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After Myocardial Infarction: The IDEAL Study: A Randomized Controlled Trial. Yearbook of Medicine 2007, 521-523
CrossRef780
Xiankai Li, Jue Li, Thach Nguyen, Mingzhong Zhao, Liqiang Zheng, Buaijiaer Hasimu, Jinming Yu, Yingyi Luo, Dayi Hu. (2007) Effect of Statins and Calcium Channel Blockers on All-Cause Mortality and Cardiovascular and Cerebrovascular Disease Mortality in 958 Chinese Hospitalized Patients with Peripheral Arterial Disease after 13 Months of Follow-up. JOURNAL OF HEALTH SCIENCE 53:2, 226-233
CrossRef781
Gema Vega, Silvia Martínez, Pedro A. Jiménez, Amalia Navarro, Fernando Bernad. (2007) Effect of Cardiovascular Risk Factors on Long-Term Morbidity and Mortality Following Acute Myocardial Infarction. Revista Española de Cardiología (English Edition) 60:7, 703-713
CrossRef782
Gy??rgy Paragh, L??szlo M??rk, K??roly Z??molyi, Gyula Pados, P??ter Ofner. (2007) Lipid-Modifying Therapy and Attainment of Cholesterol Goals in Hungary. Clinical Drug Investigation 27:9, 647-660
CrossRef783
Hiroaki Takashima, Yukio Ozaki, Tatsuya Yasukawa, Katsuhisa Waseda, Kenji Asai, Yoshinori Wakita, Yasuo Kuroda, Takashi Kosaka, Yasushi Kuhara, Takayuki Ito. (2007) Impact of Lipid-Lowering Therapy With Pitavastatin, a New HMG-CoA Reductase Inhibitor, on Regression of Coronary Atherosclerotic Plaque. Circulation Journal 71:11, 1678-1684
CrossRef784
Ryozo Nagai, Tohru Izumi, Masahiko Kurabayashi, Hiroyuki Daida, Taiki Tojo, Akira Hasegawa, Katsumi Miyauchi, Dobun Hayashi, Takahide Kohro, Yoshihiro Okada, Tsutomu Yamazaki, The JCADII Investigators. (2007) Rationale and Design of a Study to Examine Lower Targets for Low-Density Lipoprotein-Cholesterol and Blood Pressure in Coronary Artery Disease Patients. Circulation Journal 72:4, 515-520
CrossRef785
Carmen Suárez. (2007) Baseline Characteristics of Patients with Cerebrovascular Disease in the REACH Registry: The Spanish Contribution. Cerebrovascular Diseases 24:1, 89-95
CrossRef786
Tadashi YAMAKAWA, Tatsuro TAKANO, Hirotoshi UTSUNOMIYA, Kazuaki KADONOSONO, Atushi OKAMURA. (2007) Effect of Colestimide Therapy for Glycemic Control in Type 2 Diabetes Mellitus with Hypercholesterolemia. Endocrine Journal 54:1, 53-58
CrossRef787
Bruce Ovbiagele, Sandeep Sachdeva. (2007) Preventing another event: Role of the hospitalist in discharge stroke prevention. Journal of Hospital Medicine 2:1, 31-38
CrossRef788
Koichi Tamita, Minako Katayama, Tsutomu Takagi, Takashi Akasaka, Atsushi Yamamuro, Shuichiro Kaji, Shigefumi Morioka, Yasuki Kihara. (2007) Impact of Newly Diagnosed Abnormal Glucose Tolerance on Long-Term Prognosis in Patients With Acute Myocardial Infarction. Circulation Journal 71:6, 834-841
CrossRef789
Marcello Arca. (2007) Atorvastatin Efficacy in the Prevention of Cardiovascular Events in Patients with Diabetes Mellitus and/or Metabolic Syndrome. Drugs 67:Supplement 1, 43-54
CrossRef790
2007. M. , 125-137.
CrossRef791
Tomohiro Sakamoto, Sunao Kojima, Hisao Ogawa, Hideki Shimomura, Kazuo Kimura, Yasuhiro Ogata, Naritsugu Sakaino, Akira Kitagawa, The MUSASHI-AMI Investigators. (2007) Usefulness of Hydrophilic vs Lipophilic Statins After Acute Myocardial Infarction. Circulation Journal 71:9, 1348-1353
CrossRef792
Tadateru Takayama, Takafumi Hiro, Masakazu Yamagishi, Hiroyuki Daida, Satoshi Saito, Tetsu Yamaguchi, Masunori Matsuzaki. (2007) Rationale and Design for a Study Using Intravascular Ultrasound to Evaluate Effects of Rosuvastatin on Coronary Artery Atheroma in Japanese Subjects. Circulation Journal 71:2, 271-275
CrossRef793
Kyeong Ho Yun, Hyun-Young Park, Jun-Ho Choi, Mi-Jin Song, Eun Mi Park, Yun Kyung Kim, Sang Jae Rhee, Eun Mi Lee, Je Lee, Nam Jin Yoo, Nam-Ho Kim, Seok Kyu Oh, Jin-Won Jeong. (2007) Comparison of Efficacy and Safety after Administering High Potency Statin to High Risk Patients: Rosuvastatin 10 mg versus Atorvastatin 20 mg. Korean Circulation Journal 37:4, 154
CrossRef794
Michael Miller. (2007) Optimal Treatment of Dyslipidemia in High-Risk Patients: Intensive Statin Treatment or Combination Therapy?. Preventive Cardiology 10:1, 31-35
CrossRef795
Anna Frisinghelli, Antonio Mafrici. (2007) Regression or Reduction in Progression of Atherosclerosis, and Avoidance of Coronary Events, With Lovastatin in Patients With or at High Risk of Cardiovascular Disease. Clinical Drug Investigation 27:9, 591-604
CrossRef796
Tomoko Kayanuma, Etsuko Negishi, Hitoshi Anzai, Yutaro Nishi, Nobuhiro Takao, Tadao Inoue, Koichi Ueno. (2007) Study on Drugs Prescribed for Treatment of Hyperlipidemia. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) 33:9, 781-787
CrossRef797
Lloyd W. Klein. (2007) Atherosclerosis Regression, Vascular Remodeling, and Plaque Stabilization. Journal of the American College of Cardiology 49:2, 271-273
CrossRef798
Kristian B. Filion, J. A. Chris Delaney, James M. Brophy, Pierre Ernst, Samy Suissa. (2007) The impact of over-the-counter simvastatin on the number of statin prescriptions in the United Kingdom: a view from the General Practice Research Database. Pharmacoepidemiology and Drug Safety 16:1, 1-4
CrossRef799
(2007) Invited Synopses. Acute Cardiac Care 9:3, 134-174
CrossRef800
Ryoko Mitsutake, Shin-ichiro Miura, Keisuke Okamura, Hideya Niimura, Akira Kawamura, Keijiro Saku. (2007) Successful Intensive Lipid-lowering Therapy Using Atorvastatin Stabilizes Coronary Artery Plaque as Assessed by Multi-detector Row Computed Tomography. Internal Medicine 46:12, 859-863
CrossRef801
Juan Ascaso, Pedro Gonzalez Santos, Antonio Hernandez Mijares, Alipio Mangas Rojas, Luis Masana, Jesus Millan, Luis Felipe Pallardo, Juan Pedro-Botet, Francisco Perez Jimenez, Xavier Pint??, Ignacio Plaza, Juan Rubi??s, Manuel Z????iga. (2007) Management of Dyslipidemia in the Metabolic Syndrome. American Journal of Cardiovascular Drugs 7:1, 39-58
CrossRef802
Chaitanya A. Sarawate, Mark J. Cziraky, Eric J. Stanek, Vincent J. Willey, John C. Corbelli, Scott L. Charland. (2007) Achievement of optimal combined lipid values in a managed care setting: Is a new treatment paradigm needed?. Clinical Therapeutics 29:1, 196-209
CrossRef803
Shigemasa HASHIMOTO, Koichi NODE. (2007) Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 38:5, 317-321
CrossRef804
Chin‐Sang Chung, Louis R. Caplan. 2007. Stroke and Other Neurovascular Disorders. , 1019-1051.
CrossRef805
Dominique Beaudry, Kenneth E. Stone, Suzanne Wetherold, John Hemphill, Dat Do, John McClish, Robert Chilton. (2007) Statin therapy in cardiovascular diseases other than atherosclerosis. Current Atherosclerosis Reports 9:1, 25-32
CrossRef806
M. Böhm, U. Laufs, C. Hamm, D. Andresen, H.-J. Becker, M. Borggrefe, J. Brachmann, R. Dietz, G. Ertl, E. Fleck, M.G. Gottwik, F. Haan, H.M. Hoffmeister, G. Heusch, T. Meinertz, A. Osterspey, S. Silber, H.-J. Trappe. (2007) Positionspapier zur Statintherapie. Clinical Research in Cardiology Supplements 2:1, 8-15
CrossRef807
G.L. Moneta. (2007) Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease. Yearbook of Vascular Surgery 2007, 90-92
CrossRef808
Masaaki Ii, Douglas W. Losordo. (2007) Statins and the endothelium. Vascular Pharmacology 46:1, 1-9
CrossRef809
Yan Chen, Koji Ohmori, Mizuki Mizukawa, Junji Yoshida, Yu Zeng, Ling Zhang, Kaori Shinomiya, Hiroaki Kosaka, Masakazu Kohno. (2007) Differential Impact of Atorvastatin vs Pravastatin on Progressive Insulin Resistance and Left Ventricular Diastolic Dysfunction in a Rat Model of Type II Diabetes. Circulation Journal 71:1, 144-152
CrossRef810
Takahide Kohro, Dobun Hayashi, Yoshihiro Okada, Tsutomu Yamazaki, Ryozo Nagai, The JCAD Investigators. (2007) Effects of Medication on Cardiovascular Events in the Japanese Coronary Artery Disease (JCAD) Study. Circulation Journal 71:12, 1835-1840
CrossRef811
Rubin Minhas. (2007) Statin utilisation - recognising the role of the invisible hand. International Journal of Clinical Practice 61:1, 3-6
CrossRef812
J. David Spence. (2007) Intensive management of risk factors for accelerated atherosclerosis: the role of multiple interventions. Current Neurology and Neuroscience Reports 7:1, 42-48
CrossRef813
Vijay S Ramanath, Kim A Eagle. (2007) Evidence-Based Medical Therapy of Patients with Acute Coronary Syndromes. American Journal of Cardiovascular Drugs 7:2, 95-116
CrossRef814
Greg L Plosker, Katherine A Lyseng-Williamson. (2007) Atorvastatin. PharmacoEconomics 25:12, 1031-1053
CrossRef815
Thomas I. Barron, Kathleen Bennett, John Feely. (2006) Impact of high dose statin trials on hospital prescribers. European Journal of Clinical Pharmacology 63:1, 65-72
CrossRef816
Riza C Ozsoy, Sander I van Leuven, John JP Kastelein, Lambertus Arisz, Marion G Koopman. (2006) The dyslipidemia of chronic renal disease: effects of statin therapy. Current Opinion in Lipidology 17:6, 659-666
CrossRef817
, G. Breithardt. (2006) Empfehlungen zur Diagnostik und Behandlung von Patienten mit koronarer Herzkrankheit und Niereninsuffizienz. Clinical Research in Cardiology Supplements 1:2, 103-117
CrossRef818
Gerald W. Smetana, Steven L. Cohn, Donna L. Mercado, Amir K. Jaffer. (2006) Update in Perioperative Medicine. Journal of General Internal Medicine 21:12, 1329-1337
CrossRef819
Markus Müller. (2006) Grenzen der ökonomischen Bewertung von Arzneimitteln aus klinischpharmakologischer Sicht. Wiener Medizinische Wochenschrift 156:23-24, 619-621
CrossRef820
JV (Ian) Nixon. (2006) Who should receive a statin drug to lower cardiovascular risk? Does the drug and the dose of the drug matter?. Vascular Health and Risk Management 2:4, 441-446
CrossRef821
Stephen D Wiviott, Christopher P Cannon. (2006) The safety and efficacy of achieving very low LDL-cholesterol concentrations with high dose statin therapy. Current Opinion in Lipidology 17:6, 626-630
CrossRef822
John J. Mahmarian, Habib A. Dakik, Neil G. Filipchuk, Leslee J. Shaw, Sherif S. Iskander, Terrence D. Ruddy, Felix Keng, Milena J. Henzlova, Adel Allam, Lemuel A. Moyé, Craig M. Pratt. (2006) An Initial Strategy of Intensive Medical Therapy Is Comparable to That of Coronary Revascularization for Suppression of Scintigraphic Ischemia in High-Risk But Stable Survivors of Acute Myocardial Infarction. Journal of the American College of Cardiology 48:12, 2458-2467
CrossRef823
Daria Roccatagliata, Fausto Avanzini, Lara Monesi, Vittorio Caimi, Davide Lauri, Paolo Longoni, Roberto Marchioli, Massimo Tombesi, Gianni Tognoni, Maria Carla Roncaglioni, . (2006) Is global cardiovascular risk considered in current practice? Treatment and control of hypertension, hyperlipidemia, and diabetes according to patients' risk level. Vascular Health and Risk Management 2:4, 507-514
CrossRef824
S Pierno, M P Didonna, V Cippone, A Luca, M Pisoni, A Frigeri, G P Nicchia, M Svelto, G Chiesa, C Sirtori, E Scanziani, C Rizzo, D Vito, D Conte Camerino. (2006) Effects of chronic treatment with statins and fenofibrate on rat skeletal muscle: a biochemical, histological and electrophysiological study. British Journal of Pharmacology 149:7, 909-919
CrossRef825
Benjamin Ansell, F. D. Richard Hobbs. (2006) The potential for CETP inhibition to reduce cardiovascular disease risk. Current Medical Research and Opinion 22:12, 2467-2478
CrossRef826
Wilbert S Aronow. (2006) Management of hyperlipidemia with statins in the older patient. Clinical Interventions in Aging 1:4, 433-438
CrossRef827
Antonio M Gotto, John A Farmer. (2006) Drug Insight: the role of statins in combination with ezetimibe to lower LDL cholesterol. Nature Clinical Practice Cardiovascular Medicine 3:12, 664-672
CrossRef828
Allen J. Taylor, Hyun J. Lee, Lance E. Sullenberger. (2006) The effect of 24 months of combination statin and extended-release niacin on carotid intima‐media thickness: ARBITER 3*. Current Medical Research and Opinion 22:11, 2243-2250
CrossRef829
Antonio Maiques Galán. (2006) Nuevas indicaciones y objetivos terapéuticos en las dislipemias. Atención Primaria 38:9, 473-475
CrossRef830
Nobuhiro Tahara, Hisashi Kai, Masatoshi Ishibashi, Hiroyuki Nakaura, Hayato Kaida, Kenkichi Baba, Naofumi Hayabuchi, Tsutomu Imaizumi. (2006) Simvastatin Attenuates Plaque Inflammation. Journal of the American College of Cardiology 48:9, 1825-1831
CrossRef831
Michiel L. Bots. (2006) Carotid intima-media thickness as a surrogate marker for cardiovascular disease in intervention studies. Current Medical Research and Opinion 22:11, 2181-2190
CrossRef832
J. Suk Danik, D. I. Chasman, C. P. Cannon, D. T. Miller, R. Y. L. Zee, P. Kozlowski, D. J. Kwiatkowski, P. M. Ridker. (2006) Influence of Genetic Variation in the C-Reactive Protein Gene on the Inflammatory Response During and After Acute Coronary Ischemia. Annals of Human Genetics 70:6, 705-716
CrossRef833
Anders G. Olsson. (2006) Expanding options with a wider range of rosuvastatin doses. Clinical Therapeutics 28:11, 1747-1763
CrossRef834
Sophia Boudoulas Meis, Richard Snow, Michelle LaLonde, James Falko, Teresa Caulin-Glaser. (2006) A Systematic Approach to Improve Lipids in Coronary Artery Disease Patients Participating in a Cardiac Rehabilitation Program. Journal of Cardiopulmonary Rehabilitation 26:6, 355-360
CrossRef835
Adnan K Chhatriwalla, Stephen J Nicholls, Steven E Nissen. (2006) The ASTEROID trial: coronary plaque regression with high-dose statin therapy. Future Cardiology 2:6, 651-654
CrossRef836
Nader N. Boushra, Muhammad Muntazar. (2006) Review article: The role of statins in reducing perioperative cardiac risk: physiologic and clinical perspectives. Canadian Journal of Anesthesia/Journal canadien d'anesthésie 53:11, 1126-1147
CrossRef837
Jeffrey S Berger, John L Petersen, James E Tcheng, Harry R Phillips. (2006) Clinical implications of vulnerable plaque. Future Cardiology 2:6, 721-731
CrossRef838
Jacob A Udell, Joel G Ray. (2006) Primary and secondary prevention of heart failure with statins. Expert Review of Cardiovascular Therapy 4:6, 917-926
CrossRef839
Michael H. Davidson, James M. McKenney, Charles L. Shear, James H. Revkin. (2006) Efficacy and Safety of Torcetrapib, a Novel Cholesteryl Ester Transfer Protein Inhibitor, in Individuals With Below-Average High-Density Lipoprotein Cholesterol Levels. Journal of the American College of Cardiology 48:9, 1774-1781
CrossRef840
Richard V. Milani, Carl J. Lavie. (2006) Cholesteryl Ester Transfer Protein Inhibition. Journal of the American College of Cardiology 48:9, 1791-1792
CrossRef841
Nanette K. Wenger. (2006) Lipid Abnormalities in Women. Cardiology in Review 14:6, 276-280
CrossRef842
James M. McKenney, Michael H. Davidson, Charles L. Shear, James H. Revkin. (2006) Efficacy and Safety of Torcetrapib, a Novel Cholesteryl Ester Transfer Protein Inhibitor, in Individuals With Below-Average High-Density LipoproteinCholesterolLevelsonaBackgroundofAtorvastatin. Journal of the American College of Cardiology 48:9, 1782-1790
CrossRef843
Masataka Kuwana. (2006) Potential benefit of statins for vascular disease in systemic sclerosis. Current Opinion in Rheumatology 18:6, 594-600
CrossRef844
D Charytan, R E Kuntz. (2006) The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. Kidney International
CrossRef845
2006. Acute Coronary Syndrome: NSTEMI. .
CrossRef846
Paul Schoenhagen. (2006) Atherosclerosis Imaging with Intravascular Ultrasound. The International Journal of Cardiovascular Imaging 22:5, 615-618
CrossRef847
Barry A. Franklin. (2006) Coronary revascularization and medical management of coronary artery disease: changing paradigms and perceptions. European Journal of Cardiovascular Prevention & Rehabilitation 13:5, 669-673
CrossRef848
James T. Willerson, Paul W Armstrong. 2006. Acute Myocardial Infarction. , 611-646.
CrossRef849
Gerd Assmann, Heike Benecke, Albrecht Neiss, Paul Cullen, Helmut Schulte, Kurt Bestehorn. (2006) Gap between guidelines and practice: attainment of treatment targets in patients with primary hypercholesterolemia starting statin therapy. Results of the 4E-Registry (Efficacy Calculation and Measurement of Cardiovascular and Cerebrovascular Events including Physicians?? Experience and Evaluation). European Journal of Cardiovascular Prevention & Rehabilitation 13:5, 776-783
CrossRef850
Arun Kalyanasundaram, James C. Blankenship, Jamshid Shirani. (2006) Non-ST Segment Elevation Acute Coronary Syndromes. Southern Medical Journal 99:10, 1053-1054
CrossRef851
Felix K. Yam, Wendell S. Akers, Victor A. Ferraris, Kelly Smith, Chand Ramaiah, Phillip Camp, Jeremy D. Flynn. (2006) Interventions to improve guideline compliance following coronary artery bypass grafting. Surgery 140:4, 541-552
CrossRef852
Kiran K. Khush, David D. Waters. (2006) Effects of Statin Therapy on the Development and Progression of Heart Failure: Mechanisms and Clinical Trials. Journal of Cardiac Failure 12:8, 664-674
CrossRef853
Stella S. Daskalopoulou, Dimitri P. Mikhailidis. (2006) Ezetimibe/simvastatin single tablet versus rosuvastatin in patients with hypercholesterolemia. Current Medical Research and Opinion 22:10, 2037-2039
CrossRef854
Alberico L. Catapano, Michael H. Davidson, Christie M. Ballantyne, William E. Brady, Russell A. Gazzara, Joanne E. Tomassini, Andrew M. Tershakovec. (2006) Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients*. Current Medical Research and Opinion 22:10, 2041-2053
CrossRef855
Michael Cuffe. (2006) The patient with cardiovascular disease: Treatment strategies for preventing major events. Clinical Cardiology 29:S2, 4-12
CrossRef856
A. Gómez-Belda, E. Rodilla, C. González, J.A. Costa, B. Serra, J.M. Pascual. (2006) Objetivos del tratamiento hipolipemiante en pacientes con alto riesgo y muy alto riesgo cardiovascular: ¿un reto posible?. Revista Clínica Española 206:9, 417-421
CrossRef857
Vera Bittner. 2006. Women and Coronary Heart Disease. , 689-720.
CrossRef858
Alice YY Cheng, Lawrence A Leiter. (2006) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Current Opinion in Internal Medicine 5:5, 461-465
CrossRef859
Kausik K Ray, Christopher P Cannon. (2006) Intensive statin therapy for treating acute coronary syndromes. Expert Opinion on Investigational Drugs 15:10, 1151-1159
CrossRef860
Abelardo Martinez-Rumayor, James L. Januzzi. (2006) Non-ST Segment Elevation Acute Coronary Syndromes: A Comprehensive Review. Southern Medical Journal 99:10, 1103-1110
CrossRef861
Peter P Toth, Antonio M Gotto. 2006. High-Density Lipoprotein Cholesterol. , 295-340.
CrossRef862
Stéphane Bissonnette, Rafik Habib, Fotini Sampalis, Stella Boukas, John S. Sampalis. (2006) Efficacy and tolerability of ezetimibe 10 mg/day coadministered with statins in patients with primary hypercholesterolemia who do not achieve target LDL-C while on statin monotherapy: A Canadian, multicentre, prospective study – the Ezetrol® Add-On Study. Canadian Journal of Cardiology 22:12, 1035-1044
CrossRef863
John A. Farmer. 2006. Inflammatory Mediators and C-Reactive Protein. , 441-462.
CrossRef864
Stefano Bellosta, Rodolfo Paoletti, Alberto Corsini. 2006. Safety of Dyslipidemic Agents. , 389-408.
CrossRef865
Alpesh Amin. (2006) Improving the management of patients after myocardial infarction, from admission to discharge. Clinical Therapeutics 28:10, 1509-1539
CrossRef866
J. SHEPHERD. (2006) Who should receive a statin these days? Lessons from recent clinical trials. Journal of Internal Medicine 260:4, 305-319
CrossRef867
Anthony A. Bavry, Dharam J. Kumbhani, Andrew N. Rassi, Deepak L. Bhatt, Arman T. Askari. (2006) Benefit of Early Invasive Therapy in Acute Coronary Syndromes. Journal of the American College of Cardiology 48:7, 1319-1325
CrossRef868
Walter S. Schroeder, Linda Ghobrial, Pritesh J. Gandhi. (2006) Possible mechanisms of drug-induced aspirin and clopidogrel resistance. Journal of Thrombosis and Thrombolysis 22:2, 139-150
CrossRef869
Mehmet Kanadaşı, Murat Çaylı, Mustafa Demirtaş, Tamer İnal, Mesut Demir, Mevlut Koç, Mahir Avkaroǧulları, Yurdaer Dönmez, Ayhan Usal, Cumhur C. Alhan, Mustafa Şan. (2006) The effect of early statin treatment on inflammation and cardiac events in acute coronary syndrome patients with low-density lipoprotein cholesterol. Heart and Vessels 21:5, 291-297
CrossRef870
Michel de Lorgeril, Patricia Salen. (2006) Cholesterol lowering and mortality: Time for a new paradigm?. Nutrition, Metabolism and Cardiovascular Diseases 16:6, 387-390
CrossRef871
H.-J. Rupprecht. (2006) Kardiovaskuläre Sekundärprävention. Clinical Research in Cardiology 95:S6, vi1-vi5
CrossRef872
John Mulhall, Patrick Teloken, Gerald Brock, Edward Kim. (2006) Obesity, Dyslipidemias and Erectile Dysfunction: A Report of a Subcommittee of the Sexual Medicine Society of North America. The Journal of Sexual Medicine 3:5, 778-786
CrossRef873
Jae Woo Lee. (2006) Statins and Cardiovascular Risks. International Anesthesiology Clinics 43:2, 55-68
CrossRef874
Julie Ramos, Qamar A Khan, Martin Thoenes, Bobby V Khan. (2006) Atorvastatin: beyond lipid-lowering effects in the diabetic population. Future Cardiology 2:5, 527-533
CrossRef875
Nitin Khosla, Henry R. Black. (2006) Expanding the definition of hypertension to incorporate global cardiovascular risk. Current Hypertension Reports 8:5, 384-390
CrossRef876
Haruo Nakamura, Kikuo Arakawa, Hiroshige Itakura, Akira Kitabatake, Yoshio Goto, Takayoshi Toyota, Noriaki Nakaya, Shoji Nishimoto, Masaharu Muranaka, Akira Yamamoto, Kyoichi Mizuno, Yasuo Ohashi. (2006) Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. The Lancet 368:9542, 1155-1163
CrossRef877
J.V. Nixon. (2006) Lower Is Better?The Contemporary Concept of Low-Density Lipoprotein Lowering in the Preventive Management of Cardiovascular Risk: Does This Apply to All Patients?. Preventive Cardiology 9:4, 219-227
CrossRef878
Ruth McPherson, Jiri Frohlich, George Fodor, Jacques Genest. (2006) Canadian Cardiovascular Society position statement – Recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Canadian Journal of Cardiology 22:11, 913-927
CrossRef879
Peter P. Toth. (2006) Clinical Trials Report. Current Atherosclerosis Reports 8:5, 353-355
CrossRef880
C. Luley. (2006) Fettstoffwechselstörungen—Cholesterin und Triglyceride. Clinical Research in Cardiology 95:S6, vi17-vi22
CrossRef881
, G. Breithardt. (2006) Empfehlungen zur Diagnostik und Behandlung von Patienten mit koronarer Herzkrankheit und Niereninsuffizienz. Clinical Research in Cardiology Supplements 1:1, 8-30
CrossRef882
Rubinder S. Ruby, Imran S. Virk, John Ip, David Tepper. (2006) The Debate Over Anticoagulation in Patients With Heart Failure. Congestive Heart Failure 12:5, 285-287
CrossRef883
Glen J. Pearson, Gordon A. Francis, Jacques S. Romney, Dawna M. Gilchrist, Andrea Opgenorth, Gabor T. Gyenes. (2006) The clinical effect and tolerability of ezetimibe in high-risk patients managed in a specialty cardiovascular risk reduction clinic. Canadian Journal of Cardiology 22:11, 939-945
CrossRef884
Anders G. Olsson. (2006) Are lower levels of low-density lipoprotein cholesterol beneficial? A review of recent data. Current Atherosclerosis Reports 8:5, 382-389
CrossRef885
T. A. Jacobson. (2006) The Safety of Aggressive Statin Therapy: How Much Can Low-Density Lipoprotein Cholesterol Be Lowered?. Mayo Clinic Proceedings 81:9, 1225-1231
CrossRef886
T. A. Pearson, M. A. Denke, P. E. McBride, W. P. Battisti, R. A. Gazzara, W. E. Brady, J. Palmisano. (2006) Effectiveness of Ezetimibe Added to Ongoing Statin Therapy in Modifying Lipid Profiles and Low-Density Lipoprotein Cholesterol Goal Attainment in Patients of Different Races and Ethnicities: A Substudy of the Ezetimibe Add-On to Statin for Effectiveness Trial. Mayo Clinic Proceedings 81:9, 1177-1185
CrossRef887
Charles D. Collard, Simon C. Body, Stanton K. Shernan, Shirley Wang, Dennis T. Mangano. (2006) Preoperative statin therapy is associated with reduced cardiac mortality after coronary artery bypass graft surgery. The Journal of Thoracic and Cardiovascular Surgery 132:2, 392-400.e1
CrossRef888
Jacques Genest. (2006) Combination of statin and ezetimibe for the treatment of dyslipidemias and the prevention of coronary artery disease. Canadian Journal of Cardiology 22:10, 863-868
CrossRef889
Kavitha Gopal, Timothy C. Johnson, Saraswathi Gopal, Aaron Walfish, Christine T. Bang, Pauline Suwandhi, Helene N. Pena-Sahdala, David J. Clain, Henry C. Bodenheimer, Albert D. Min. (2006) Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment. Hepatology 44:2, 335-340
CrossRef890
Patricia M Kearney, Colin Baigent. (2006) Statins: are any questions unanswered?. Current Opinion in Lipidology 17:4, 418-425
CrossRef891
Franz H. Messerli, George L. Bakris, R. David Ferrera, Mark C. Houston, Robert J. Petrella, John M. Flack, William Sun, EunMee Lee, Joel M. Neutel, . (2006) Efficacy and Safety of Coadministered Amlodipine and Atorvastatin in Patients With Hypertension and Dyslipidemia: Results of the AVALON Trial. The Journal of Clinical Hypertension 8:8, 571-583
CrossRef892
Jessica L. Mega, David A. Morrow, Christopher P. Cannon, Sabina Murphy, Richard Cairns, Paul M. Ridker, Eugene Braunwald. (2006) Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapy. Journal of Thrombosis and Thrombolysis 22:1, 71-76
CrossRef893
Alberto de Luis, Ingrid Roca, Tamara Jiménez, Maite Sastre, Margarita Lladó, F. Javier Poza, Fernando Espada, Àngels Martos. (2006) Tratamiento de los factores de riesgo cardiovascular en pacientes con accidente vascular cerebral. Clínica e Investigación en Arteriosclerosis 18:4, 115-120
CrossRef894
Anthony S Wierzbicki. (2006) Future approaches to reducing low-density lipoprotein cholesterol. Future Lipidology 1:4, 463-476
CrossRef895
Antonio Bellasi, Paolo Raggi. (2006) Lipid-lowering therapy with statins in postmenopausal women: a few answered and many unanswered questions. Future Lipidology 1:4, 375-379
CrossRef896
J. V. PATEL, E. A. HUGHES. (2006) Efficacy, safety and LDL-C goal attainment of ezetimibe 10 mg-simvastatin 20 mg vs. placebo-simvastatin 20 mg in UK-based adults with coronary heart disease and hypercholesterolaemia. International Journal of Clinical Practice 60:8, 914-921
CrossRef897
Jennifer G Robinson, Michael H Davidson. (2006) How low to target LDL?. Nature Clinical Practice Endocrinology & Metabolism 2:8, 414-415
CrossRef898
Stephen D Wiviott, Christopher P Cannon. (2006) Update on lipid-lowering therapy and LDL-cholesterol targets. Nature Clinical Practice Cardiovascular Medicine 3:8, 424-436
CrossRef899
Liam R. Brunham, Roshni R. Singaraja, Michael R. Hayden. (2006) Variations on a Gene: Rare and Common Variants in ABCA1 and Their Impact on HDL Cholesterol Levels and Atherosclerosis. Annual Review of Nutrition 26:1, 105-129
CrossRef900
Bernd Genser, Winfried März. (2006) Low density lipoprotein cholesterol, statins and cardiovascular events: a meta–analysis. Clinical Research in Cardiology 95:8, 393-404
CrossRef901
Marc W Merx, Christian Weber. (2006) Statins in the intensive care unit. Current Opinion in Critical Care 12:4, 309-314
CrossRef902
Stephen J Nicholls, Ilke Sipahi, Paul Schoenhagen. (2006) The ACTIVATE study: lessons for the future of atherosclerotic therapy. Future Lipidology 1:4, 421-428
CrossRef903
Jean-Claude Tardif. (2006) Prevention challenges: The era of atherosclerosis regression. Canadian Journal of Cardiology 22, 27C-30C
CrossRef904
Christopher P. Cannon, Benjamin A. Steinberg, Sabina A. Murphy, Jessica L. Mega, Eugene Braunwald. (2006) Meta-Analysis of Cardiovascular Outcomes Trials Comparing Intensive Versus Moderate Statin Therapy. Journal of the American College of Cardiology 48:3, 438-445
CrossRef905
David H. Fitchett, Lawrence A. Leiter, Shaun G. Goodman, Anatoly Langer. (2006) Lower is better: Implications of the Treating to New Targets (TNT) study for Canadian patients. Canadian Journal of Cardiology 22:10, 835-839
CrossRef906
Jennifer G Robinson, Michael H Davidson. (2006) Managing cholesterol in the elderly. Aging Health 2:4, 623-638
CrossRef907
(2006) Is Rosuvastatin Really a More Efficient Therapeutic Option than Atorvastatin?. Value in Health 9:4, 276-277
CrossRef908
Sabine Steffens, François Mach. (2006) Drug Insight: immunomodulatory effects of statins—potential benefits for renal patients?. Nature Clinical Practice Nephrology 2:7, 378-387
CrossRef909
Jeffrey A. Switzer, David C. Hess. (2006) Statin therapy for coronary heart disease and its effect on stroke. Current Atherosclerosis Reports 8:4, 337-342
CrossRef910
William L. Isley. (2006) Low-density lipoprotein cholesterol lowering in the prevention of CHD: How low should we go?. Current Treatment Options in Cardiovascular Medicine 8:4, 289-297
CrossRef911
W.G. Goettsch, E.M. Heintjes, J.J.P. Kastelein, T.J. Rabelink, Saga Johansson, R.M.C. Herings. (2006) Results from a rosuvastatin historical cohort study in more than 45 000 Dutch statin users, a PHARMO study. Pharmacoepidemiology and Drug Safety 15:7, 435-443
CrossRef912
Matthew K Ito, Robert L Talbert, Sotirios Tsimikas. (2006) Statin-Associated Pleiotropy: Possible Beneficial Effects Beyond Cholesterol Reduction. Pharmacotherapy 26:7part2, 85S-97S
CrossRef913
Katie M Speidel, Daniel E Hilleman. (2006) Pharmacoeconomic considerations with statin therapy. Expert Opinion on Pharmacotherapy 7:10, 1291-1304
CrossRef914
Andrew T. McAfee, Eileen E. Ming, John D. Seeger, Sherry G. Quinn, Eva W. Ng, Jared D. Danielson, Jennifer A. Cutone, Jonathan C. Fox, Alexander M. Walker. (2006) The comparative safety of rosuvastatin: a retrospective matched cohort study in over 48 000 initiators of statin therapy. Pharmacoepidemiology and Drug Safety 15:7, 444-453
CrossRef915
Matthew K Ito, Robert L Talbert, Sotirios Tsimikas. (2006) Panel Discussion. Pharmacotherapy 26:7part2, 98S-101S
CrossRef916
Peter H. Jones. (2006) Dyslipidemia in Older Adults. The American Journal of Geriatric Cardiology 15:4, 239-244
CrossRef917
Jennifer G Robinson, Michael H Davidson. (2006) Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction. Expert Review of Cardiovascular Therapy 4:4, 461-476
CrossRef918
Steven G. Chrysant, Mohammad Ibrahim. (2006) Niacin-ER/Statin Combination for the Treatment of Dyslipidemia: Focus on Low High-Density Lipoprotein Cholesterol. The Journal of Clinical Hypertension 8:7, 493-501
CrossRef919
Carl J. Lavie, Richard V. Milani. (2006) Lipid Therapy in the Elderly?Emphasis on Clinical Event Reduction and Safety. The American Journal of Geriatric Cardiology 15:4, 245-247
CrossRef920
Sarkis B Baghdasarian, Paul D Thompson. (2006) How safe are very low LDL cholesterol levels?. Nature Clinical Practice Cardiovascular Medicine 3:6, 306-307
CrossRef921
O Christopher Raffel, Harvey D White. (2006) Drug Insight: statin use in the elderly. Nature Clinical Practice Cardiovascular Medicine 3:6, 318-328
CrossRef922
Ken Kitayama, Daisuke Nakai, Keita Kono, Arthur Gerritsen van der Hoop, Hitoshi Kurata, Elly C. de Wit, Louis H. Cohen, Toshimori Inaba, Takafumi Kohama. (2006) Novel non-systemic inhibitor of ileal apical Na+-dependent bile acid transporter reduces serum cholesterol levels in hamsters and monkeys. European Journal of Pharmacology 539:1-2, 89-98
CrossRef923
F. Civeira, E. Bustamante, E. Jarauta, E. Meriño-Ibarra. (2006) Lipoproteínas clásicas, terapéuticas modernas. Farmacología de las lipoproteínas de alta densidad. Clínica e Investigación en Arteriosclerosis 18, 10-19
CrossRef924
Philip Barter, Kerry-Anne Rye. (2006) Are we lowering LDL cholesterol sufficiently?. Nature Clinical Practice Cardiovascular Medicine 3:6, 290-291
CrossRef925
A. Middleton, A. S. Binbrek, F. A. H. Fonseca, W. Wilpshaar, C. Watkins, T. E. Strandberg. (2006) Achieving 2003 European lipid goals with rosuvastatin and comparator statins in 6743 patients in real-life clinical practice: DISCOVERY meta-analysis. Current Medical Research and Opinion 22:6, 1181-1191
CrossRef926
P. Nair, A. Roguin. (2006) Statins and the acute coronary syndrome: ‘the early bird catches the worm’. International Journal of Clinical Practice 60:6, 716-727
CrossRef927
David H. Fitchett, Bjug Borgundvaag, Warren Cantor, Eric Cohen, Sanjay Dhingra, Stephen Fremes, Milan Gupta, Michael Heffernan, Heather Kertland, Mansoor Husain, Anatoly Langer, Eric Letovsky, Shaun G. Goodman. (2006) Non-ST segment elevation acute coronary syndromes: A simplified risk-oriented algorithm. Canadian Journal of Cardiology 22:8, 663-677
CrossRef928
Mouhamad H. Abdallah, Wassef Karrowni, Habib A. Dakik. (2006) Profound regression of coronary atherosclerosis with statins. Canadian Journal of Cardiology 22:8, 709
CrossRef929
Stephen J. Nicholls, Ilke Sipahi, Paul Schoenhagen, Tim Crowe, E. Murat Tuzcu, Steven E. Nissen. (2006) Application of intravascular ultrasound in anti-atherosclerotic drug development. Nature Reviews Drug Discovery 5:6, 485-492
CrossRef930
Erin D. MacDougall, Farah Kramer, Patti Polinsky, Shelley Barnhart, Bardia Askari, Fredrik Johansson, Rebecca Varon, Michael E. Rosenfeld, Kazuhiro Oka, Lawrence Chan, Stephen M. Schwartz, Karin E. Bornfeldt. (2006) Aggressive Very Low-Density Lipoprotein (VLDL) and LDL Lowering by Gene Transfer of the VLDL Receptor Combined with a Low-Fat Diet Regimen Induces Regression and Reduces Macrophage Content in Advanced Atherosclerotic Lesions in LDL Receptor-Deficient Mice. The American Journal of Pathology 168:6, 2064-2073
CrossRef931
Borja Ibanez, Juan Badimon. (2006) Ezetimibe: one step beyond in the battle against atherosclerosis. Future Lipidology 1:3, 255-266
CrossRef932
Guido Lastra Gonzalez, Camila Margarita Manrique, James R. Sowers. (2006) High Cardiovascular Risk in Patients With Diabetes and the Cardiometabolic Syndrome: Mandate for Statin Therapy. Journal of the CardioMetabolic Syndrome 1:3, 178-183
CrossRef933
Demiana William Faltaos, Saik Urien, Valerie Carreau, Marina Chauvenet, Jean Sebastian Hulot, Philippe Giral, Eric Bruckert, Philippe Lechat. (2006) Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients. Fundamental and Clinical Pharmacology 20:3, 321-330
CrossRef934
Terry A. Jacobson, Stephen W. Gutkin, Charles R. Harper. (2006) Effects of a global risk educational tool on primary coronary prevention: the Atherosclerosis Assessment Via Total Risk (AVIATOR) study. Current Medical Research and Opinion 22:6, 1065-1073
CrossRef935
Benjamin M. Scirica, David A. Morrow, Christopher P. Cannon, Kausik K. Ray, Marc S. Sabatine, Petr Jarolim, Amy Shui, Carolyn H. McCabe, Eugene Braunwald. (2006) Intensive Statin Therapy and the Risk of Hospitalization for Heart Failure After an Acute Coronary Syndrome in the PROVE IT–TIMI 22 Study. Journal of the American College of Cardiology 47:11, 2326-2331
CrossRef936
Robert M. Guthrie. (2006) How Safe Is Aggressive Statin Therapy?. Progress in Cardiovascular Nursing 21:3, 140-145
CrossRef937
Jun Yang, Xiang-Ping Li, Shui-Ping Zhao, Jiang Li, Jing-Dong Li, Xiao-Ming Xie. (2006) The effect of different doses of fluvastatin on inflammatory markers in the early phase of acute coronary syndrome. Clinica Chimica Acta 368:1-2, 183-187
CrossRef938
Tracy S. Zimmermann, Amy C. H. Lee, Akin Akinc, Birgit Bramlage, David Bumcrot, Matthew N. Fedoruk, Jens Harborth, James A. Heyes, Lloyd B. Jeffs, Matthias John, Adam D. Judge, Kieu Lam, Kevin McClintock, Lubomir V. Nechev, Lorne R. Palmer, Timothy Racie, Ingo Röhl, Stephan Seiffert, Sumi Shanmugam, Vandana Sood, Jürgen Soutschek, Ivanka Toudjarska, Amanda J. Wheat, Ed Yaworski, William Zedalis, Victor Koteliansky, Muthiah Manoharan, Hans-Peter Vornlocher, Ian MacLachlan. (2006) RNAi-mediated gene silencing in non-human primates. Nature 441:7089, 111-114
CrossRef939
Mark D. Kelemen. (2006) Angina Pectoris: Evaluation in the Office. Medical Clinics of North America 90:3, 391-416
CrossRef940
Graham Jackson. (2006) ASTEROID - when spinning a star leads to a collision with reality. International Journal of Clinical Practice 60:5, 505-505
CrossRef941
Stamatios Lerakis, Mikhael F. El-Chami, Amar D. Patel, Emir Veledar, Elias Alexopoulos, Achilleas Zacharoulis, Aggeliki Triantafyllou. (2006) Effect of Lipid Levels and Lipid-Lowering Therapy on Restenosis after Coronary Artery Stenting. The American Journal of the Medical Sciences 331:5, 270-273
CrossRef942
Annemarie Armani, Peter P Toth. (2006) Colesevelam hydrochloride in the management of dyslipidemia. Expert Review of Cardiovascular Therapy 4:3, 283-291
CrossRef943
Sidney C. Smith, Jerilyn Allen, Steven N. Blair, Robert O. Bonow, Lawrence M. Brass, Gregg C. Fonarow, Scott M. Grundy, Loren Hiratzka, Daniel Jones, Harlan M. Krumholz, Lori Mosca, Richard C. Pasternak, Thomas Pearson, Marc A. Pfeffer, Kathryn A. Taubert. (2006) AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update. Journal of the American College of Cardiology 47:10, 2130-2139
CrossRef944
Sid Gilman. (2006) Pharmacologic management of ischemic stroke: Relevance to stem cell therapy. Experimental Neurology 199:1, 28-36
CrossRef945
H J Milionis, E N Liberopoulos, A Achimastos, M S Elisaf, D P Mikhailidis. (2006) Statins: another class of antihypertensive agents?. Journal of Human Hypertension 20:5, 320-335
CrossRef946
Donna M. Polk, Karol Watson. (2006) Hospital discharge treatments after an acute event: evidence for a systems approach to prevention. Coronary Artery Disease 17:3, 239-241
CrossRef947
G. W. Stone, H. D. Aronow. (2006) Long-term Care After Percutaneous Coronary Intervention: Focus on the Role of Antiplatelet Therapy. Mayo Clinic Proceedings 81:5, 641-652
CrossRef948
K. K. Ray, P. J. Sheridan, J. Bolton, T. C. Clayton, A. Veitch, R. Manivarmane, A. Al Rifai, G. Payne, W. Baig. (2006) Management and outcomes of acute coronary syndrome with minimal myocardial necrosis: analysis of a large prospective registry from a non-interventional centre*. International Journal of Clinical Practice 60:4, 383-390
CrossRef949
Richard Chudleigh, Julia Platts. (2006) Prevention is better than cure. Current Opinion in Lipidology 17:2, 188-191
CrossRef950
Jessica M. Ma, Cynthia A. Jackevicius, Uchenwa Genus, Vladimir Dzavik. (2006) The use of lipid-lowering therapy for secondary prevention in patients undergoing percutaneous coronary intervention. Canadian Journal of Cardiology 22:5, 419-423
CrossRef951
Haris Athar, Anuj R Shah, Paul D Thompson. (2006) Possible mechanisms for statin myopathy and its relationship to physical exercise. Future Lipidology 1:2, 143-151
CrossRef952
Khan Pohlel, Parker Grow, Tarek Helmy, Nanette K Wenger. (2006) Treating dyslipidemia in the elderly. Current Opinion in Internal Medicine 5:2, 150-153
CrossRef953
Jonathan Sorof, Christian Berne, Annica Siewert-Delle, Leif Jørgensen, Philip Sager. (2006) Effect of rosuvastatin or atorvastatin on urinary albumin excretion and renal function in type 2 diabetic patients. Diabetes Research and Clinical Practice 72:1, 81-87
CrossRef954
James E. Muller, Ahmed Tawakol, Sekar Kathiresan, Jagat Narula. (2006) New Opportunities for Identification and Reduction of Coronary Risk. Journal of the American College of Cardiology 47:8, C2-C6
CrossRef955
Xia Zheng, Shen-Jiang Hu. (2006) Effects of simvastatin on cardiohemodynamic responses to ischemia–reperfusion in isolated rat hearts. Heart and Vessels 21:2, 116-123
CrossRef956
Leibson Philip R.. (2006) IDEAL and FIELD. Preventive Cardiology 9:2, 115-120
CrossRef957
E. Van Ganse, T. Souchet, L. Laforest, P. Moulin, M. Bertrand, P. Le Jeunne, S. Chretin, D. Yin, E. Alemao, G. de Pouvourville. (2006) Long-term achievement of the therapeutic objectives of lipid-lowering agents in primary prevention patients and cardiovascular outcomes: An observational study. Atherosclerosis 185:1, 58-64
CrossRef958
Carlos A.G. Van Mieghem, Eugène P. McFadden, Pim J. de Feyter, Nico Bruining, Johannes A. Schaar, Nico R. Mollet, Filippo Cademartiri, Dick Goedhart, Sebastiaan de Winter, Gaston Rodriguez Granillo, Marco Valgimigli, Frits Mastik, Anton F. van der Steen, Willem J. van der Giessen, Georgios Sianos, Bianca Backx, Marie-Angèle M. Morel, Gerrit-Anne van Es, Andrew Zalewski, Patrick W. Serruys. (2006) Noninvasive Detection of Subclinical Coronary Atherosclerosis Coupled With Assessment of Changes in Plaque Characteristics Using Novel Invasive Imaging Modalities. Journal of the American College of Cardiology 47:6, 1134-1142
CrossRef959
Josh Todd, John A. Farmer. (2006) Optimal low-density lipoprotein levels: Evidence from epidemiology and clinical trials. Current Atherosclerosis Reports 8:2, 157-162
CrossRef960
Steven P. Marso, William R. Hiatt. (2006) Peripheral Arterial Disease in Patients With Diabetes. Journal of the American College of Cardiology 47:5, 921-929
CrossRef961
Mark A. Kudes, Ronald G. Schwartz. (2006) Noninvasive monitoring of medical therapy. Current Cardiology Reports 8:2, 139-146
CrossRef962
Roy Blank. (2006) Amlodipine/atorvastatin single pill for the management of hypertensive patients with additional cardiovascular risk factors. Future Cardiology 2:2, 145-159
CrossRef963
Leif R. Erhardt, A. Gotto. (2006) The evolution of European guidelines: Changing the management of cholesterol levels. Atherosclerosis 185:1, 12-20
CrossRef964
Kailash Prasad. (2006) C-Reactive Protein (CRP)-Lowering Agents. Cardiovascular Drug Reviews 24:1, 33-50
CrossRef965
Paola Primatesta, Neil R. Poulter. (2006) Levels of dyslipidaemia and improvement in its management in England: results from the Health Survey for England 2003. Clinical Endocrinology 64:3, 292-298
CrossRef966
José Martínez-González, Lina Badimon. (2006) Efecto temprano de las estatinas después de un infarto de miocardio. ¿Se debe a los efectos pleiotrópicos?. Medicina Clínica 126:9, 334-336
CrossRef967
JoAnne Micale Foody, Saif S. Rathore, Deron Galusha, Frederick A. Masoudi, Edward P. Havranek, Martha J. Radford, Harlan M. Krumholz. (2006) Hydroxymethylglutaryl-CoA Reductase Inhibitors in Older Persons with Acute Myocardial Infarction: Evidence for an AgeâStatin Interaction. Journal of the American Geriatrics Society 54:3, 421-430
CrossRef968
Stella S. Daskalopoulou, Dimitri P. Mikhailidis. (2006) Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe. Current Medical Research and Opinion 22:3, 511-528
CrossRef969
Kevin C. Maki, Michael H. Davidson, Mary R. Dicklin. (2006) A comparison of Canadian and American guidelines for lipid management using data from the National Cholesterol Education Program Evaluation ProjecT Utilizing Novel E-technology (NEPTUNE) II survey. Canadian Journal of Cardiology 22:4, 315-322
CrossRef970
Jones Peter H.. (2006) REVIEW PAPER. Rationale for Intensive Statin Treatment in High-Risk Patients. Preventive Cardiology 9:2, 91-95
CrossRef971
P. J. BARTER, C. M. BALLANTYNE, R. CARMENA, M. CASTRO CABEZAS, M. JOHN CHAPMAN, P. COUTURE, J. GRAAF, P. N. DURRINGTON, O. FAERGEMAN, J. FROHLICH, C. D. FURBERG, C. GAGNE, S. M. HAFFNER, S. E. HUMPHRIES, I. JUNGNER, R. M. KRAUSS, P. KWITEROVICH, S. MARCOVINA, C. J. PACKARD, T. A. PEARSON, K. SRINATH REDDY, R. ROSENSON, N. SARRAFZADEGAN, A. D. SNIDERMAN, A. F. STALENHOEF, E. STEIN, P. J. TALMUD, A. M. TONKIN, G. WALLDIUS, K. M. S. WILLIAMS. (2006) Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. Journal of Internal Medicine 259:3, 247-258
CrossRef972
Lawrence A. Leiter. (2006) PROVE-IT proved it: Lower is better – Pro. Canadian Journal of Cardiology 22, 91B-94B
CrossRef973
Stephen D. Persell, Donald M. Lloyd-Jones, David W. Baker. (2006) Implications of changing national cholesterol education program goals for the treatment and control of hypercholesterolemia. Journal of General Internal Medicine 21:2, 171-176
CrossRef974
Jeffrey A Switzer, David C Hess. (2006) Statins in stroke: prevention, protection and recovery. Expert Review of Neurotherapeutics 6:2, 195-202
CrossRef975
Jeffrey T Kuvin, Alawi A Alsheikh-Ali, Richard H Karas. (2006) High-Density Lipoprotein Cholesterol-Raising Strategies. Journal of Cardiovascular Pharmacology 47:2, 196-204
CrossRef976
Sameer K Mehta, James A de Lemos. (2006) Appropriate invasive and conservative strategies for patients with non-ST elevation acute coronary syndromes. Current Opinion in Internal Medicine 5:1, 24-28
CrossRef977
Xavier Pintó. (2006) Las estatinas, los hábitos de vida y el tratamiento de la hipercolesterolemia: los tiempos cambian y los criterios también. Medicina Clínica 126:6, 217-219
CrossRef978
CINDY L. GRINES. (2006) The Role of Statins in Reversing Atherosclerosis: What the Latest Regression Studies Show. Journal of Interventional Cardiology 19:1, 3-9
CrossRef979
J.L. Martín-Ventura, L.M. Blanco-Colio, A. Gómez-Hernández, B. Muñoz-García, M. Vega, J. Serrano, L. Ortega, G. Hernández, J. Egido, J. Tuñón. (2006) El tratamiento con dosis altas de atorvastatina disminuye la inflamación en la aterosclerosis carotídea humana. Clínica e Investigación en Arteriosclerosis 18:1, 18-23
CrossRef980
P K Shah. (2006) HDL/apoA-I infusion for atherosclerosis management: an emerging therapeutic paradigm. Future Lipidology 1:1, 55-64
CrossRef981
Tomomi Koizumi, Andrew M. Wilson, David A. Clark, Peter J. Fitzgerald. (2006) Latent plaque rupture in a patient undergoing stenting for acute coronary syndrome and diffuse coronary disease: A case report and review of literature. Catheterization and Cardiovascular Interventions 67:2, 241-245
CrossRef982
Matthias Briel, Alain J Nordmann, Heiner C Bucher. (2006) Statin therapy for prevention and treatment of acute and chronic cardiovascular disease: update on recent trials and metaanalyses. Current Opinion in Internal Medicine 5:1, 29-33
CrossRef983
Rakesh S Birjmohun, Erik SG Stroes, John JP Kastelein. (2006) Raising high-density lipoprotein cholesterol for better prevention of cardiovascular disease. Future Lipidology 1:1, 47-54
CrossRef984
STEPHANE G. CARLIER, KAORU TANAKA. (2006) Studying Coronary Plaque Regression with IVUS: A Critical Review of Recent Studies. Journal of Interventional Cardiology 19:1, 11-15
CrossRef985
Keiichiro Kosuge, Takashi Miida, Akihiro Takahashi, Konen Obayashi, Masayuki Ito, Takako Ito, Satoshi Soda, Kazuyuki Ozaki, Satoshi Hirayama, Osamu Hanyu, Yoshifusa Aizawa, Yuichi Nakamura. (2006) Estimating the fasting triglyceride concentration from the postprandial HDL-cholesterol and apolipoprotein CIII concentrations. Atherosclerosis 184:2, 413-419
CrossRef986
Steven A. Grover. (2006) PROVE-IT proves that lower is better: A contrary view. Canadian Journal of Cardiology 22, 95B-96B
CrossRef987
Stephen D. Persell, Donald M. Lloyd-Jones, David W. Baker. (2006) Implications of Changing National Cholesterol Education Program Goals for the Treatment and Control of Hypercholesterolemia. Journal of General Internal Medicine 0:0, 060111052548001-???
CrossRef988
2006. Antianginal drugs. , 260-263.
CrossRef989
Wilbert S Aronow. (2006) Managing Hyperlipidaemia in the Elderly. Drugs & Aging 23:3, 181-189
CrossRef990
Kathlyn J Ronaldson, Justine M O???Shea, Ian W Boyd. (2006) Risk Factors for Rhabdomyolysis with Simvastatin and Atorvastatin. Drug Safety 29:11, 1061-1067
CrossRef991
Abu R Vasudevan, Alassia Burns, Vivian A Fonseca. (2006) The Effectiveness of Intensive Glycemic Control for the Prevention of Vascular Complications in Diabetes Mellitus. Treatments in Endocrinology 5:5, 273-286
CrossRef992
H. T. Ong. (2006) Evidence-Based Prescribing of Statins: A Developing World Perspective. PLoS Medicine 3:3, e50
CrossRef993
Stephen J. Nicholls, Ilke Sipahi, E. Murat Tuzcu. (2006) Evaluación de la progresión y la regresión de la aterosclerosis coronaria mediante ecografía intravascular. ¿Un nuevo cambio de paradigma?. Revista Española de Cardiología 59:1, 57-66
CrossRef994
B.J. Gersh. (2006) Intensive Lipid Lowering With Atorvastatin in Patients With Stable Coronary Disease. Yearbook of Cardiology 2006, 280-281
CrossRef995
Yuji Yoshitomi, Toshikazu Ishii, Masashi Kaneki, Takashi Tsujibayashi, Shun-ichiro Sakurai, Chieko Nagakura, Atsuyoshi Miyauchi. (2006) Efficacy of a Low Dose of Pitavastatin Compared with Atorvastatin in Primary Hyperlipidemia: Results of a 12-week, open label study. Journal of Atherosclerosis and Thrombosis 13:2, 108-113
CrossRef996
Katsumi Miyauchi, Takeshi Kimura, Takeshi Morimoto, Yoshihisa Nakagawa, Masakazu Yamagishi, Yukio Ozaki, Takafumi Hiro, Hiroyuki Daida, Masunori Matsuzaki. (2006) Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome (JAPAN-ACS). Circulation Journal 70:12, 1624-1628
CrossRef997
Michael Clearfield. (2006) Clinical trials report. Current Atherosclerosis Reports 8:1, 7-12
CrossRef998
James M. Brophy, Vania Costa. (2006) Statin wars following coronary revascularization – Evidence-based clinical practice?. Canadian Journal of Cardiology 22:1, 54-58
CrossRef999
Ezra A. Amsterdam. (2006) The IDEAL Trial: Less Is More. Preventive Cardiology 9:1, 66-66
CrossRef1000
Terry A Jacobson. (2006) Overcoming ???Ageism??? Bias in the Treatment of Hypercholesterolaemia. Drug Safety 29:5, 421-448
CrossRef1001
J P Forman, B M Brenner. (2006) ‘Hypertension’ and ‘microalbuminuria’: The bell tolls for thee. Kidney International 69:1, 22-28
CrossRef1002
Anup K. Sabharwal, Jeffrey B. Boord. (2006) Low-density lipoprotein reduction: Is the risk worth the benefit?. Current Atherosclerosis Reports 8:1, 19-25
CrossRef1003
Sidney C. Smith, Ted E. Feldman, John W. Hirshfeld, Alice K. Jacobs, Morton J. Kern, Spencer B. King, Douglass A. Morrison, William W. O’Neill, Hartzell V. Schaff, Patrick L. Whitlow, David O. Williams, Elliott M. Antman, Sidney C. Smith, Cynthia D. Adams, Jeffrey L. Anderson, David P. Faxon, Valentin Fuster, Jonathan L. Halperin, Loren F. Hiratzka, Sharon Ann Hunt, Alice K. Jacobs, Rick Nishimura, Joseph P. Ornato, Richard L. Page, Barbara Riegel. (2006) ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention. Journal of the American College of Cardiology 47:1, e1-e121
CrossRef1004
Jun Sasaki, Mikio Iwashita, Suminori Kono. (2006) Statins: Beneficial or Adverse for Glucose Metabolism. Journal of Atherosclerosis and Thrombosis 13:3, 123-129
CrossRef1005
Karen P. Alexander, Eric D. Peterson. (2006) Treatment of Non?ST-Elevation Acute Coronary Syndrome in the Elderly: Current Practice and Future Opportunities. The American Journal of Geriatric Cardiology 15:1, 42-49
CrossRef1006
Hiromi Tasaki, Masaharu Miyamoto, Takahiro Kubara, Fumihiko Kamezaki, Seiya Tanaka, Kazuhito Yamashita, Masato Tsutsui, Yasuhide Nakashima. (2006) Cross-Over Trial of Intensive Monotherapy With Atorvastatin and Combined Therapy With Atorvastatin and Colestimide for Japanese Familial Hypercholesterolemia. Circulation Journal 70:1, 14-20
CrossRef1007
Soo Lim, Hak Chul Jang, Hong Kyu Lee, Kyu Chan Kimm, Chan Park, Nam H. Cho. (2006) The relationship between body fat and C-reactive protein in middle-aged Korean population. Atherosclerosis 184:1, 171-177
CrossRef1008
Armand Mekontso-Dessap, Christian Brun-Buisson. (2006) Statins: the next step in adjuvant therapy for sepsis?. Intensive Care Medicine 32:1, 11-14
CrossRef1009
Leiv Ose, Finn E Skjeldestad, Inger J Bakken, Andr??e Levorsen, Evo A Alemao, Don D Yin, Fredrik Borgstr??m, Linus J??nsson. (2006) Lipid Management and Cholesterol Goal Attainment in Norway. American Journal of Cardiovascular Drugs 6:2, 121-128
CrossRef1010
James J Ferguson. (2006) The Role of Oral Antiplatelet Agents in Atherothrombotic Disease. American Journal of Cardiovascular Drugs 6:3, 149-157
CrossRef1011
E. Hodenberg, Th. Breidenbach, J. Melichercik. (2006) Die Bedeutung der Cholesterinsenkung bei Patienten nach aortokoronarer Bypassoperation. Clinical Research in Cardiology 95:S1, i78-i82
CrossRef1012
Shinji Koba, Jun Sasaki. (2006) Treatment of Hyperlipidemia from Japanese Evidence. Journal of Atherosclerosis and Thrombosis 13:6, 267-280
CrossRef1013
Kumar Rajamani, Seemant Chaturvedi. (2006) New strategies in the medical treatment of carotid artery disease. Current Cardiology Reports 8:1, 33-37
CrossRef1014
Lionel H Opie, Patrick J Commerford, Bernard J Gersh. (2006) Controversies in stable coronary artery disease. The Lancet 367:9504, 69-78
CrossRef1015
Srdjan Boskovic, Aleksandar Neskovic. (2006) Atherosclerosis plaque regression. Medicinski pregled 59:1-2, 38-45
CrossRef1016
W HOWARD. (2006) C-Reactive Protein Levels and Outcomes After Statin TherapyRidker PM, for the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators (Harvard Med School, Boston) N Engl J Med 352:20–28, 2005§. Yearbook of Endocrinology 2006, 95-97
CrossRef1017
A RABINSTEIN. (2006) Effects of Acute Treatment With Pravastatin on Cerebral Vasospasm, Autoregulation, and Delayed Ischemic Deficits After Aneurysmal Subarachnoid Hemorrhage: A Phase II Randomized Placebo-Controlled TrialTseng M-Y, Czosnyka M, Richards H, et al (Univ of Cambridge, England) Stroke 36:1627–1632, 2005§. Yearbook of Neurology and Neurosurgery 2006, 30-32
CrossRef1018
(2005) Management of Acute Coronary Syndromes. New England Journal of Medicine 353:25, 2714-2718
Full Text1019
Vijay K Verma, Steven M Hollenberg. (2005) Update on acute coronary syndromes and ST-elevation myocardial infarction. Current Opinion in Internal Medicine 4:6, 614-618
CrossRef1020
Gregg C. Fonarow, Karol E. Watson. (2005) Treating to Low-Density Lipoprotein Goal. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 4:4, 174-176
CrossRef1021
Eric Bruckert, Marie Baccara-Dinet, Fran McCoy, John Chapman. (2005) High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients. Current Medical Research and Opinion 21:12, 1927-1934
CrossRef1022
Benjamin A. Steinberg, Alexandria J. M. Braganza, Gemma Eminowicz, Peter M. Dibattiste, Gregory C. Flaker, Sabina A. Murphy, Christopher P. Cannon. (2005) Are Statins Being Underdosed in Clinical Practice?. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 4:4, 169-173
CrossRef1023
Michael Schachter. (2005) Strategies for Modifying High-Density Lipoprotein Cholesterol: A Role for Nicotinic Acid. Cardiovascular Drugs and Therapy 19:6, 415-422
CrossRef1024
Eyal Leibovitz, Rafi Bitzur, Dror Harats, Dov Gavish. (2005) Beyond guidelines: achieving the optimum in LDL cholesterol control. Current Opinion in Lipidology 16:6, 635-639
CrossRef1025
C. Verny. (2005) Management of dyslipidemia in elderly diabetic patients. Diabetes & Metabolism 31, 5S74-5S81
CrossRef1026
H. Holdaas, B. Fellström, E. Cole, G. Nyberg, A.G. Olsson, T.R. Pedersen, S. Madsen, C. Grönhagen-Riska, H.-H. Neumayer, B. Maes, P. Ambühl, A. Hartmann, B. Staffler, A.G. Jardine, . (2005) Long-term Cardiac Outcomes in Renal Transplant Recipients Receiving Fluvastatin: The ALERT Extension Study. American Journal of Transplantation 5:12, 2929-2936
CrossRef1027
Steven T. DeKosky. (2005) Statin therapy in the treatment of Alzheimer disease: what is the rationale?. The American Journal of Medicine 118:12, 48-53
CrossRef1028
Peter S. Sever. (2005) Lipid-lowering therapy and the patient with multiple risk factors: what have we learned from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)?. The American Journal of Medicine 118:12, 3-9
CrossRef1029
Bruce S. Sachais, Julie Katz, Joyce Ross, Daniel J. Rader. (2005) Long-term effects of LDL apheresis in patients with severe hypercholesterolemia. Journal of Clinical Apheresis 20:4, 252-255
CrossRef1030
John McB. Hodgson. (2005) IVUS max. Catheterization and Cardiovascular Interventions 66:4, 519-520
CrossRef1031
Michael J. Koren. (2005) Statin use in a “real-world” clinical setting: aggressive lipid lowering compared with usual care in the Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE) trial. The American Journal of Medicine 118:12, 16-21
CrossRef1032
J. J. P. Kastelein, R. R. Sankatsing. (2005) Ezetimibe/simvastatin (INEGY™) in the treatment of hyperlipidaemia. International Journal of Clinical Practice 59:12, 1464-1471
CrossRef1033
John Betteridge. (2005) Benefits of lipid-lowering therapy in patients with type 2 diabetes mellitus. The American Journal of Medicine 118:12, 10-15
CrossRef1034
S.A. Jensen, L.J. Vatten, T.I.L. Nilsen, P.R. Romundstad, H.O. Myhre. (2005) Serum Lipids and Anthropometric Factors Related to the Prevalence of Intermittent Claudication. European Journal of Vascular and Endovascular Surgery 30:6, 582-587
CrossRef1035
James K Liao. (2005) Clinical implications for statin pleiotropy. Current Opinion in Lipidology 16:6, 624-629
CrossRef1036
Masao Moroi, Taeko Kunimasa, Tatsuhiko Furuhashi, Hiroshi Fukuda, Kaoru Sugi. (2005) Possible Assessment of Coronary Plaque Morphology Before and After Treatment With Statin by Multislice Spiral Computed Tomographic Coronary Angiography—A Case Report. International Journal of Angiology 14:4, 225-227
CrossRef1037
Sean M Donahoe, Marc S Sabatine. (2005) Adding clopidogrel to aspirin improves outcome in ST-elevation myocardial infarction patients receiving fibrinolytic therapy. Expert Review of Pharmacoeconomics & Outcomes Research 5:6, 751-761
CrossRef1038
H. M. Colhoun, D. J. Betteridge, P. N. Durrington, G. A. Hitman, H. A. W. Neil, S. J. Livingstone, M. J. Thomason, J. H. Fuller, . (2005) Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia 48:12, 2482-2485
CrossRef1039
Scott Kinlay. (2005) Potential vascular benefits of statins. The American Journal of Medicine 118:12, 62-67
CrossRef1040
Keisuke Watanabe, Seigo Sugiyama, Kiyotaka Kugiyama, Osamu Honda, Hironobu Fukushima, Hidenobu Koga, Yoko Horibata, Toshinori Hirai, Tomohiro Sakamoto, Michihiro Yoshimura, Yasuyuki Yamashita, Hisao Ogawa. (2005) Stabilization of Carotid Atheroma Assessed by Quantitative Ultrasound Analysis in Nonhypercholesterolemic Patients With Coronary Artery Disease. Journal of the American College of Cardiology 46:11, 2022-2030
CrossRef1041
Steven E. Nissen. (2005) Halting the progression of atherosclerosis with intensive lipid lowering: results from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial. The American Journal of Medicine 118:12, 22-27
CrossRef1042
Thomas F. Whayne. (2005) Women and Cardiovascular Disease—Prevention of Heart Disease. International Journal of Angiology 14:4, 218-224
CrossRef1043
S. Fischer. (2005) Risikoadaptierte Therapie von Gefäßerkrankungen—. Zeitschrift für Kardiologie 94:S4, iv24-iv27
CrossRef1044
David B Brieger. (2005) Medications for the treatment of acute coronary syndromes. Expert Opinion on Pharmacotherapy 6:16, 2843-2854
CrossRef1045
Jean Rouleau. (2005) Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 (PROVE IT–TIMI 22) trial. The American Journal of Medicine 118:12, 28-35
CrossRef1046
Ian Graham. (2005) What impact will current trial data have on future guideline recommendations?. The American Journal of Medicine 118:12, 42-47
CrossRef1047
V. Barrios, N. Amabile, F. Paganelli, J-W Chen, C. Allen, A. O. Johnson-Levonas, R. Massaad, K. Vandormael. (2005) Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease. International Journal of Clinical Practice 59:12, 1377-1386
CrossRef1048
Robert Menuet, Carl J. Lavie, Richard V. Milani. (2005) Importance and Management of Dyslipidemia in the Metabolic Syndrome. The American Journal of the Medical Sciences 330:6, 295-302
CrossRef1049
Richard A Krasuski. (2005) HDL-raising strategies in the treatment of coronary artery disease: perspectives from the Armed Forces Regression Study. Current Opinion in Lipidology 16:6, 652-657
CrossRef1050
Vera Bittner. (2005) Perspectives on Dyslipidemia and Coronary Heart Disease in Women. Journal of the American College of Cardiology 46:9, 1628-1635
CrossRef1051
(2005) Part 5: Acute coronary syndromes. Resuscitation 67:2-3, 249-269
CrossRef1052
Sukesh Burjonroppa, Ken Fujise. 2005. Resveratrol as Cardioprotective Agent. , 539-555.
CrossRef1053
Joshua S. Benner, Timothy W. Smith, David Klingman, Jonothan C. Tierce, C. Daniel Mullins, Ned Pethick, John C. O'Donnell. (2005) Cost-Effectiveness of Rosuvastatin Compared with Other Statins from a Managed Care Perspective. Value in Health 8:6, 618-628
CrossRef1054
B. M. Biccard, J. W. Sear, P. Foëx. (2005) Statin therapy: a potentially useful peri-operative intervention in patients with cardiovascular disease. Anaesthesia 60:11, 1106-1114
CrossRef1055
M. R. ROSSIELLO, S. MOMI, R. CARACCHINI, S. GIANNINI, G. GUGLIELMINI, A. MONOPOLI, E. ONGINI, N. SEMERARO, M. COLUCCI, P. GRESELE. (2005) A novel nitric oxide-releasing statin derivative exerts an antiplatelet/antithrombotic activity and inhibits tissue factor expression1. Journal of Thrombosis and Haemostasis 3:11, 2554-2562
CrossRef1056
S. Lim, H.K. Lee, K.C. Kimm, C. Park, C. Shin, N.H. Cho. (2005) C-reactive protein level as an independent risk factor of metabolic syndrome in the Korean population. Diabetes Research and Clinical Practice 70:2, 126-133
CrossRef1057
Paolo Calabr??, Edward T.H Yeh. (2005) The pleiotropic effects of statins. Current Opinion in Cardiology 20:6, 541-546
CrossRef1058
Antonio M. Gotto, John C. Larosa. (2005) The benefits of statin therapy-what questions remain?. Clinical Cardiology 28:11, 499-503
CrossRef1059
J.I. Bernardino de la Serna, J. García Puig. (2005) Factores metabólicos de riesgo cardiovascular. Relevancia epidemiológica. Tratamiento farmacológico. Situaciones de especial relevancia. Medicine - Programa de Formación Médica Continuada Acreditado 9:46, 3032-3043
CrossRef1060
B. M. Biccard, J. W. Sear, P. Foëx. (2005) The pharmaco-economics of peri-operative statin therapy. Anaesthesia 60:11, 1059-1063
CrossRef1061
Jennifer G. Robinson, Brian Smith, Nidhi Maheshwari, Helmut Schrott. (2005) Pleiotropic Effects of Statins: Benefit Beyond Cholesterol Reduction?. Journal of the American College of Cardiology 46:10, 1855-1862
CrossRef1062
Daniel E. Rosenberg, Serge A. Jabbour, Barry J. Goldstein. (2005) Insulin resistance, diabetes and cardiovascular risk: approaches to treatment. Diabetes, Obesity and Metabolism 7:6, 642-653
CrossRef1063
Thomas Thum, Dimitrios Tsikas, Sylvia Stein, Maximilian Schultheiss, Martin Eigenthaler, Stefan D. Anker, Philip A. Poole-Wilson, Georg Ertl, Johann Bauersachs. (2005) Suppression of Endothelial Progenitor Cells in Human Coronary Artery Disease by the Endogenous Nitric Oxide Synthase Inhibitor Asymmetric Dimethylarginine. Journal of the American College of Cardiology 46:9, 1693-1701
CrossRef1064
Jerzy-Roch Nofer, Michael Walter, Gerd Assmann. (2005) Current understanding of the role of high-density lipoproteins in atherosclerosis and senescence. Expert Review of Cardiovascular Therapy 3:6, 1071-1086
CrossRef1065
Jeetesh V Patel, Elizabeth A Hughes. (2005) Effectiveness of using rosuvastatin in difficult-to-control dyslipidemia patients: an audit in secondary care. Therapy 2:6, 895-900
CrossRef1066
James M McKenney, Michael H Davidson, Joseph Saponaro, Paul D Thompson, Harold E Bays. (2005) Use of A Treatment Algorithm to Achieve NCEP ATP III Goals With Atorvastatin. Journal of Cardiovascular Pharmacology 46:5, 594-599
CrossRef1067
Jonathan Sackner-Bernstein. (2005) Reducing the risks of sudden death and heart failure post myocardial infarction: Utility of optimized pharmacotherapy. Clinical Cardiology 28:S1, 19-27
CrossRef1068
Kausik K Ray, Christopher P Cannon. (2005) Optimal goals for statin use in patients with coronary artery disease. Current Opinion in Cardiology 20:6, 525-529
CrossRef1069
Antonio M. Gotto. (2005) Evolving Concepts of Dyslipidemia, Atherosclerosis, and Cardiovascular Disease. Journal of the American College of Cardiology 46:7, 1219-1224
CrossRef1070
Stephen D. Wiviott, Christopher P. Cannon, David A. Morrow, Kausik K. Ray, Marc A. Pfeffer, Eugene Braunwald. (2005) Can Low-Density Lipoprotein Be Too Low? The Safety and Efficacy of Achieving Very Low Low-Density Lipoprotein With Intensive Statin Therapy. Journal of the American College of Cardiology 46:8, 1411-1416
CrossRef1071
Gastón A. Rodríguez-Granillo, Evelyn Regar, Johannes A. Schaar, Patrick W. Serruys. (2005) Nuevas tendencias en la evaluación de la placa vulnerable mediante técnicas de cateterismo. Revista Española de Cardiología 58:10, 1197-1206
CrossRef1072
Sheila A Doggrell. (2005) More support for high-dose atorvastatin in coronary artery disease. Expert Opinion on Pharmacotherapy 6:13, 2365-2368
CrossRef1073
Grant H Skrepnek. (2005) Cost–effectiveness of HMG-CoA reductase inhibitors in the treatment of dyslipidemia and prevention of CHD. Expert Review of Pharmacoeconomics & Outcomes Research 5:5, 603-623
CrossRef1074
(2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. The Lancet 366:9493, 1267-1278
CrossRef1075
Harjot K. Saini, Yan-Jun Xu, Amarjit S. Arneja, Paramjit S. Tappia, Naranjan S. Dhalla. (2005) Pharmacological basis of different targets for the treatment of atherosclerosis. Journal of Cellular and Molecular Medicine 9:4, 818-839
CrossRef1076
Kausik K. Ray, Christopher P. Cannon, Richard Cairns, David A. Morrow, Nader Rifai, Ajay J. Kirtane, Carolyn H. McCabe, Allan M. Skene, C. Michael Gibson, Paul M. Ridker, Eugene Braunwald. (2005) Relationship Between Uncontrolled Risk Factors and C-Reactive Protein Levels in Patients Receiving Standard or Intensive Statin Therapy for Acute Coronary Syndromes in the PROVE IT-TIMI 22 Trial. Journal of the American College of Cardiology 46:8, 1417-1424
CrossRef1077
Kausik K. Ray, Christopher P. Cannon, Carolyn H. McCabe, Richard Cairns, Andrew M. Tonkin, Frank M. Sacks, Graham Jackson, Eugene Braunwald. (2005) Early and Late Benefits of High-Dose Atorvastatin in Patients With Acute Coronary Syndromes. Journal of the American College of Cardiology 46:8, 1405-1410
CrossRef1078
Gerd Assmann, Paul Cullen, Jean-Charles Fruchart, Heiner Greten, Marek Naruszewicz, Anders Olsson, Rodolfo Paoletti, Walter Riesen, Monika Stoll, Matti Tikkanen, Arnold von Eckardstein. (2005) Implications of emerging risk factors for therapeutic intervention. Nutrition, Metabolism and Cardiovascular Diseases 15:5, 373-381
CrossRef1079
Ian N. Bruce. (2005) Cardiovascular disease in lupus patients: Should all patients be treated with statins and aspirin?. Best Practice & Research Clinical Rheumatology 19:5, 823-838
CrossRef1080
Kausik K. Ray, Christopher P. Cannon. (2005) The Potential Relevance of the Multiple Lipid-Independent (Pleiotropic) Effects of Statins in the Management of Acute Coronary Syndromes. Journal of the American College of Cardiology 46:8, 1425-1433
CrossRef1081
Damian Franzen, Ingo Stamm, Gerhard Bauriedel, Dieter Beyer. (2005) Non-invasive Imaging of a Coronary Bypass Stenosis using CT Angiography in a Patient with Negative Stress Testing. The International Journal of Cardiovascular Imaging 21:5, 549-554
CrossRef1082
Katherine M. Field. (2005) Effect of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors on High-Sensitivity C-Reactive Protein Levels. Pharmacotherapy 25:10, 1365-1377
CrossRef1083
Peter Libby. (2005) The Forgotten Majority. Journal of the American College of Cardiology 46:7, 1225-1228
CrossRef1084
J.M. Mostaza, C. Lahoz. (2005) Implicaciones clínicas del estudio TNT. Clínica e Investigación en Arteriosclerosis 17:5, 249-254
CrossRef1085
Pablo Gómez-Fernández. (2005) Estatinas y efectos beneficiosos. Medicina Clínica 125:15, 578-579
CrossRef1086
Stefano De Servi, Matteo Mariani, Giuseppe Mariani, Antonino Mazzone. (2005) C-Reactive Protein Increase in Unstable Coronary Disease. Journal of the American College of Cardiology 46:8, 1496-1502
CrossRef1087
F. D. R. Hobbs, H. Southworth. (2005) Achievement of English National Service Framework lipid-lowering goals: pooled data from recent comparative treatment trials of statins at starting doses. International Journal of Clinical Practice 59:10, 1171-1177
CrossRef1088
Boden, William E., . (2005) Acute Coronary Syndromes without ST-Segment Elevation — What Is the Role of Early Intervention?. New England Journal of Medicine 353:11, 1159-1161
Full Text1089
de Winter, Robbert J., Windhausen, Fons, Cornel, Jan Hein, Dunselman, Peter H.J.M., Janus, Charles L., Bendermacher, Peter E.F., Michels, H. Rolf, Sanders, Gerard T., Tijssen, Jan G.P., Verheugt, Freek W.A., . (2005) Early Invasive versus Selectively Invasive Management for Acute Coronary Syndromes. New England Journal of Medicine 353:11, 1095-1104
Full Text1090
Judith A. Aberg, Robert A. Zackin, Susan W. Brobst, Scott R. Evans, Beverly L. Alston, W. Keith Henry, Marshall J. Glesby, Francesca J. Torriani, Yijun Yang, Susan I. Owens, Carl J. Fichtenbaum. (2005) A Randomized Trial of the Efficacy and Safety of Fenofibrate versus Pravastatin in HIV-Infected Subjects with Lipid Abnormalities: AIDS Clinical Trials Group Study 5087. AIDS Research and Human Retroviruses 21:9, 757-767
CrossRef1091
Harold Bays, James McKenney, Michael Davidson. (2005) Torcetrapib/atorvastatin combination therapy. Expert Review of Cardiovascular Therapy 3:5, 789-820
CrossRef1092
John C. Larosad. (2005) Is aggressive lipid-lowering effective and safe in the older adult?. Clinical Cardiology 28:9, 404-407
CrossRef1093
Keith C Ferdinand. (2005) Rosuvastatin: a risk–benefit assessment for intensive lipid lowering. Expert Opinion on Pharmacotherapy 6:11, 1897-1910
CrossRef1094
Michael Davidson. (2005) Considerations in the Treatment of Dyslipidemia Associated With Chronic Kidney Failure and Renal Transplantation. Preventive Cardiology 8:4, 244-249
CrossRef1095
Eric Van Ganse, Laurent Laforest, Evo Alemao, Glenn Davies, Stephen Gutkin, Don Yin. (2005) Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study. Current Medical Research and Opinion 21:9, 1389-1399
CrossRef1096
Mark Y Chan, Chi Hang Lee. (2005) Fluvastatin: efficacy and safety in reducing cardiac events. Expert Opinion on Pharmacotherapy 6:11, 1883-1895
CrossRef1097
Robert P. Giugliano, Eugene Braunwald. (2005) The Year in Non
ST-Segment Elevation Acute Coronary Syndromes. Journal of the American College of Cardiology 46:5, 906-919
CrossRef1098
Rebecca J Cheung, Matthew K Ito. (2005) Clinical utility of extended-release niacin: update and summary. Future Cardiology 1:5, 571-578
CrossRef1099
Jeanne P. Dieleman, Jacobus T. van Wyk, Marc A. M. van Wijk, Gé van Herpen, Sabine M. J. M. Straus, Hans Dunselman, Miriam C. J. M. Sturkenboom. (2005) Differences between statins on clinical endpoints: a population-based cohort study. Current Medical Research and Opinion 21:9, 1461-1468
CrossRef1100
F. CIPOLLONE, M. FAZIA, A. MEZZETTI. (2005) Novel determinants of plaque instability. Journal of Thrombosis and Haemostasis 3:9, 1962-1975
CrossRef1101
Judy W.M. Cheng. (2005) Management of Stable Angina and Acute Coronary Syndromes. American Journal of Pharmaceutical Education 69:5, 99
CrossRef1102
Peter P. Toth. (2005) New insights in the treatment of dyslipidemia: A focus on cardiovascular event reduction and the antiatherosclerotic effects of atorvastatin. Current Atherosclerosis Reports 7:5, 335-343
CrossRef1103
CJ Slager, JJ Wentzel, FJH Gijsen, A Thury, AC van der Wal, JA Schaar, PW Serruys. (2005) The role of shear stress in the destabilization of vulnerable plaques and related therapeutic implications. Nature Clinical Practice Cardiovascular Medicine 2:9, 456-464
CrossRef1104
R. Jaumdally, G. Y. H. Lip, C. Varma. (2005) Percutaneous coronary interventions for coronary artery disease: the long and short of optimizing medical therapy. International Journal of Clinical Practice 59:9, 1070-1081
CrossRef1105
Neil L. Coplan, Alexander Chernobelsky. (2005) Global Risk Stratification to Improve Cardiovascular Prevention: Integration of Traditional Risk Factors, Emerging Risk Factors, and New, Noninvasive Cardiovascular Imaging. The American Heart Hospital Journal 3:4, 265-268
CrossRef1106
Guo-Ping Shi. (2005) Cathepsins: novel drug targets for cardiovascular diseases?. Future Cardiology 1:5, 563-565
CrossRef1107
John PD Reckless. (2005) Statin therapy should be considered routinely for people with diabetes mellitus. Practical Diabetes International 22:7, 233-236
CrossRef1108
R. A. Krasuski, D. Doeppenschmidt, J. S. Henry, P. B. Smith, J. Adinaro, B. Rachel, C. M. Thompson. (2005) Conversion to Atorvastatin in Patients Intolerant or Refractory to Simvastatin Therapy: The CAPISH Study. Mayo Clinic Proceedings 80:9, 1163-1168
CrossRef1109
Ian R Reid, Andrew Tonkin, Christopher P. Cannon. (2005) Comparison of the effects of pravastatin and atorvastatin on fracture incidence in the PROVE IT-TIMI 22 trial—Secondary analysis of a randomized controlled trial. Bone 37:2, 190-191
CrossRef1110
Jeppe N. Rasmussen, Gunnar H. Gislason, Steen Z. Abildstrom, Soren Rasmussen, Ida Gustafsson, Pernille Buch, Jens Friberg, Lars Kober, Christian Torp-Pedersen, Mette Madsen, Steen Stender. (2005) Statin use after acute myocardial infarction: a nationwide study in Denmark. British Journal of Clinical Pharmacology 60:2, 150-158
CrossRef1111
Howard S. Weintraub. (2005) Treatment of multiple-risk patients: Using combination therapy to treat beyond LDL lowering. Current Hypertension Reports 7:4, 265-270
CrossRef1112
Raaj R Sankatsing, Eric de Groot, J Wouter Jukema, Pim J de Feyter, Dudley J Pennell, Paul Schoenhagen, Steven E Nissen, Erik SG Stroes, John JP Kastelein. (2005) Surrogate markers for atherosclerotic disease. Current Opinion in Lipidology 16:4, 434-441
CrossRef1113
Kenneth A. LaBresh. (2005) Using “get with the guidelines” to prevent recurrent cardiovascular disease. Current Treatment Options in Cardiovascular Medicine 7:4, 287-292
CrossRef1114
Francisco A. H. Fonseca, Alvaro Ruiz, Ernesto G. Cardona-Muñoz, Jose M. Silva, Nery Fuenmayor, Marcelo Marotti. (2005) The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL‐C Value – an Evaluation of Rosuvastatin therapY compared with atorvastatin*. Current Medical Research and Opinion 21:8, 1307-1315
CrossRef1115
Sheila A Doggrell. (2005) Relating statin therapy to C-reactive protein levels. Expert Opinion on Pharmacotherapy 6:9, 1597-1600
CrossRef1116
Vasilios G. Athyros, Dimitri P. Mikhailidis, Athanasios A. Papageorgiou, Triandafillos P. Didangelos, Athanasia Peletidou, Drosia Kleta, Asterios Karagiannis, Anna I. Kakafika, Konstantinos Tziomalos, Moses Elisaf. (2005) Targeting vascular risk in patients with metabolic syndrome but without diabetes. Metabolism 54:8, 1065-1074
CrossRef1117
John C. Marshall, Jean-Louis Vincent, Gordon Guyatt, Derek C. Angus, Edward Abraham, Gordon Bernard, Claire Bombardier, Thierry Calandra, Henrik Stig J??rgensen, Richard Sylvester, Maarten Boers. (2005) Outcome measures for clinical research in sepsis: A report of the 2nd Cambridge Colloquium of the International Sepsis Forum. Critical Care Medicine 33:8, 1708-1716
CrossRef1118
F. Mach, D. Senouf, P. Fontana, F. Boehlen, G. Reber, Y. Daali, P. de Moerloose, U. Sigwart. (2005) Not all statins interfere with clopidogrel during antiplatelet therapy. European Journal of Clinical Investigation 35:8, 476-481
CrossRef1119
Paul Schoenhagen. (2005) Atherosclerosis imaging and circulating blood biomarkers: insights into subclinical atherosclerotic plaque burden and disease activity. The International Journal of Cardiovascular Imaging 21:4, 443-445
CrossRef1120
Antonio Tello, Francisco Marín, Vanessa Roldán, Ana García-Herola, Sofía Lorenzo, Vicente E. Climent, Luis de Teresa, Francisco Sogorb. (2005) Efecto de dosis máximas de atorvastatina en la inflamación, la trombogénesis y la función fibrinolítica en pacientes con cardiopatía isquémica de alto riesgo. Revista Española de Cardiología 58:8, 934-940
CrossRef1121
Annette M. Vollrath, Christian Sinclair, James Hallenbeck. (2005) Discontinuing Cardiovascular Medications at the End of Life: Lipid-Lowering Agents. Journal of Palliative Medicine 8:4, 876-881
CrossRef1122
G Assmann. (2005) Kardiovaskuläre Risikoabschätzung – PROCAM und neue Algorithmen der Stratifizierung / Assessment of Cardiovascular Risk – PROCAM and New Algorithms. Biomedizinische Technik/Biomedical Engineering 50:7-8, 227-232
CrossRef1123
David F. Blackburn, Roy T. Dobson, James L. Blackburn, Thomas W. Wilson. (2005) Cardiovascular Morbidity Associated with Nonadherence to Statin Therapy. Pharmacotherapy 25:8, 1035-1043
CrossRef1124
(2005) Intensive Lipid Lowering with Atorvastatin in Coronary Disease. New England Journal of Medicine 353:1, 93-96
Full Text1125
Yadon Arad, Louise A. Spadaro, Marguerite Roth, David Newstein, Alan D. Guerci. (2005) Treatment of Asymptomatic Adults With Elevated Coronary Calcium Scores With Atorvastatin, Vitamin C, and Vitamin E. Journal of the American College of Cardiology 46:1, 166-172
CrossRef1126
Marc L. Berger, Steven Teutsch. (2005) Cost-Effectiveness Analysis. Medical Care 43:Supplement, II-49-II-53
CrossRef1127
Amar M Salam, Jassim Al Suwaidi. (2005) Selected highlights from the 54th Annual Scientific Session of the American College of Cardiology, Orlando, USA, 6 – 9 March 2005. Expert Opinion on Pharmacotherapy 6:8, 1425-1436
CrossRef1128
Carol M. Mason. (2005) The Nurse Practitioner's Role in Helping Patients Achieve Lipid Goals with Statin Therapy. Journal of the American Academy of Nurse Practitioners 17:7, 256-262
CrossRef1129
M. R. Cowie. (2005) Simultaneous treatment of hypertension and dyslipidaemia may help to reduce overall cardiovascular risk: focus on amlodipine/atorvastatin single-pill therapy. International Journal of Clinical Practice 59:7, 839-846
CrossRef1130
Sungha Park, Hyun-Jae Kang, Se-Joong Rim, Jong-Won Ha, Byung-Hee Oh, Namsik Chung, Seung-Yun Cho. (2005) A randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in korean patients with hypercholesterolemia. Clinical Therapeutics 27:7, 1074-1082
CrossRef1131
Danielle Duffy, Daniel J Rader. (2005) Drugs in development: targeting high-density lipoprotein metabolism and reverse cholesterol transport. Current Opinion in Cardiology 20:4, 301-306
CrossRef1132
A. Maiques Galán, M. Blasco Valle. (2005) Bases de la evidencia científica del tratamiento hipolipemiante. Factores que condicionan su efectividad e indicaciones en prevención cardiovascular. Atención Primaria 36, 31-39
CrossRef1133
Charles Daniel Meyers, Nathan Wong, Moti L Kashyap. (2005) Anticipating the evolution of clinical cholesterol guidelines: implications of recent statin intervention trials. Future Cardiology 1:4, 461-471
CrossRef1134
Mahesh Patel, Darren K. McGuire. (2005) How aggressive should lipid lowering be among patients with acute coronary syndromes?. Current Cardiology Reports 7:4, 283-287
CrossRef1135
C. Llor Vila. (2005) Manejo de las dislipemias en poblaciones especiales: tratamiento de la dislipemia diabética. Atención Primaria 36, 47-51
CrossRef1136
Nicole S. Culhane, Shana L. Lettieri, Jeannine R. Skae. (2005) Rosuvastatin for the Treatment of Hypercholesterolemia. Pharmacotherapy 25:7, 990-1000
CrossRef1137
Roberto Corti, Valentin Fuster, Zahi A. Fayad, Stephen G. Worthley, Gerard Helft, William F. Chaplin, Jörg Muntwyler, Juan F. Viles-Gonzalez, Jesse Weinberger, Donald A. Smith, Gabor Mizsei, Juan J. Badimon. (2005) Effects of Aggressive Versus Conventional Lipid-Lowering Therapy by Simvastatin on Human Atherosclerotic Lesions. Journal of the American College of Cardiology 46:1, 106-112
CrossRef1138
Gary E. Sander, Thomas D. Giles. (2005) Medical Management of Myocardial Ischemia. The American Journal of Geriatric Cardiology 14:4, 205-209
CrossRef1139
Michael J Zema. (2005) Colesevelam HCl and Ezetimibe Combination Therapy Provides Effective Lipid-Lowering in Difficult-to-Treat Patients with Hypercholesterolemia. American Journal of Therapeutics 12:4, 306-310
CrossRef1140
Abrams, Jonathan, . (2005) Chronic Stable Angina. New England Journal of Medicine 352:24, 2524-2533
Full Text1141
Javier Jurado, Paul D. Thompson. (2005) Prevention of coronary artery disease in cancer patients. Pediatric Blood & Cancer 44:7, 620-624
CrossRef1142
Philip R Liebson. (2005) Womens? Health Study (Aspirin) and TNT. Preventive Cardiology 8:3, 181-185
CrossRef1143
Russell A. Wilke, Jason H. Moore, James K. Burmester. (2005) Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage. Pharmacogenetics and Genomics 15:6, 415-421
CrossRef1144
Guenther Boden. (2005) New benefits of statin treatment. Current Diabetes Reports 5:3, 165-166
CrossRef1145
Helena Vaverkova, Jiri Frohlich, Dagmar Jackuliakova, Dalibor Novotny. (2005) Comparison of apolipoprotein B and plasma lipids as targets for lipid lowering treatment. Clinical Biochemistry 38:6, 509-513
CrossRef1146
William Bestermann, Mark C. Houston, Jan Basile, Brent Egan, Carlos M. Ferrario, Dan Lackland, Ralph G. Hawkins, James Reed, Philip Rogers, Daniel Wise, Michael A. Moore. (2005) Addressing the Global Cardiovascular Risk of Hypertension, Dyslipidemia, Diabetes Mellitus, and the Metabolic Syndrome in the Southeastern United States, Part II: Treatment Recommendations for Management of the Global Cardiovascular Risk of Hypertension, Dyslipidemia, Diabetes Mellitus, and the Metabolic Syndrome. The American Journal of the Medical Sciences 329:6, 292-305
CrossRef1147
Sander I van Leuven, John JP Kastelein. (2005) Atorvastatin. Expert Opinion on Pharmacotherapy 6:7, 1191-1203
CrossRef1148
Alan Wilkinson, Jaime Davidson, Francesco Dotta, Philip D Home, Paul Keown, Bryce Kiberd, Alan Jardine, Naomi Levitt, Piero Marchetti, Mariana Markell, Sarala Naicker, Philip O'Connell, Mark Schnitzler, Eberhard Standl, Jose-VicenteTorregosa, Kazuharu Uchida, Hannah Valantine, Federico Villamil, Flavio Vincenti, Martin Wissing. (2005) Guidelines for the treatment and management of new-onset diabetes after transplantation1.. Clinical Transplantation 19:3, 291-298
CrossRef1149
J. M. CRUZ-Fernández, G. V. Bedarida, J. Adgey, C. Allen, A. O. Johnson-Levonas, R. Massaad. (2005) Efficacy and safety of ezetimibe co-administered with ongoing atorvastatin therapy in achieving low-density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease. International Journal of Clinical Practice 59:6, 619-627
CrossRef1150
Rahul Garg, Chandrasekhar R. Vasamreddy, Roger S. Blumenthal. (2005) PERSPECTIVES. Non-High-Density Lipoprotein Cholesterol: Why Lower Is Better. Preventive Cardiology 8:3, 173-177
CrossRef1151
Daniel G. Hackam. (2005) Cardiovascular risk prevention in peripheral artery disease. Journal of Vascular Surgery 41:6, 1070-1073
CrossRef1152
D. John Betteridge. (2005) Long-term risk reduction: Who needs treatment?. Diabetes Research and Clinical Practice 68, S15-S22
CrossRef1153
Colin Macphee, G Martin Benson, Yi Shi, Andrew Zalewski. (2005) Lipoprotein-associated phospholipase A 2 : a novel marker of cardiovascular risk and potential therapeutic target. Expert Opinion on Investigational Drugs 14:6, 671-679
CrossRef1154
Peter H. Stone. (2005) Evaluating Cardiovascular Pathophysiology and Anatomy in Atherosclerosis. The American Heart Hospital Journal 3:3, 187-192
CrossRef1155
Kausik K Ray, Christopher P Cannon. (2005) Atorvastatin and cardiovascular protection: a review and comparison of recent clinical trials. Expert Opinion on Pharmacotherapy 6:6, 915-927
CrossRef1156
Alawi A. Alsheikh-Ali, Jeffrey T. Kuvin, Richard H. Karas. (2005) High-density lipoprotein cholesterol in the cardiovascular equation: Does the “good” still count?. Atherosclerosis 180:2, 217-223
CrossRef1157
Graham Jackson. (2005) Lipids and cardiovascular risk reduction - new targets, new challenges. International Journal of Clinical Practice 59:6, 617-618
CrossRef1158
Katharine Douaihy. (2005) Prediabetes & Atherosclerosis: What???s the Connection?. The Nurse Practitioner 30:6, 24-35
CrossRef1159
P. J. Barter, C. M. Ballantyne. (2005) Discussion. International Journal of Clinical Practice 59:s148, 15-16
CrossRef1160
Prakash Deedwania, Natalia Volkova. (2005) Dyslipidemia and lipid-lowering therapy in the elderly. Expert Review of Cardiovascular Therapy 3:3, 453-463
CrossRef1161
James Shepherd, John Betteridge, Luc Van Gaal. (2005) Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel. Current Medical Research and Opinion 21:5, 665-682
CrossRef1162
Thomas F. Rehring, Brian G. Sandhoff, Ryan S. Stolcpart, John A. Merenich, H. Whitton Hollis. (2005) Atherosclerotic risk factor control in patients with peripheral arterial disease. Journal of Vascular Surgery 41:5, 816-822
CrossRef1163
H.C. Geiss, C. Otto, E. Hund-Wissner, K.G. Parhofer. (2005) Effects of ezetimibe on plasma lipoproteins in severely hypercholesterolemic patients treated with regular LDL-apheresis and statins. Atherosclerosis 180:1, 107-112
CrossRef1164
Allan Gaw. (2005) Rosuvastatin: achieving cholesterol targets. Future Cardiology 1:3, 289-297
CrossRef1165
A. D. Mooradian. (2005) Commentary. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 60:5, 598-598
CrossRef1166
Karen H. Costenbader, Jonathan S. Coblyn. (2005) Statin Therapy in Rheumatoid Arthritis. Southern Medical Journal 98:5, 534-540
CrossRef1167
Paul M. Ridker, David A. Morrow, Lynda M. Rose, Nader Rifai, Christopher P. Cannon, Eugene Braunwald. (2005) Relative Efficacy of Atorvastatin 80 mg and Pravastatin 40 mg in Achieving the Dual Goals of Low-Density Lipoprotein Cholesterol <70 mg/dl and C-Reactive Protein <2 mg/l. Journal of the American College of Cardiology 45:10, 1644-1648
CrossRef1168
M. Rosenberg, M. Haass. (2005) Leitlinien der Lipidtherapie. Der Internist 46:S01, S11-S17
CrossRef1169
Sheila A Doggrell. (2005) Berberine – a novel approach to cholesterol lowering. Expert Opinion on Investigational Drugs 14:5, 683-685
CrossRef1170
A. Pérez, L. Sojo. (2005) Diabetes mellitus tipo 2. ¿Cómo tratar la dislipemia diabética?. Clínica e Investigación en Arteriosclerosis 17, 40-51
CrossRef1171
W. S. Aronow. (2005) Should the NCEP III Guidelines Be Changed in Elderly and Younger Persons at High Risk for Cardiovascular Events?. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 60:5, 591-592
CrossRef1172
E. Hodenberg. (2005) Optimierte Cholesterinsenkung. Der Internist 46:S01, S18-S23
CrossRef1173
Q. Wang, P.H. Wang, C. McLachlan, P.T.-H. Wong. (2005) Simvastatin reverses the downregulation of dopamine D1 and D2 receptor expression in the prefrontal cortex of 6-hydroxydopamine-induced Parkinsonian rats. Brain Research 1045:1-2, 229-233
CrossRef1174
I. S. Nash. (2005) Aim Low. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 60:5, 599-600
CrossRef1175
Roy Blank, James LaSalle, Russell Reeves, Jaman Maroni, Lisa Tarasenko, Franklin Sun. (2005) Single-Pill Therapy in the Treatment of Concomitant Hypertension and Dyslipidemia (The Amlodipine/Atorvastatin Gemini Study). The Journal of Clinical Hypertension 7:5, 264-273
CrossRef1176
D. L. Hurley, W. L. Isley. (2005) Getting There: Statin Plus Ezetimibe for Low-Density Lipoprotein Cholesterol Goals. Mayo Clinic Proceedings 80:5, 585-586
CrossRef1177
H. Holdaas. (2005) Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation. Nephrology Dialysis Transplantation 20:5, 974-980
CrossRef1178
Cannon, Christopher P., Braunwald, Eugene, McCabe, Carolyn H., Grayston, J. Thomas, Muhlestein, Brent, Giugliano, Robert P., Cairns, Richard, Skene, Allan M., . (2005) Antibiotic Treatment of Chlamydia pneumoniae after Acute Coronary Syndrome. New England Journal of Medicine 352:16, 1646-1654
Full Text1179
Pitt, Bertram, . (2005) Low-Density Lipoprotein Cholesterol in Patients with Stable Coronary Heart Disease — Is It Time to Shift Our Goals?. New England Journal of Medicine 352:14, 1483-1484
Full Text1180
LaRosa, John C., Grundy, Scott M., Waters, David D., Shear, Charles, Barter, Philip, Fruchart, Jean-Charles, Gotto, Antonio M., Greten, Heiner, Kastelein, John J.P., Shepherd, James, Wenger, Nanette K., . (2005) Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease. New England Journal of Medicine 352:14, 1425-1435
Full Text1181
Daniel S Kamin, Steven K Grinspoon. (2005) Cardiovascular disease in HIV-positive patients. AIDS 19:7, 641-652
CrossRef1182
Thuy Anh Nguyen, Jean G. Diodati, Chantal Pharand. (2005) Resistance to clopidogrel: A review of the evidence. Journal of the American College of Cardiology 45:8, 1157-1164
CrossRef1183
Patrick Linsel-Nitschke, Alan R. Tall. (2005) HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nature Reviews Drug Discovery 4:3, 193-205
CrossRef1184
Atsushi Yonemura, Yukihiko Momiyama, Zahi A. Fayad, Makoto Ayaori, Reiko Ohmori, Kenji Higashi, Teruyoshi Kihara, Shojiro Sawada, Noriyuki Iwamoto, Masatsune Ogura, Hiroaki Taniguchi, Masatoshi Kusuhara, Masayoshi Nagata, Haruo Nakamura, Seiichi Tamai, Fumitaka Ohsuzu. (2005) Effect of lipid-lowering therapy with atorvastatin on atherosclerotic aortic plaques detected by noninvasive magnetic resonance imaging. Journal of the American College of Cardiology 45:5, 733-742
CrossRef1185
Kausik K. Ray, Christopher P. Cannon. (2005) Time to Benefit. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 4:1, 43-45
CrossRef1186
Joan Montaner. (2005) Treatment with statins in the acute phase of ischemic stroke. Expert Review of Neurotherapeutics 5:2, 211-221
CrossRef1187
JL Anderson, JB Muhlestein. (2005) Update of antibiotic trials for secondary prevention of coronary heart disease. Future Cardiology 1:2, 225-234
CrossRef1188
Wilbert S. Aronow. (2005) Updated National Cholesterol Education Program III guidelines. Journal of the American Medical Directors Association 6:2, 160-161
CrossRef1189
Robert J. Straka, Reza Taheri, Susan L. Cooper, James C. Smith. (2005) Achieving Cholesterol Target in a Managed Care Organization (ACTION) Trial. Pharmacotherapy 25:3, 360-371
CrossRef1190
Alessia Fornoni, Leopoldo Raij. (2005) Metabolic syndrome and endothelial dysfunction. Current Hypertension Reports 7:2, 88-95
CrossRef1191
Christopher H. Strey, Joanna M. Young, Sarah L. Molyneux, Peter M. George, Christopher M. Florkowski, Russell S. Scott, Christopher M. Frampton. (2005) Endothelium-ameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure. Atherosclerosis 179:1, 201-206
CrossRef1192
Ellis W. Lader, Christopher P. Cannon. (2005) How to Join a Clinical Trial. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 4:1, 26-29
CrossRef1193
Carl J. Lavie, Richard V. Milani. (2005) Optimal lipids, statins, and dementia. Journal of the American College of Cardiology 45:6, 963-964
CrossRef1194
John A. Farmer. (2005) Clinical trials report. Current Atherosclerosis Reports 7:2, 85-87
CrossRef1195
Stephen D. Persell, Saverio M. Maviglia, David W. Bates, John Z. Ayanian. (2005) Ambulatory Hypercholesterolemia Management in Patients with Atherosclerosis. Gender and Race Differences in Processes and Outcomes. Journal of General Internal Medicine 20:2, 123-130
CrossRef1196
James K. Liao, Ulrich Laufs. (2005) PLEIOTROPIC EFFECTS OF STATINS. Annual Review of Pharmacology and Toxicology 45:1, 89-118
CrossRef1197
Kausik K Ray, Christopher P Cannon. (2005) Intensive statin therapy in acute coronary syndromes: clinical benefits and vascular biology. Current Opinion in Internal Medicine 4:1, 27-33
CrossRef1198
James H Stein. (2005) Managing Cardiovascular Risk in Patients With HIV Infection. JAIDS Journal of Acquired Immune Deficiency Syndromes 38:2, 115-123
CrossRef1199
R.Y.A. Mukhtar, J. Reid, J.P.D. Reckless. (2005) Pitavastatin. International Journal of Clinical Practice 59:2, 239-252
CrossRef1200
Juhani Kahri, Miia Valkonen, Tom B
cklund, Matti Vuoristo, Kari T. Kivist
CrossRef1201
MATTHEW T. RONDINA, JOSEPH B. MUHLESTEIN. (2005) Early Initiation of Statin Therapy in Acute Coronary Syndromes: A Review of the Evidence. Journal of Interventional Cardiology 18:1, 55-63
CrossRef1202
Pia Salo, Anu Hopia, Jari Ekblom, Ritva Lahtinen, Päivi Laakso. 2005. Plant Stanol Ester as a Cholesterol-Lowering Ingredient of Benecol® Foods. .
CrossRef1203
Nissen, Steven E., Tuzcu, E. Murat, Schoenhagen, Paul, Crowe, Tim, Sasiela, William J., Tsai, John, Orazem, John, Magorien, Raymond D., O'Shaughnessy, Charles, Ganz, Peter, . (2005) Statin Therapy, LDL Cholesterol, C-Reactive Protein, and Coronary Artery Disease. New England Journal of Medicine 352:1, 29-38
Full Text1204
Ridker, Paul M, Cannon, Christopher P., Morrow, David, Rifai, Nader, Rose, Lynda M., McCabe, Carolyn H., Pfeffer, Marc A., Braunwald, Eugene, . (2005) C-Reactive Protein Levels and Outcomes after Statin Therapy. New England Journal of Medicine 352:1, 20-28
Full Text1205
Pang H. Chong, Dwight Varner. (2005) Cost-Efficacy Analysis of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Based on Results of the STELLAR Trial: Clinical Implications for Therapeutic Selection. Pharmacotherapy 25:2, 270-278
CrossRef1206
Flavio Ribichini, Valeria Ferrero, Andrea Rognoni, Giovanni Vacca, Corrado Vassanelli. (2005) Angiotensin Antagonism in Coronary Artery Disease. Drugs 65:8, 1073-1096
CrossRef1207
Margarite J Vale, Michael V Jelinek, James D Best. (2005) Impact of Coaching Patients on Coronary Risk Factors. Disease Management & Health Outcomes 13:4, 225-244
CrossRef1208
Hirotaka Nagashima, Hiroshi Kasanuki. (2005) The Status of Lipid Management in 1,836 Patients with Coronary Artery Disease: A multicenter survey to evaluate the percentage of Japanese coronary artery disease patients achieving the target low-density lipoprotein cholesterol level specified by the Japan Atherosclerosis Society. Journal of Atherosclerosis and Thrombosis 12:6, 338-342
CrossRef1209
Thomas J Povsic, Eric D Peterson. (2005) Progenitor cell therapy of ischemic heart disease: the new frontier. Future Cardiology 1:1, 87-98
CrossRef1210
Yasuhiko Sakata, Hiroshi Sato, Kunihiro Kinjo, Kenshi Fujii, Kazuhisa Kodama, Jun Tanouchi, Masayoshi Mishima, Hideo Kusuoka, Daisaku Nakatani, Hiroya Mizuno, Masahiko Shimizu, Masatsugu Hori. (2005) Rationale and Design of the OACIS-LIPID Study That Evaluates Early Use of Pravastatin in Acute Myocardial Infarction. Heart Drug 5:4, 193-196
CrossRef1211
Steven E Nissen. (2005) Does intensive statin therapy lower mortality and cardiovascular event risk in patients with acute coronary syndrome?. Nature Clinical Practice Cardiovascular Medicine 2:1, 10-11
CrossRef1212
Wilbert S. Aronow. (2005) Updated National Cholesterol Education Program III guidelines. Journal of the American Medical Directors Association 6:2, 160???161
CrossRef1213
Allison M. J. Ross, Theodore G. Ganiats. (2005) Results of new statin trials: Should the low-density lipoprotein cholesterol treatment guidelines be revised?. Current Atherosclerosis Reports 7:1, 11-16
CrossRef1214
Daniel I Chasman, Paul M Ridker. (2005) Pharmacogenetics: the outlook for genetic testing in statin therapy. Nature Clinical Practice Cardiovascular Medicine 2:1, 2-3
CrossRef1215
Gerd Assmann. (2005) Beyond statin therapy: why we need new thinking. Current Medical Research and Opinion 21:s6, S3-S8
CrossRef1216
Tsung O. Cheng. (2005) PROVE IT then believe it. International Journal of Clinical Practice 59:1, 124-124
CrossRef1217
Sam Riahi, Erik Berg Schmidt, Jeppe Hagstrup Christensen, Finn Heath, Anders Kirstein Pedersen, Jens Cosedis Nielsen, Henning Mølgaard, Egon Toft. (2005) Statins, Ventricular Arrhythmias and Heart Rate Variability in Patients with Implantable Cardioverter Defibrillators and Coronary Heart Disease. Cardiology 104:4, 210-214
CrossRef1218
Rosario Scalia. (2005) Statins and the Response to Myocardial Injury. American Journal of Cardiovascular Drugs 5:3, 163-170
CrossRef1219
Teresa M. Seccia, Gian Paolo Rossi. (2005) Clinical Use and Pathogenetic Basis of Laboratory Tests for the Evaluation of Primary Arterial Hypertension. Critical Reviews in Clinical Laboratory Sciences 42:5-6, 393-452
CrossRef1220
Erik Stroes. (2005) Statins and LDL‐cholesterol lowering: an overview. Current Medical Research and Opinion 21:s6, S9-S16
CrossRef1221
Rod Jackson, Carlene MM Lawes, Derrick A Bennett, Richard J Milne, Anthony Rodgers. (2005) Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. The Lancet 365:9457, 434-441
CrossRef1222
Masakazu Yamagishi, Takeo Higashikata, Hatsue Ishibashi-Ueda, Hiroaki Sasaki, Hitoshi Ogino, Koji Iihara, Susumu Miyamoto, Noritoshi Nagaya, Hitonobu Tomoike, Aiji Sakamoto. (2005) Sustained Upregulation of Inflammatory Chemokine and Its Receptor in Aneurysmal and Occlusive Atherosclerotic Disease. Circulation Journal 69:12, 1490-1495
CrossRef1223
Joji Ishikawa, Kazuomi Kario. (2005) American Heart Association Scientific Sessions 2004: Brain and Heart. Expert Review of Cardiovascular Therapy 3:1, 11-14
CrossRef1224
Winfried März. (2005) Lowering LDL Cholesterol: Where Is the End of the Journey?. Heart Drug 5:1, 39-50
CrossRef1225
Thomas C. Wascher. (2005) The Era of Statins – Is There Still a Place for Other Classes of Lipid-Lowering Drugs?. Heart Drug 5:1, 34-38
CrossRef1226
L. Capron. (2005) Faut-il mettre une statine dans le biberon des nourrissons ?. La Revue de Médecine Interne 26:1, 1-4
CrossRef1227
M. John Chapman. (2005) The potential role of HDL‐ and LDL‐cholesterol modulation in atheromatous plaque development. Current Medical Research and Opinion 21:s6, S17-S22
CrossRef1228
Lluís Masana, Nuria Plana. (2005) Planificación del tratamiento de la hipercolesterolemia orientada a la obtención de objetivos. Medicina Clínica 124:3, 108-110
CrossRef1229
Vijay Nambi, Christie M. Ballantyne. (2005) Utility of statin therapy using high-sensitivity C-reactive protein as an indicator of coronary heart disease risk. Current Atherosclerosis Reports 7:1, 22-28
CrossRef1230
Wolfgang Bocksch, Suzanne Fateh-Moghadam, Sonja Huehns, Michael Schartl. (2005) Influence of Different Lipid-Lowering Strategies on Plaque Volume and Plaque Composition in Patients with Coronary Artery Disease: Role of Intravascular Ultrasound Imaging. Kidney and Blood Pressure Research 28:5-6, 290-294
CrossRef1231
Michael Clearfield. (2005) Clinical trials report. Current Atherosclerosis Reports 7:1, 7-10
CrossRef1232
D. Bulut, C. Hanefeld, N. Bulut-Streich, C. Graf, A. Mügge, M. Spiecker. (2005) Endothelial Function in the Forearm Circulation of Patients with the Metabolic Syndrome – Effect of Different Lipid-Lowering Regimens. Cardiology 104:4, 176-180
CrossRef1233
Andrea Bartok, Sabine Steiner, Daniela Seidinger, Angelika Jetzl, Kurt Huber, Erich Minar, Thomas Stefenelli, Christoph W. Kopp. (2005) Atorvastatin reduces thrombin generation after percutaneous coronary intervention independent of soluble tissue factor. Thrombosis Research 115:6, 469-474
CrossRef1234
Philip R Liebson. (2005) CARDS and A to Z. Preventive Cardiology 8:1, 59-62
CrossRef1235
Yasushi Saito. (2005) JAS Guideline and Statin Treatment. Journal of Atherosclerosis and Thrombosis 12:6, 343-343
CrossRef1236
Joseph J Saseen, Setareh A Williams, Robert J Valuck, John C O??Donnell, Kenneth McDonough. (2005) The Performance Gap between Clinical Trials and Patient Treatment for Dyslipidemia. Disease Management & Health Outcomes 13:4, 255-265
CrossRef1237
Robin J. Edison, Maximilian Muenke. (2004) Mechanistic and epidemiologic considerations in the evaluation of adverse birth outcomes following gestational exposure to statins. American Journal of Medical Genetics 131A:3, 287-298
CrossRef1238
Kausik K Ray, Christopher P Cannon. (2004) Intensive statin therapy in acute coronary syndromes: clinical benefits and vascular biology. Current Opinion in Lipidology 15:6, 637-643
CrossRef1239
Pedro R. Moreno, Valentin Fuster. (2004) The year in atherothrombosis. Journal of the American College of Cardiology 44:11, 2099-2110
CrossRef1240
Kathy Berra. (2004) Clinical Update on the Use of Niacin for the Treatment of Dyslipidemia. Journal of the American Academy of Nurse Practitioners 16:12, 526-534
CrossRef1241
Yong S. K. Moon, Moti L. Kashyap. (2004) Pharmacologic Treatment of Type 2 Diabetic Dyslipidemia. Pharmacotherapy 24:12, 1692-1713
CrossRef1242
James H O'Keefe. (2004) Have recent statin trial findings affected the National Cholesterol Education Program guidelines?. Nature Clinical Practice Cardiovascular Medicine 1:2, 76-77
CrossRef1243
Christopher J Boos, Gregory YH Lip. (2004) Novel therapies for the prevention of stroke. Expert Opinion on Investigational Drugs 13:12, 1615-1630
CrossRef1244
Terje R Pedersen, Jonathan A Tobert. (2004) Simvastatin: a review. Expert Opinion on Pharmacotherapy 5:12, 2583-2596
CrossRef1245
William L. Isley. (2004) What Did PROVE-IT Prove?. Diabetes Technology & Therapeutics 6:6, 864-867
CrossRef1246
Paul Schoenhagen, Timothy Crowe, Murat Tuzcu, Steven E Nissen. (2004) Pharmacologic strategies for the prevention of atherosclerotic plaque progression. Expert Review of Cardiovascular Therapy 2:6, 855-866
CrossRef1247
Michael H Davidson. (2004) Rosuvastatin safety: lessons from the FDA review and post-approval surveillance. Expert Opinion on Drug Safety 3:6, 547-557
CrossRef1248
Ronald Lieberman. (2004) Evidence-based Medical Perspectives: The Evolving Role of PSA for Early Detection, Monitoring of Treatment Response, and as a Surrogate End Point of Efficacy for Interventions in Men with Different Clinical Risk States for the Prevention and Progression of Prostate Cancer. American Journal of Therapeutics 11:6, 501-506
CrossRef1249
Brian K Irons. (2004) Early, aggressive lipid management in the treatment of acute coronary syndromes. Therapy 1:2, 213-216
CrossRef1250
Angie Veverka, Jamie L Jolly. (2004) Recent advances in the secondary prevention of coronary heart disease. Expert Review of Cardiovascular Therapy 2:6, 877-889
CrossRef1251
Kathie L. Hermayer. (2004) Treatment of lipids and type 2 diabetes. Current Cardiology Reports 6:6, 443-450
CrossRef1252
Michael J. Koren, Donald B. Hunninghake. (2004) Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics. Journal of the American College of Cardiology 44:9, 1772-1779
CrossRef1253
Harold E. Bays, Leiv Ose, Neil Fraser, Diane L. Tribble, Katherine Quinto, Robert Reyes, Amy O. Johnson-Levonas, Aditi Sapre, Steven R. Donahue. (2004) A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clinical Therapeutics 26:11, 1758-1773
CrossRef1254
Robert S Rosenson. (2004) Statins: can the new generation make an impression?. Expert Opinion on Emerging Drugs 9:2, 269-279
CrossRef1255
Stella S. Daskalopoulou, Gerard Stansby, Dimitri P. Mikhailidis. (2004) Clopidogrel and vascular disease prevention. Current Medical Research and Opinion 20:11, 1835-1838
CrossRef1256
Peter W. F. Wilson. (2004) Clinical trials report. Current Cardiology Reports 6:6, 437-438
CrossRef1257
Athanasios Stoyioglou, Michael R. Jaff. (2004) Medical Treatment of Peripheral Arterial Disease: A Comprehensive Review. Journal of Vascular and Interventional Radiology 15:11, 1197-1207
CrossRef1258
J. Tuomilehto, L. A. Leiter, D. Kallend. (2004) A review of the efficacy of rosuvastatin in patients with type 2 diabetes. International Journal of Clinical Practice 58, 30-40
CrossRef1259
Todd W. Rice, Gordon R. Bernard. (2004) Drotrecogin Alfa (Activated) for the Treatment of Severe Sepsis and Septic Shock. The American Journal of the Medical Sciences 328:4, 205-214
CrossRef1260
Alexander Geppert, Kurt Huber. (2004) Inflammation and cardiovascular diseases: lessons that can be learned for the patient with cardiogenic shock in the intensive care unit. Current Opinion in Critical Care 10:5, 347-353
CrossRef1261
J. K. Liao. (2004) Statins: potent vascular anti-inflammatory agents. International Journal of Clinical Practice 58, 41-48
CrossRef1262
M. B. Tumber, K. Dickersin. (2004) Publication of clinical trials: accountability and accessibility. Journal of Internal Medicine 256:4, 271-283
CrossRef1263
Gerald McGwin, Cynthia Owsley. (2004) Statins and age-related macular degeneration. American Journal of Ophthalmology 138:4, 688
CrossRef1264
K. D. Flemming, R. D. Brown. (2004) Secondary Prevention Strategies in Ischemic Stroke: Identification and Optimal Management of Modifiable Risk Factors. Mayo Clinic Proceedings 79:10, 1330-1340
CrossRef1265
Vasilios G. Athyros, Dimitri P. Mikhailidis, Athanasios A. Papageorgiou, Athanasios N. Symeonidis, Stella S. Daskalopoulou, Anna I. Kakafika, Anthimos N. Pehlivanidis, Vasilios I. Bouloukos, Anatoly Langer. (2004) Relationship between LDL-C and non-HDL-C levels and clinical outcome in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Current Medical Research and Opinion 20:9, 1385-1392
CrossRef1266
H. R. Vries. (2004) Hoge dosis atorvastatine bij coronaire ziekte. MFM 42:9, 255-256
CrossRef1267
Patrick J. Skerrett, Richard C. Pasternak. (2004) ALLHAT-LLT: Questions, questions, and more questions (and some answers). Current Atherosclerosis Reports 6:5, 375-380
CrossRef1268
Charles Q Meng. (2004) A new era in atherosclerosis drug discovery. Expert Review of Cardiovascular Therapy 2:5, 633-636
CrossRef1269
Peter P. Toth. (2004) Low-density lipoprotein reduction in high-risk patients: How low do you go?. Current Atherosclerosis Reports 6:5, 348-352
CrossRef1270
Sheila A Doggrell. (2004) Atorvastatin versus pravastatin: intensive versus moderate lipid lowering. Expert Opinion on Pharmacotherapy 5:9, 2025-2028
CrossRef1271
Micah J. Eimer, Neil J. Stone. (2004) Evidence-based treatment of lipids in the elderly. Current Atherosclerosis Reports 6:5, 388-397
CrossRef1272
Vijay Nambi, Christie M. Ballantyne. (2004) ASCOT-LLA and the primary prevention of coronary artery disease in hypertensive patients. Current Atherosclerosis Reports 6:5, 353-358
CrossRef1273
K. L. Lentine. (2004) Statin use after renal transplantation: a systematic quality review of trial-based evidence. Nephrology Dialysis Transplantation 19:9, 2378-2386
CrossRef1274
(2004) Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. New England Journal of Medicine 351:7, 714-717
Full Text1275
M. John Chapman, Gerd Assmann, Jean-Charles Fruchart, James Shepherd, Cesare Sirtori. (2004) Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid – a position paper developed by the European Consensus Panel on HDL-C*. Current Medical Research and Opinion 20:8, 1253-1268
CrossRef1276
Scott M. Grundy, James I. Cleeman, C. Noel Bairey Merz, H. Bryan Brewer, Luther T. Clark, Donald B. Hunninghake, Richard C. Pasternak, Sidney C. Smith, Neil J. Stone. (2004) Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Journal of the American College of Cardiology 44:3, 720-732
CrossRef1277
Paul Durrington. (2004) Statin policy and target populations: evidence-based or evidence-biased?. Current Opinion in Lipidology 15:4, 381-386
CrossRef1278
Robert A. Harrington. (2004) Myocardial ischemia and infarction. Journal of the American College of Cardiology 44:2, S10-S12
CrossRef1279
Harold E Bays. (2004) Extended-release niacin/lovastatin: the first combination product for dyslipidemia. Expert Review of Cardiovascular Therapy 2:4, 485-501
CrossRef1280
Carl J. Lavie. (2004) Vascular disease, hypertension, and prevention. Journal of the American College of Cardiology 44:2, S19-S22
CrossRef1281
Philip R. Liebson. (2004) PROVE IT and REVERSAL. Preventive Cardiology 7:3, 138-141
CrossRef1282
Dennis L. DeSilvey. (2004) Aggressive Lowering of Low-Density Lipoprotein Cholesterol: Do the Studies Apply to the Elderly?. The American Journal of Geriatric Cardiology 13:4, 217-218
CrossRef1283
Abhinav Goyal, John L. Petersen, Kenneth W. Mahaffey. (2004) The evaluation and management of dyslipidemia and impaired glucose metabolism during acute coronary syndromes. Current Cardiology Reports 6:4, 300-307
CrossRef1284
Luther T. Clark. (2004) Optimizing lipid lowering in patients at risk. Clinical Cardiology 27:S3, 22-26
CrossRef1285
Graham Jackson. (2004) Statins - threatening the evidence base of effectiveness and safety. International Journal of Clinical Practice 58:6, 539-540
CrossRef1286
James H O'Keefe, Loren Cordain, William H Harris, Richard M Moe, Robert Vogel. (2004) Optimal low-density lipoprotein is 50 to 70 mg/dl. Journal of the American College of Cardiology 43:11, 2142-2146
CrossRef1287
Amar M Salam. (2004) Intensive lipid-lowering therapy in coronary artery disease: implications of the REVERSAL and PROVE-IT trials. Expert Opinion on Investigational Drugs 13:6, 707-713
CrossRef1288
Christopher P. Cannon. (2004) Risk Stratification and the Management of Non–ST-Segment Elevation Acute Coronary Syndromes. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 3:2, 83-86
CrossRef1289
Simon de Denus, Sarah A. Spinler, Kristin Miller, Andrew M. Peterson. (2004) Statins and Liver Toxicity: A Meta-Analysis. Pharmacotherapy 24:5, 584-591
CrossRef1290
Topol, Eric J., . (2004) Intensive Statin Therapy — A Sea Change in Cardiovascular Prevention. New England Journal of Medicine 350:15, 1562-1564
Full Text1291
Wilbert S. Aronow. (2004) Should the National Cholesterol Education Program Guidelines Be Changed for Persons at High Risk for Cardiovascular Events?. Preventive Cardiology 7:2, 71-72
CrossRef1292
Graham Jackson. (2004) Believe-it then PROVE-IT. International Journal of Clinical Practice 58:4, 325-326
CrossRef1293
F. J. Garc??a Ruiz, A. Mar??n Ib????ez, F. P??rez-Jim??nez, X. Pint??, G. Nocea, C. Ahumada, E. Alemao, D. Yin. (2004) Current Lipid Management and Low Cholesterol Goal Attainment in Common Daily Practice in Spain. PharmacoEconomics 22:Supplement 3, 1???12
CrossRef1294
John R. Cook, Don Yin, Evo Alemao, Glenn Davies, Karln J. Krobot, Enrico Veltri, Leslie Lipka, Xavier Badia. (2004) Cost-Effectiveness of Ezetimibe Coadministration in Statin-Treated Patients not at Cholesterol Goal. PharmacoEconomics 22:Supplement 3, 49???61
CrossRef1295
David Murdoch, Lesley J Scott. (2004) Ezetimibe/Simvastatin. American Journal of Cardiovascular Drugs 4:6, 405-422
CrossRef1296
??sa Carlsson, Fredrik Borgstr??m, Jan St??lhammar, Evo Alemao, Don Yin, Linus J??nsson. (2004) Cost of Care for Patients Treated with Lipid-Lowering Drugs. PharmacoEconomics 22:Supplement 3, 25???35
CrossRef
- Letters
